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3Abstract
In order to explore the phenotypic heterogeneity of the myeloproliferative neoplasm essential
thrombocythaemia (ET), the role of the JAK2 mutation V617F in the pathogenesis of the
disease was investigated, in particular its relationship to myeloid clonality. The clinical,
haematological and molecular characteristics of 133 ET patients were studied. JAK2 V617F was
detected in 55 (41%) patients; a clonal X-chromosome inactivation pattern (XCIP) was found in
24 (39%) of the 62 evaluable female patients. There was no association between JAK2
mutational status and XCIP status or thrombotic risk, but higher JAK2 V617F mutant levels
were noted in patients who had a thrombosis. A trend towards a higher thrombotic rate was
observed in patients whose XCIP was clonal. In 10 untreated JAK2 V617F-positive ET patients,
JAK2 WT thrombopoiesis was not suppressed despite the presence of a thrombocytosis,
suggesting that the regulation of JAK2 WT thrombopoiesis was abnormal. Eleven patients were
screened for the presence of more than one JAK2 V617F-positive population using an exonic
SNP located near the mutation. In ten (91%) of these the mutation appeared to have been
independently acquired on at least two occasions. Furthermore, XCIP analysis of JAK2 V617F-
positive erythroid colonies from six ET patients revealed that in one patient the V617F-positive
populations were not derived from a single clonal population. An association between the
reported JAK2 haplotype (known as ‘46/1’) and JAK2 V617F-positive ET patients was observed
in the cohort studied. Methylation studies indicated that this haplotype introduced additional
methylated sites near to the mutation locus, which may potentially affect conformation of the
DNA and mutability of the JAK2 locus. Together, the studies reported in this thesis suggest that
JAK2 V617F is not the initiating event at least in some cases of ET, and that its presence does
not invariably indicate the presence of a monoclonal disorder.
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1 Introduction
1.1 Essential thrombocythaemia and the myeloproliferative
neoplasms
Essential thrombocythaemia (ET) is a chronic haematological disorder characterised by the
sustained overproduction of megakaryocytes (MKs) and platelets in the absence of a
recognisable physiological stimulus. It is a rare condition, with an annual incidence of
approximately 0.8 new cases per 100,000 population in the UK (McNally et al, 1997), though
this figure may be as high as 2.5 per 100,000 in some regions (Mesa et al, 1999), and there is
evidence that these rates are increasing (Girodon et al, 2009; Johansson et al, 2004). The
median age at diagnosis is 65 – 70 years, but it may present at any age of life, and there is a
female-to-male preponderance of approximately 2-to-1 (Girodon et al, 2009; Jensen et al,
2000; Landgren et al, 2008).
Although it was initially described in 1934 as a haemorrhagic thrombocythaemia (Epstein and
Goedel 1934), its most significant clinical sequelae are thrombotic episodes, which may be life-
threatening. Untreated, the rate of thrombotic events in one series was 6.6% per patient-year,
though this varied markedly between 1.7% and 31.4% per patient-year depending on a
number of risk factors, with a predominance of arterial events (Cortelazzo et al, 1990).
Haemorrhagic complications are rarer, and are associated with extreme thrombocytosis
(platelets greater than 1500x109/L). ET may also transform to the more serious
myeloproliferative neoplasm (MPN) myelofibrosis (MF), or to acute myeloid leukaemia (AML),
but in the short term the risk of this is small – approximately 5-8% over 10 years, and 1-3%
over 10 years, respectively (Cervantes et al, 2002; Palandri et al, 2009a). For older patients the
diagnosis is unlikely to have a significant impact on their life expectancy, but for younger
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patients the same may not be true (Bazzan et al, 1999; Mesa et al, 1999; Passamonti et al,
2004; Wolanskyj et al, 2006). Cytoreductive therapy reduces the incidence of vascular
complications in high-risk patients (Cortelazzo et al, 1995) but may increase the risk of
malignant transformation (Finazzi et al, 2000; Randi et al, 2000).
As long ago as 1951, Dameshek recognised the similarities between ET, polycythaemia vera
(PV), MF, and chronic myeloid leukaemia (CML), and suggested that they might represent
different manifestations of the same ‘myeloproliferative syndrome’ (Dameshek 1951). He went
on to speculate about the existence of a ‘myelostimulatory factor’, which he believed might be
a steroid hormone. Although a number of rarer conditions were later classified as
myeloproliferative disorders (renamed MPN by the World Health Organisation, WHO, in 2008),
ET, PV, MF and CML still represent the great bulk of this diagnostic category in terms of
prevalence and clinical burden.
The finding in 1960 of a recurrent cytogenetic abnormality in most patients with CML – a
reciprocal translocation between chromosome 9 and chromosome 22 [t(9;22)(q34.1;q11.2)],
known as the Philadelphia chromosome (Nowell and Hungerford 1960) – greatly advanced our
understanding of this disorder and led to the recognition that it represents a distinct entity
from the other so-called Philadelphia-negative MPNs. It also resulted in significant
improvements in the diagnosis and treatment of CML, inspiring intensive efforts to find
equivalent abnormalities in ET, PV and MF.
To facilitate research efforts and to help standardise the diagnosis and treatment of patients
with MPNs, the Polycythemia Vera Study Group (PVSG) was formed in the 1960s. Its principal
role was to coordinate clinical trials of patients with MPNs and, in order to provide consistency
between clinical studies, the PVSG introduced formal diagnostic criteria for the three main
disorders, which have subsequently been refined by the WHO (Table 1.1). The most recent
Chapter 1
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Table 1.1 2008 WHO Criteria for the diagnosis of the myeloproliferative
neoplasms
Polycythaemia vera Essential thrombocythaemia Myelofibrosis
Major
criteria
1 Hb >18.5 g/dL (men)
>16.5 g/dL (women) or other
evidence of increased red cell
volume*
or
elevated red cell mass
>25% above mean normal
predicted value
Sustained platelet count
≥450x109/L
MK proliferation and atypia
accompanied by reticulin
and/or collagen fibrosis
or
in the absence of reticulin
fibrosis, MK changes must be
accompanied by increased
marrow cellularity,
granulocytic proliferation and
often decreased
erythropoiesis (i.e. pre-fibrotic
PMF)
2 Presence of JAK2V617F or
similar mutation (e.g. JAK2
exon 12)
Bone marrow biopsy
specimen showing
proliferation mainly of the
megakaryocytic lineage with
increased numbers of
enlarged, mature MKs.
No significant increase or left-
shift of neutrophil
granulopoiesisor
erythropoiesis
3 Not meeting WHO criteria for
CML, PV, PMF, MDS or other
myeloid neoplasm
Not meeting WHO criteria for
CML, PV, MDS, or other
myeloid neoplasm
4 Demonstration of JAK2V617F
or other clonal marker
or
no evidence of reactive
thrombocytosis
Demonstration of JAK2V617F
or other clonal marker
or
no evidence of reactive
marrow fibrosis
Minor
criteria
1 Bone marrow biopsy showing
hypercellularity for age with
trilineage growth (panmyelosis)
with prominent erythroid,
granulocytic, and
megakaryocytic proliferation
Leukoerythroblastosis
2 Subnormal serum Epo level Increased serum LDH
3 EEC growth Anaemia
4 Palpable splenomegaly
Based on Tefferi and Vardiman (2008).
The diagnosis of PV requires fulfilment of either both major criteria and one minor criterion or the first
major criterion and 2 minor criteria. The diagnosis of ET requires fulfilment of all 4 major criteria. The
diagnosis of PMF requires fulfilment of all 3 major criteria and 2 minor criteria.
* Hb or Hct >99th percentile of reference range for age, sex or altitude of residence; or Hb >17 g/dL
(men), >15 g/dL (women) if associated with sustained increase of ≥2g/dL from baseline that cannot 
be attributed to correction of iron deficiency
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WHO definition of ET requires all four major diagnostic criteria to be fulfilled: the presence of
a sustained thrombocytosis, defined as a platelet count of ≥450x109/L; the presence in the
bone marrow of megakaryocytic proliferation with increased numbers of mature forms and no
increase in immature granulocytic and erythroid precursors; no evidence of another myeloid
disorder, i.e. MF, myelodysplasia (MDS), CML or PV; and either the detection of a specific
clonal marker or no evidence of a reactive thrombocytosis.
Despite exhaustive studies, cytogenetic analysis of the Philadelphia-negative MPNs has not
yielded the same breakthrough as in CML, and so numerous other approaches have been
adopted to elucidate the pathogenic processes underlying them. The discovery that PV was
characterised by the presence of endogenous erythroid colonies (EECs) – progenitors which
proliferate in vitro in the absence of erythropoietin (EPO) – and that endogenous
megakaryocytic colonies were present in some cases of ET, raised the possibility that
aberrations in the regulation of haemopoiesis might contribute to their pathogenesis (see
section 1.3.4). Consequently, the major haemopoietic growth factors, EPO, granulocyte-colony
stimulating factor (G-CSF), and thrombopoietin (TPO) were systemically analysed for the
presence of genetic mutations, transcriptional defects and disruption of the normal
homeostatic mechanisms. Unfortunately, no abnormality proved sufficiently common or
specific to an individual disease to offer a major insight into its pathogenesis or be of
diagnostic value, with the exception of suppression of EPO in most cases of PV (Messinezy et
al, 1995). Similarly, the cell surface receptors with which these growth factors interact were
not found to harbour recurrent abnormalities in the majority of patients with acquired MPNs.
In the 1980s and 1990s, this failure to discover a common, specific cytogenetic or molecular
marker in the Philadelphia-negative MPNs prompted intense interest in the use of clonal
markers as an alternative means to identify the haemopoietic population involved in the
disease process (see section 1.3.5). Hypothesising that the disorders were initiated by a single,
transforming event in a myeloid precursor which then proliferated to generate a population of
Chapter 1
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phylogenetically related progeny, it was argued that an affected patient should have evidence
of clonal myelopoiesis, and it was hoped that this would be of diagnostic use. It soon became
apparent, however, that a proportion of patients with bona fide MPNs had polyclonal or
oligoclonal myelopoiesis.
The molecular pathogenesis of the Philadelphia-negative MPNs therefore remained obscure
for at least forty years after the discovery of the Philadelphia chromosome. Clinically, the
absence of a common cytogenetic or molecular marker hindered both diagnostic and
therapeutic advances. Distinguishing individuals with ET and PV from those with reactive
conditions was frequently a diagnostic challenge, and without a molecular lesion, designing
targeted drugs (an approach which proved so successful in CML) was impossible.
For these reasons, the identification in 2005 of a specific point mutation affecting exon 14 of
the JAK2 gene (JAK2 V617F) in a large proportion of patients with Philadelphia-negative MPNs
was greeted by great excitement in the field (section 1.3.7). This finding, it was hoped, would
finally explain the pathogenic process which gave rise to these disorders and revolutionise
their management, as the discovery of the Philadelphia chromosome had done in CML.
1.2 Physiological megakaryopoiesis and platelet production
1.2.1 MK development and platelet biogenesis
Platelets play a key role in initiating haemostasis following vascular injury, and may also be
involved in wound healing, inflammation and the innate immune response. They are small
(3.0µm by 0.5µm), discoid anucleate cells, rich in cytoskeletal and signalling proteins, which
are produced by budding from their precursor cell, the MK (Hoffbrand et al, 2005).
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MKs are large (50-100µm diameter) cells, with a polyploid, multilobated nucleus. They arise in
the bone marrow from MK progenitor cells (burst-forming unit-MK, BFU-MK, colony-forming
unit-MK, CFU-MK, and high-proliferative potential-colony-forming unit-MK). These progenitors
are themselves derived from a common MK-erythroid progenitor (MEP) cell, which in turn
originates from the haemopoietic stem cell (HSC), via a common myeloid precursor (CMP)
(Adolfsson et al, 2005; Debili et al, 1996; Figure 1.1).
Figure 1.1 Haemopoietic cell differentiation pathway
Schematic representation of the principal stages in MK maturation, with some stages in the maturation
pathway of other haemopoietic cells also shown.
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During maturation, MKs undergo a number of specific changes which allow effective platelet
production. They greatly amplify their DNA content, up to 128N, by a process of endomitosis,
which results in cytoplasmic expansion and ribosomal proliferation, in preparation for the
rapid production of platelet-specific proteins (Patel et al, 2005). MK maturation is also
accompanied by the development of extensive internal membrane systems, continuous with
the plasma membrane (Behnke 1968; Nakao and Angrist 1968). These internal membrane
systems evaginate to form MK pseudopodial extensions called proplatelets, which then
fragment to produce platelets (Behnke 1969; Radley and Haller 1982). Before the proplatelets
form, large amounts of platelet-specific proteins are synthesised, and either transported to the
MK surface or loaded into granules derived from Golgi complexes (Heijnen et al, 1998). At the
same time, a dense tubular network and a system of channels called the open canalicular
network is created to facilitate granule release (Gerrard et al, 1976).
Under steady-state conditions MKs represent approximately one in 2000 nucleated bone
marrow cells; each one may release 1000-5000 platelets and in total around 2x1011 platelets
are formed every day (Kaushansky 2005; Trowbridge et al, 1984). However, in times of
increased platelet consumption (e.g. immune thrombocytopenia), the MK mass may increase
3-fold, with a corresponding increase in platelet production (Branehög et al, 1975). The
regulation of MK proliferation and platelet production is controlled by a complex system of
humoral factors, cell surface receptors, intracellular signalling pathways, and nuclear
transcription factors.
1.2.2 Hormonal regulation of megakaryopoiesis and thrombopoiesis
Interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF are
all important in the early stages of megakaryopoiesis, but the primary humoral regulator of
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megakaryopoiesis and thrombopoiesis is undoubtedly TPO, formerly known as the c-Mpl
ligand. TPO is critical for all stages of megakaryopoiesis and thrombopoiesis, from the survival
of HSCs to platelet formation, and even affects the haemostatic activity of mature platelets
(Kojima et al, 2001). TPO infusions markedly increase MK ploidy and number, and stimulate
platelet production (Kaushansky et al, 1994) whereas TPO-knockout mice have dramatically
reduced numbers of MK progenitors and are severely thrombocytopenic (de Sauvage et al,
1996). MKs cultured in vitro in the presence of TPO extend numerous proplatelets, which
structurally resemble those seen in vivo, and generate platelets which are functionally and
structurally similar to normal platelets (Choi et al, 1995; Cramer et al, 1997).
TPO is encoded by a gene on chromosome 3q26.3-3q27, and is initially synthesised as a 353
amino acid propeptide, which is subsequently modified to a heavily glycosylated 332 amino
acid functional protein. Under steady-state conditions, TPO is constitutively produced by the
liver and kidneys and secreted into the bloodstream (Lok et al, 1994). Following binding to its
receptor, c-Mpl on the surface of platelets and MKs, TPO is internalised and degraded (Fielder
et al, 1996). Consequently, its levels generally vary inversely with platelet and MK mass
(Emmons et al, 1996; Kuter and Rosenberg 1995). Of note, although endothelial cells also
express c-Mpl and have a 100-fold greater surface area than platelets and MKs combined, they
seem not to play a significant role in the regulation of serum TPO levels (Cardier and Dempsey
1998; Geddis et al, 2006).
In certain conditions, however, TPO levels are not inversely proportional to the platelet count.
In immune thrombocytopenia, characterised by immune-mediated platelet and MK
destruction, TPO levels may be near-normal (Houwerzijl et al, 2005; Kosugi et al, 1996),
possibly due to its uptake by the increased MK mass and the sequestered platelets. In other
circumstances, serum TPO concentrations may be influenced by factors outside this
autoregulatory loop: reactive thrombocytosis, commonly seen in inflammatory states, is often
accompanied by a rise rather than a fall in TPO levels, due primarily to IL-6 (an acute phase
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protein, secreted by macrophages, fibroblasts and endothelial cells in response to bacterial
infection and tissue damage) upregulating hepatic TPO synthesis (Hollen et al, 1991; Kaser et
al, 2001; Kishimoto 1989). TPO levels may also be inappropriately normal or elevated in ET
(discussed in section 1.3.3). Finally, during severe thrombocytopenia, additional TPO may be
expressed by bone marrow stromal cells, though the mechanism for this is poorly understood
(Sungaran et al, 1997).
1.2.3 Molecular signalling pathways involved in thrombopoiesis
TPO binds to c-Mpl on MKs, other haemopoietic precursors, and platelets, inducing
conformational changes in the receptor which initiate signal transduction. This TPO/c-Mpl
interaction plays a critical role in the regulation of both megakaryocytic and non-
megakaryocytic haemopoietic progenitors: c-Mpl knockout mice have a marked reduction in
MKs and are severely thrombocytopenic, but are also severely deficient in progenitors
committed to all haemopoietic lineages (Alexander et al, 1996). Like other type 1
haemopoietic growth factor receptors, such as the erythropoietin receptor (EPOR) and the
granulocyte-colony stimulating factor receptor (G-CSFR), c-Mpl is a single chain molecule
without intrinsic tyrosine kinase activity but instead binds and relies on the activity of a non-
receptor tyrosine kinase, Janus kinase 2 (JAK2).
In its unbound state, c-Mpl is expressed as a monomer on the cell surface (Horan et al, 1996;
Alexander et al, 1996). Ligand binding induces dimerisation of two adjacent receptors,
resulting in mutual cross-activation and activation of the bound JAK2 molecules (Kaushansky
2005). The activated JAK kinases initiate downstream signalling, by phosphorylating tyrosine
residues on the receptor itself and on intracellular intermediaries, in particular the signal
transducers and activators of transcription (STATs). STATs are critical for the survival and
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expansion of haemopoietic progenitors (Kirito et al, 2002a; Snow et al, 2002), both by inducing
transcription of anti-apoptotic genes such Bcl-xL (Kirito et al, 2002b), and by interacting with
the GATA family of transcription factors (TFs) (Ezoe et al, 2005).
In addition, JAK kinases can activate Ras and, by phosphorylating phosphoinositide 3-kinase
(PI3K), generate phosphoinositol3,4,5 triphosphate (PIP3). Both PIP3 and activated Ras inhibit the
pro-apoptotic TF forkhead box O (FOXO) 3a, via activation of its negative regulator Akt, and
thus promote MK survival (Geddis et al, 2001; Miyakawa et al, 2001; Nakao et al, 2008).
Phosphorylated Ras can also activate members of the mitogen-activated protein kinase
(MAPK) family, in particular the extracellular signal-regulated kinases (ERK) 1 and 2 which
induce MK maturation via activation of the Runt-related TF 1 (RUNX1) (Hamelin et al, 2006;
Rojnuckarin et al, 1999).
The resulting signalling cascade results in MK proliferation, growth and maturation, with
increased ploidy, and platelet maturation and release. Modulation of this cascade is provided
by simultaneous phosphorylation by JAK kinases of the suppressors of cytoplasmic signalling
(SOCS) proteins, and SHP1 and SHIP1 phosphatases, which block cell signalling, primarily by
inhibiting the phosphorylating activity of the JAK kinases (Kaushansky 2009; Figure 1.2).
1.2.4 Transcriptional control of megakaryopoiesis and thrombopoiesis
A number of TFs control MK development and thrombopoiesis, of which the best characterised
are GATA-1, RUNX1, hypoxia-inducible factor (HIF) and nuclear factor erythroid 2 (NF-E2).
GATA-1 is a zinc-finger protein which plays a critical role in all stages of megakaryopoiesis, and
MK progenitors from GATA-1-deficient mice show maturation arrest at the promegakaryocyte
stage (Shivdasani et al, 1997; Vyas et al, 1999). The role of GATA-1 in MK development is
mediated in part by its interaction with another TF, friend of GATA-1 (FOG-1) and GATA-1
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mutations which disrupt this association result in thrombocytopenia due to MK maturation
arrest, and anaemia (Muntean and Crispino 2005). GATA-1 also binds the TF RUNX1, resulting
in activation of MK promoters such as the αIIb integrin promoter (Elagib et al, 2003), and
upregulates expression of key genes involved in megakaryopoiesis and platelet assembly,
including those encoding the p45 subunit of NF-E2, c-Mpl, platelet factor 4 and a number of
platelet glycoproteins (Tsang et al, 1997; Vyas et al, 1999).
Figure 1.2 Principal JAK2-mediated MK signalling pathways
Following TPO binding, c-Mpl receptor dimerisation occurs, leading to JAK2 cross-activation and
activation of downstream signalling proteins, including STAT, RAS and PI3K. This results in MK
proliferation, growth and differentiation via induction of transcription factors such as the GATA family,
Bcl-xL and RUNX1 and inhibition of the pro-apoptotic transcription factor FOXO 3a.
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Like GATA-1, the TF HIF is important both in early and late megakaryopoiesis. It consists of two
subunits: HIF-1α, whose expression is regulated by TPO, and HIF-1β, which is stably expressed. 
By regulating expression of vascular endothelial growth factor (VEGF), which in turn supports
the survival of HSCs, HIF-1α is important in the very early stages of megakaryopoiesis (Kirito et
al, 2005). Further, HIF-1α controls production of stromal cell-derived factor-1 (SDF-1), a trophic 
factor which induces proliferation of MK progenitors, polyploidisation of MKs, cell migration,
and platelet production, and is therefore also involved in the later stages of megakaryopoiesis
(Ceradini et al, 2004; Lane et al, 2000).
The heterodimeric leucine-zipper protein NF-E2 is another TF which plays a crucial role in
terminal MK differentiation and platelet release, probably by regulating expression of several
genes which encode MK proteins required for thrombopoiesis, including thromboxane
synthase, β1-tubulin and Rab27b (Schulze and Shivdasani 2005). Loss of NF-E2 function does 
not markedly affect early MK differentiation, but results in disorganised internal membranes,
severely impaired proplatelet formation and platelet release, and profound thrombocytopenia
(Lecine et al, 1998).
1.3 ET – pathology and clues to pathogenesis
1.3.1 Cytological and histological changes
Although blood from ET patients usually looks macroscopically normal, using even low-power
microscopy the thrombocytosis becomes obvious (Figure 1.3). Platelet anisocytosis may be
evident, ranging from tiny forms to giant platelets, but frank morphological abnormalities are
rare (Hehlmann et al, 1988). Histologically, the bone marrow cellularity varies from normal to
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moderately hypercellular for age with a marked proliferation of large and giant MKs, which are
characteristically arranged in loose clusters. They typically have deeply lobulated and
hyperlobated nuclei, and abundant mature cytoplasm. Expansion of the myeloid and erythroid
compartments and reticulin fibrosis are not prominent in ET (Thiele et al, 1999).
Ultrastructurally, ET platelets show defective pseudopod development (finger-like projections
which appear following platelet activation at the site of vessel injury), reduced concentrations
of alpha granules and abnormal tubular systems (Barnhart et al, 1980; Tablin et al, 1989). Such
morphological changes might explain the impairment in platelet aggregation frequently seen
in ET patients, who characteristically exhibit a reduced response to adrenaline stimulation
(Avram et al, 2001; Hehlmann et al, 1988; Tsantes et al, 2010). Electron microscopy of ET MKs
reveals a loss of the cytoplasmic organisation seen in normal MKs. In particular, there is a
marked disturbance of the membrane systems, which are greatly increased in amount,
disordered, vesiculated, and do not form the clearly-delineated platelet fields required to form
normal proplatelets (Tablin et al, 1989).
A B
Figure 1.3 Peripheral blood smear from a patient with ET and from a
haematologically normal control
A. Patient with ET. B. Haematologically normal control
Arrows indicate platelets
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1.3.2 Cytogenetics
Cytogenetic abnormalities are uncommon in ET, present in up to 7% of cases, and none are
specific to the disease (Bacher et al, 2005; Sessarego et al, 1989). The most frequent
abnormalities include trisomy 8 and 9, deletions in 13q and 20q (Case Jr 1984; Gangat et al,
2009), and abnormalities of chromosome 1 (Gangat et al, 2009). Recent single-nucleotide
polymorphism (SNP) microarray analysis has also failed to demonstrate the presence of
recurrent genomic deletions or amplifications (Kawamata et al, 2008; Stegelmann et al, 2010),
although occasionally acquired loss of heterozygosity affecting the short arm of chromosome 9
(9pLOH) has been identified in ET patients (Kralovics et al, 2003; Kralovics et al, 2005). The
presence of cytogenetic abnormalities appears not to affect prognosis in ET (Gangat et al,
2009) and their role in the pathogenesis of the disorder is uncertain.
1.3.3 TPO levels and c-Mpl expression
A number of studies have demonstrated that, in ET, serum TPO levels are similar or elevated
compared to normal controls (Table 1.2), which contrasts with the situation in PV, where levels
of the principal regulator of erythropoiesis, EPO, are usually suppressed (Johansson et al, 2002;
Mossuz et al, 2004). The reason why TPO is not suppressed in ET has not been convincingly
elucidated. In reactive thrombocytosis, the increased hepatic TPO synthesis is due to elevated
IL-6 levels (Hollen et al, 1991; Kaser et al, 2001). In ET, however, serum IL-6 levels are either
normal (Hollen et al, 1991; Panteli et al, 2005) or suppressed (Griesshammer et al, 1998;
Tefferi et al, 1994).
One hypothesis is that the c-Mpl-mediated internalisation/degradation mechanism which
underpins normal TPO autoregulation is defective in ET. Horikawa et al (1997) found that
surface c-Mpl expression on platelets from all 17 ET patients studied was dramatically lower
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than on normal control samples, with correspondingly lower c-Mpl mRNA expression.
Subsequent studies have largely confirmed these findings, but with some variation: Li et al
(2000) observed a 10-fold reduction in c-Mpl surface expression in ET platelets; Harrison et al
(1999b) reported a less marked (but still significant) difference, with overlap between ET,
other MPNs, and reactive thrombocytosis; Moliterno et al (1998), however, found no
difference between the ET patients and normal controls. A similar downregulation in surface c-
Mpl expression has also been described in ET MKs (Mesa et al, 2002). Of note, in the 23 ET
patients reported by Li et al (2000) whose TPO levels were similar to normal controls, the
reduction in platelet c-Mpl expression was accompanied by a four-fold decrease in platelet-
mediated TPO clearance. Such a reduction in TPO clearance might explain its elevated levels in
some patients with ET, and account for their thrombocytosis. In a murine model, suppression
of c-Mpl expression resulted in a dramatic thrombocytosis (Tiedt et al, 2009).
Another possible explanation for the elevated TPO levels seen in ET is that transcriptional or
translational regulation of TPO synthesis is defective. Mutations in the 5’-untranslated region
(5’-UTR) or a splice donor site in intron 3 of the TPO gene have been identified in four families
with familial thrombocythaemia (FT; Table 1.3A). In haematologically normal individuals, a
number of upstream open reading frames (uORFs) located within the 5’-UTR inhibit translation
of TPO mRNA (Ghilardi et al, 1998); the mutations observed in FT reduce this uORF-mediated
inhibition, resulting in excessive TPO protein synthesis and thrombocytosis. Equivalent
abnormalities in patients with sporadic ET have not, however, been identified (Allen et al,
2001; Harrison et al, 1998).
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1.3.4 Growth factor hypersensitivity in ET progenitors and possible causes
Another hypothesis put forward to explain excessive platelet production in ET, especially in
patients whose TPO levels are not elevated, is that the progenitors are hypersensitive to TPO,
or even proliferate in its absence. The existence of EECs in PV is well described (Prchal and
Axelrad 1974; Zanjani et al, 1977) and represents a minor diagnostic criterion in the latest
WHO classification (Swerdlow et al, 2008; Table 1.1). Indeed, the presence of EECs has been
described in some ET patients (Juvonen et al, 1987; Partanen et al, 1983), though its
significance is unclear. It is possible that it may be an artefact caused by growth factor
secretion by contaminating T-cells, or that the majority of patients with a thrombocytosis and
EECs actually have PV masked by iron deficiency (Shih and Lee 1994).
A number of studies have demonstrated the presence of endogenous MK colonies (EMCs) in
ET (Battegay et al, 1989; Juvonen et al, 1987), though the rate varies between 63% (Florensa et
al, 1995) and 100% of cases (Mi et al, 2001). Although EMCs have not been reported in
reactive thrombocytosis (Dobo et al, 2004; Rolovic et al, 1995), they have been detected in
between 33% and 95% of PV patients (Escoffre-Barbe et al, 2006; Mi et al, 2001), indicating
that they are not specific to ET. Moreover, it has been suggested that components of the
‘serum-free media’ used to screen for EMCs (e.g. albumin) may in fact have been
contaminated by serum, and that the ‘spontaneous’ megakaryocytic growth actually
represented progenitor hypersensitivity to TPO (Axelrad et al, 2000). Indeed, Axelrad et al
(2000) did demonstrate that megakaryocytic progenitors in ET were on average 53-times more
sensitive to TPO than were those from normal controls, findings which have been confirmed
by subsequent studies (Kawasaki et al, 2001; Mi et al, 2001). Axelrad et al (2000) went on to
speculate that progenitor hypersensitivity to regulatory cytokines might exist in every MPN,
and that the lineage of the hypersensitive progenitor determined the phenotype.
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The observation that transforming factor beta 1 (TGF-β1), a platelet and MK-derived cytokine, 
was involved in the negative regulation of megakaryopoiesis in mice (Ishibashi et al, 1987)
prompted speculation that defects in this pathway might be responsible for the presence of
EMCs in ET. In keeping with this, Zauli et al (1993) demonstrated that megakaryocyte
progenitors in ET were less sensitive to TGF-β1 than those from healthy controls. It is possible 
that this effect is mediated by the TF NFI-B: increased NFI-B has been associated with 9pLOH in
some MPN patients (the gene encoding NFI-B is located on chromosome 9p), and in a murine
model overexpression of this gene resulted in TGF-β insensitivity (Kralovics et al, 2002). A
subsequent larger study by the same group, however, refuted the association between 9pLOH
and increased NFI-B expression and attributed their earlier findings to chance (Kralovics et al,
2003).
Another hypothesis to explain TPO hypersensitivity in ET was that that myeloid progenitors in
this disease secreted TPO, generating an autocrine feedback loop. This, however, was refuted
by the finding that CD34+ cells only express TPO mRNA at very low levels, and that addition of
a neutralising antibody to TPO did not affect EMC activity (Taksin et al, 1999). The same group
and others also investigated the possibility that the activating mutations in c-Mpl observed in
FT (Table 1.3B), might also account for the thrombocytosis and autonomous MK proliferation
seen in sporadic ET. Two groups therefore sequenced the entire coding region of the gene in a
total of 19 patients with non-familial ET, but no mutations were detected (Kiladjian et al, 1997;
Taksin et al, 1999). Subsequent technical advances have allowed larger number of patients to
be screened and mutations in the gene encoding c-Mpl have since been identified in
approximately 5% of ET patients (see section 1.3.8).
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1.3.5 Clonality in ET
Dameshek’s original hypothesis for the aetiology of the MPNs suggested that myeloid
proliferation occurred in response to a myelostimulatory factor (Dameshek 1951), but he did
not speculate on whether the proliferating myeloid cells were derived from a single
haemopoietic progenitor or many – i.e. whether it was a monoclonal or polyclonal process.
This distinction is of fundamental importance to our understanding of the diseases, since
monoclonality is a characteristic feature of neoplastic disorders. Although the Philadelphia
chromosome was subsequently detected in most patients with CML (Nowell and Hungerford
1960), in keeping with it being a monoclonal disease, no equivalent abnormality was apparent
in the majority of PV and ET patients.
In order to address the issue of clonality in the MPNs, Fialkow et al (1967) pioneered the use of
X-chromosome inactivation pattern (XCIP) analysis. This technique exploits the cellular
mosaicism present in most females (with regard to X-chromosome inactivation) to determine
whether a cell population has arisen from a single progenitor without requiring the presence
of a specific disease marker. Seminal works by Lyon et al (1961) and Beutler et al (1962) had
shown that in females one X-chromosome is randomly inactivated in every cell during
embryogenesis in order to maintain comparable X-linked gene dosage with males. Mohendas
et al (1981) subsequently demonstrated that the mechanism for this X-chromosome
inactivation was methylation. By a process of imprinting, all progeny of these cells inactivate
the same X-chromosome as their original progenitor.
In normal polyclonal haemopoiesis one would, therefore, expect some blood cells to inactivate
the maternal X-chromosome, and others to inactivate the paternal X-chromosome, since the
probability of every stem cell in the original pool inactivating the same X-chromosome by
chance is small. By contrast, if a particular population of cells is clonal and has arisen from a
single transformed precursor, every cell in that population will inactivate the same X-
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chromosome, and the XCIP for the whole population will be ‘skewed’ if the clonal population is
large enough.
In order to determine the XCIP of a tissue or population of cells it is necessary to distinguish
between the maternal and the paternal X-chromosome, and between the active and the
inactive X-chromosome. The first criterion requires that the individual is heterozygous for an X-
linked gene or allelic marker, such as a tandem repeat sequence. The second involves either
measuring the relative expression (at the mRNA or protein level) of each X-linked allele for
which the individual is heterozygous, or analysing their DNA methylation patterns.
Using this approach, Fialkow et al (1967) investigated the clonality of granulocytes from three
CML female patients who were heterozygous for isoenzymes of the X-linked gene glucose-6-
phosphate dehydrogenase (G6PD). In all three patients, only a single G6PD isoenzyme was
detectable in their granulocytes whereas both isoenzymes were detected in their fibroblasts,
and the authors concluded that this implied that CML was a clonal disease. Whether the same
was true for ET was not investigated until 1981, when the same group studied three ET female
patients who were also heterozygous for isoenzymes of G6PD. In two patients, only a single
G6PD isoenzyme was detectable in all erythrocytes, granulocytes and platelets, whilst in the
third patient there was evidence of 95% skewing towards one isoenzyme which had become
100% four months later, a finding which was interpreted as evidence for myeloid clonality in
ET. Several other groups subsequently confirmed these observations (Gaetani et al, 1982;
Singal et al, 1983), though patient numbers in these early protein-based studies were limited
by the relatively low frequency of G6PD isoenzyme heterozygosity in individuals of non-African
ancestry.
Evaluation of much larger cohorts, however, was made feasible by the development of DNA
methylation-based approaches to XCIP analysis, allowing approximately 50% of females to be
analysed using polymorphic sites within the X-linked genes phosphoglycerate kinase and
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hypoxanthine-guanine phosphoribosyltransferase (Vogelstein et al, 1985; Vogelstein et al,
1987). The proportion of evaluable females was further increased by the analysis of other X-
linked loci, such as the highly polymorphic variable number tandem repeat (VNTR) sequences
in the DXS255 locus and the human androgen receptor (HUMAR) gene, for which more than
90% of females are polymorphic (Allen et al, 1992; Boyd and Fraser 1990; Gale et al, 1992;
Lucas et al, 1989; Tsukamoto et al, 1994). In addition, PCR rather than Southern blotting-based
analysis allowed assessment of smaller amounts of tissue (Gilliland et al, 1991).
An alternative approach to the XCIP analysis involves assaying the transcribed mRNA products
of an X-linked gene. Early studies exploited a polymorphism in the G6PD gene, different from
that used in protein-based clonality studies and more frequently informative, to distinguish
between the maternal and paternal X-chromosomes (Curnutte et al, 1992; Prchal and Guan
1993). Subsequently a number of genes, including iduronate-2-sulfatase, MPP1 and FHL-1,
have proved useful in transcription-based clonality analysis, allowing over 95% of females to
be evaluated (Gregg et al, 2000; Liu et al, 2003; Luhovy et al, 1995).
Use of XCIP-based clonality analysis in ET expanded rapidly in the 1990s as a result of these
technical advances. Initial studies were often interpreted as confirming the results of the
earlier protein-based assays – that ET was a clonal disorder – even though some ET patients
appeared to have non-clonal myelopoiesis (Anger et al, 1990; Kassar et al, 1995; Lucas et al,
1989; Tsukamoto et al, 1994). With increasing use of the technique, however, a number of
limitations and caveats became apparent. First, it cannot be used to investigate males, or
indeed females who are not heterozygous for an X-linked marker gene. Since about 70% of ET
patients are female (Jensen et al, 2000), and approximately 90-95% of these are informative
for an X-linked marker, at most about two-thirds of ET patients are evaluable using XCIP
analysis.
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Second, the XCIP only describes the overall clonality pattern for the entire cell population
analysed; even if the XCIP of the clonal cells is grossly imbalanced, the presence of non-clonal
cells (where the XCIP would be expected to be more balanced) will diminish the degree of
skewing of the overall population. To accommodate this, the minimum X-allele inactivation
ratio which most studies use to define clonality is 75%:25% – i.e. the degree of inactivation of
one allele is at least 3-fold greater than the other (Vogelstein et al, 1987). Even so, a small
clone within a large polyclonal population may be missed (Levine et al, 2006).
Third, since the XCIP is established early in embryogenesis in a small pool of haemopoietic
stem cells, extreme skewing may occur by chance (Gale et al, 1991; Gale et al, 1993). It has
been estimated that degree of X-chromosome inactivation commonly used to define clonality
(75%:25%) would arise purely by chance in 18% of individuals if XCI occurred in a haemopoietic
stem cell pool consisting of eight cells (Gale and Linch 1994). An apparently clonal pattern in
myeloid cells may, therefore, reflect an imbalanced constitutional pattern, and would not
necessarily indicate the presence of an abnormal population – a phenomenon termed
constitutional skewing. T-cells arise from the same haemopoietic stem cell as myeloid cells and
are assumed to have the same constitutive XCIP. They are not believed to be involved with the
abnormal clone in ET. Using the patient’s T-cell XCIP as a control, therefore, allows individuals
with constitutional skewing to be identified.
Finally, elderly women may appear to have a clonal XCIP even in the absence of a
haematological disorder, a consequence of ‘age-related’ skewing. Busque et al (1996)
observed that 38% of haematologically normal elderly females (≥60 years old) had an 
apparently clonal XCIP, compared to 16% of younger adults, and Gale et al (1997) reported
equivalent figures of 56% in elderly female controls (≥75 years old) compared to 22% in 
younger women. T-cell clonality does not correlate well with myeloid clonality in elderly
women and a balanced T-cell XCIP does not, therefore, reliably exclude the presence of this
phenomenon (Gale et al, 1997). Consequently, an imbalanced myeloid XCIP in an elderly
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woman does not necessarily imply the presence of a clonal myeloid population and such a
result cannot be meaningfully interpreted – a significant limitation in a disease which
predominantly affects older people. The finding of a balanced XCIP, however, does indicate the
presence of polyclonal myelopoiesis, regardless of age.
Taking all these caveats into account, in order to fulfil the criteria of clonal myelopoiesis the
patient must be younger than 65 years and have a myeloid XCIP which shows more than 75%
inactivation of one allele, which is also at least 20% different from the control (T-cell) XCIP.
As these refinements to the interpretation of XCIP analysis became better understood in the
late 1990’s, a number of studies were published which suggested that a proportion (between
31% and 57%) of ET patients did not have evidence of clonal haemopoiesis (Table 1.4). This
finding was of great significance since it contradicted the notion that ET was invariably a clonal,
neoplastic disorder. The suggestion that ET was a heterogeneous disease was supported by the
observation that the rate of vascular events was influenced by clonality status: of the four
studies which examined the clinical associations of myeloid clonality, two found that patients
with clonal haemopoiesis appeared more likely to suffer a thrombotic complication during
their illness than those without (Chiusolo et al, 2001; Harrison et al, 1999a), whilst the other
two found no significant difference (El-Kassar et al, 1997; Shih et al, 2002).
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1.3.6 PRV-1 expression
Whilst XCIP analysis undoubtedly advanced our understanding of the clonal origins of ET, the
specific molecular defects which initiated the MPNs remained obscure. In an attempt to
identify these abnormalities, Temerinac et al (2000) analysed differences in gene expression
between MPN and normal cells. Using subtractive mRNA hybridisation in neutrophils from 19
PV and six ET patients, and 21 normal controls, they demonstrated overexpression of a novel
gene which they called polycythemia vera-1 (PRV-1) in all PV patients and two ET patients.
Since PRV-1 mRNA was not detectable in any normal controls, it was hoped that PRV-1 analysis
would be useful diagnostically. PRV-1 encodes a granulocyte cell surface receptor – the antigen
CD-177 – the function of which is unknown. Surprisingly, despite overexpression of PRV-1
mRNA, protein expression was not elevated in most PV patients (Klippel et al, 2002).
Although a subsequent study found PRV-1 overexpression in all 37 ET patients investigated
(Teofili et al, 2002), later studies found lower rates of PRV-1 overexpression in ET patients –
between 17% and 67% (Griesshammer et al, 2004; Kralovics et al, 2003; Liu et al, 2003; Tefferi
et al, 2004). Taking all the reports together, 69 of 114 (61%) ET patients were PRV-1 positive
(Table 1.5), although the lack of a standard definition for PRV-1 positivity or overexpression
makes direct comparison between the seven studies difficult. Two studies found that PRV-1
overexpression was strongly associated with EEC formation, usually a hallmark of PV
(Griesshammer et al, 2004; Kralovics et al, 2003). Combined with the observation that 40% of
PRV-1 positive ET patients went on to develop PV, this association led to speculation that PRV-
1 positive ET patients actually had ‘masked’ PV (Griesshammer et al, 2004). Interest in PRV-1,
however, was soon largely overshadowed by a more significant discovery.
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1.3.7 JAK2 V617F
In 2005, five groups independently reported a recurrent G>T transversion in exon 14 of the
gene encoding JAK2, resulting in a valine-to-phenylalanine substitution in residue 617 (JAK2
V617F) in patients with MPNs (Table 1.6). Three different routes led the five groups to
investigate JAK2. James et al (2005) had previously observed that impairing JAK2 activity using
a tyrosine kinase inhibitor reduced EEC formation (Ugo et al, 2004). Kralovics et al (2002; 2003)
had reported that approximately 30% of PV patients and one of the 15 ET patients studied had
9pLOH – i.e. acquired uniparental disomy involving the short arm of chromosome 9 as a result
of mitotic recombination. In their 2005 study, high-definition mapping identified a 6.3Mbp
region on chromosome 9p common to all patients which included JAK2 (Kralovics et al, 2005).
The other three groups analysed JAK2 as part of a systematic tyrosine kinase mutation screen
(Baxter et al, 2005; Levine et al, 2005; Zhao et al, 2005).
At least 16 other studies have subsequently examined the frequency of JAK2 V617F in ET, with
rates ranging between 23% and 75%, and an overall mean of 53% (Table 1.7). Some of this
variation is due to methodological differences, since direct sequencing is less sensitive than
allele-specific polymerase chain reaction (AS-PCR) or PCR-restriction enzyme digestion
approaches (Campbell et al, 2006b), and some may be due to different stringencies in applying
the diagnostic criteria. In most studies which have looked for it, JAK2 V617F has not been
identified in normal controls (Table 1.6), though one study of nearly 4000 Chinese hospitalised
patients not known to have an MPN did detect it in about 1% of individuals (Xu et al, 2007).
This study used nested PCR to increase its sensitivity, however, and it is possible that this
increased the risk of false-positivity due to contamination.
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Table 1.7 Frequency of JAK2 V617F in ET – published studies to date
Reference n Mutated (n) Mutationfrequency (%)
Method*
(Levine et al, 2005) 21 9 43 PCR sequencing
(Kralovics et al, 2005) 93 21 23 PCR sequencing
(Levine et al, 2005) 115 37 32 PCR sequencing
(Baxter et al, 2005) 51 29 57 AS-PCR
(Jones et al, 2005) 59 24 41 ARMS-PCR
(Jelinek et al, 2005) 10 3 30 Pyrosequencing
(Goerttler et al, 2005) 42 14 33 PCR sequencing (cDNA)
(Campbell et al, 2005) 776 411 53 AS-PCR and PCR-enzymedigestion
(Vizmanos et al, 2006) 243 151 62 AS-PCR
(Cheung et al, 2006) 60 29 48 AS-PCR
(Kiladjian et al, 2006) 44 19 43 Real-time AS-PCR
(Lippert et al, 2006) 60 45 75 AS- and q-real time-PCR
(Moliterno et al, 2006) 84 38 45 qPCR
(Gale et al, 2007) 111 43 39 PCR-enzyme digestion
(Larsen et al, 2007) 40 21 53 qPCR
(Kittur et al, 2007) 176 96 55 AS-qPCR
(Alvarez-Larran et al,
2007) 103 44 43 AS-PCR
(Vannucchi et al, 2007) 639 382 60 AS-PCR
(Lieu et al, 2008) 49 29 59 PCR-enzyme digestion
(Shen et al, 2009) 85 53 62 ARMS-PCR
(Palandri et al, 2009b) 275 176 64 PCR-enzyme digestion
(Hussein et al, 2009) 91 43 47 Pyrosequencing
(Pardanani et al, 2010) 226 118 52 AS-PCR
(Wong et al, 2010) 102 35 34 PCR-enzyme digestion
Overall 3555 1870 53
* AS-PCR = allele-specific PCR
ARMS-PCR = amplification refractory mutation system PCR;
qPCR = quantitative PCR
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In ET patients whose myeloid cells carry JAK2 V617F, the mutation is not detectable in
constitutional control tissue, such as buccal or hair follicle cells (Baxter et al, 2005; Kralovics et
al, 2005; Levine et al, 2005), in keeping with it being a somatically acquired mutation. Further,
the majority of studies suggest that such patients’ T-lymphocytes are negative for the
mutation, implying it is restricted to the myeloid lineage and that it arose in a myeloid
progenitor cell rather than a haemopoietic stem cell (Baxter et al, 2005).
As described in Section 1.2.3, JAK2 is a non-receptor tyrosine kinase which binds to type 1
haemopoietic growth factor receptors and initiates downstream signalling when ligand binds
to the receptor. JAK2 shares a common domain structure with other JAK family members
(JAK1, JAK2 and TYK2): a C-terminal kinase domain (JAK homology 1, JH1), adjacent to which is
a pseudokinase domain (JH2) which bears significant homology to JH1 but is enzymatically
inactive and is predicted to negatively regulate the activity of JH1 in the absence of receptor-
bound ligand, an SH2 domain (JH3-4) of unknown function, and an N-terminal FERM domain
(JH5-7), which mediates binding to the Box1 domain of the receptor’s proximal
intracytoplasmic region (Haan et al, 2001; Haan et al, 2002; Lindauer et al, 2001; Pellegrini and
Dusanter-Fourt 1997; Richter et al, 1998). The V617F mutation is located in the JH2 domain of
the molecule, and its acquisition is believed to release the JH1 domains from their JH2-
mediated inhibition. Indeed structural modelling published in 2001 had predicted that residue
617 lay within one of two small but critical interaction sites through which the JH2 domain
mediated this inhibition (Lindauer et al, 2001); replacement of valine with bulky phenyalanine
would be expected to disrupt its inhibitory effect.
In keeping with this, transfection of JAK2 V617F into cytokine-dependent cell lines resulted in
cytokine independence, with evidence of JAK2 autophosphorylation and constitutive activation
of downstream pathways (James et al, 2005; Kralovics et al, 2005; Levine et al, 2005; Zhao et
Chapter 1
54
al, 2005). Transplantation of JAK2 V617F-transfected bone marrow cells into lethally irradiated
C57BL6 mice recapitulated the polycythaemic phenotype, often with leukocytosis,
thrombocytosis and some myelofibrotic features (Akada et al, 2010; James et al, 2005; Wernig
et al, 2006).
The role of JAK2 V617F in ET will be discussed in greater detail in Chapters 3, 4, 5 and 6.
1.3.8 Other genetic mutations in ET
In FT, a number of mutations have been described in the genes encoding TPO and c-Mpl (Table
1.3). Attempts to find similar abnormalities in sporadic ET, however, proved fruitless for many
years (Allen et al, 2001; Harrison et al, 1998; Kiladjian et al, 1997; Taksin et al, 1999), partly
because technological constraints limited the number of patients who could be screened. In
2006, Pikman et al (2006) sequenced selected exons of the genes encoding c-Mpl, EPOR and G-
CSFR in 125 JAK2 WT MPN patients (66 ET, 45 MF and 14 PV) and observed a MPL W515L
mutation in four cases of MF. Subsequent studies have demonstrated that MPL W515L
mutations do also occur in a small proportion of ET patients and other mutations have been
reported (Table 1.8). Overall, MPL mutations are detectable in approximately 4% of ET
patients, of whom 90% are JAK2 WT. For this reason, the MPL mutation frequency is markedly
higher in JAK2 WT than in V617F-positive patients (6% versus 1%). The commonest mutations
are W515L and W515K, which account for 70% and 27% respectively of the mutations so far
described, with other mutations being S505N (3%) and W515A (1%). Mutations affecting K39
and P106, reported in FT, have not been described in ET, although only two large-scale studies
(Beer et al, 2008; Pikman et al, 2006) have screened for mutations outside residues 505 and
515.
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Residues 505 and 515 lie within the transmembrane domain of c-Mpl, and mutations are
believed to disrupt a motif which normally prevents autonomous receptor activation, thereby
allowing receptor dimerisation in the absence of ligand (Glembotsky et al, 2010). MPL W515L-
transduced cell lines show cytokine-independent growth, hyper-responsiveness to TPO and
constitutive activation of the JAK/STAT signalling pathway (Pikman et al, 2006). In a murine
bone marrow transplant assay, expression of MPL W515L resulted in thrombocytosis,
leukocytosis, MK hyperplasia, and splenomegaly due to extramedullary haemopoiesis, a
phenotype similar to pre-fibrotic MF (Pikman et al, 2006).
Mutations in other genes have been reported infrequently in ET patients. In 2009,
Delhommeau et al (2009) reported on the presence of mutations in the ten-eleven
translocation 2 (TET2) gene for in a variety of myeloid disorders. They initially studied six
patients with AML who were known to have rearrangements involving chromosome 4q24.
FISH analysis revealed a commonly deleted region of chromosome 4 in three of these patients
and in a further three MDS patients analysed; this region contained only the TET2 gene. They
then screened five MPN patients for copy number alterations using comparative genomic
hybridisation and SNP arrays and in three of them identified a 325kb common region of LOH
on chromosome 4q; again this region contained only the TET2 gene. Direct sequencing of TET2
in eight of the patients with deletions or LOH at 4q24 revealed mutations in six of them: one
frame shift, one in-frame deletion, two nonsense mutations, and two amino acid substitutions.
Delhommeau et al (2009) then screened 203 MPN patients (of whom 186 were JAK2 V617F-
positive) for TET2 abnormalities, and of these 27 (13%) were found to harbour TET2
alterations. Thirty-one different TET2 mutations and one whole gene deletion were detected.
The mutations were scattered widely throughout the gene, without any apparent ‘hotspots’.
Twenty-five of the 27 TET2-mutated patients were JAK2 V617F-positive and in these
individuals colony analysis suggested that acquisition of TET2 mutations occurred prior to
acquisition of JAK2 V617F. Five patients had more than one mutation and cloning in one case
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confirmed that both TET2 genes were affected. Delhommeau et al (2009) therefore speculated
that TET2 was a tumour suppressor gene – i.e. loss of function due to biallelic mutations or a
single allele mutation and deletion of the non-mutated allele resulted in disease. The precise
function of TET2 remains obscure but TET1, with which it shares two domains, is known to play
a role in the epigenetic regulation of embryonic stem cells (Tahiliani et al, 2009).
A subsequent study identified TET2 mutations in only three of 57 (5%) ET patients (Tefferi et al,
2009) and again suggested TET2 may be associated with JAK2 V617F. The over-representation
of V617F-positive patients in the Delhommeau et al (2009) study may therefore help explain
the discrepancy in TET2 mutation frequency between the two reports.
A single study has recently identified mutations in the additional sex combs-like 1 (ASXL1)
gene, which is thought to be involved in regulating chromatin remodelling and is mutated in
approximately 10% of MDS patients and 40% of chronic myelomonocytic leukaemia cases
(Carbuccia et al, 2009). Of 35 ET patients studied, three had mutations in the gene (all
different), one of whom also carried JAK2 V617F and a TET2 mutation. ASXL1 mutations were
also present in three patients with MF. Like TET2, the function of ASXL1 is unknown, but the
authors suggested it too may be involved in epigenetic regulation and have a tumour
suppressor role.
1.4 Aims of the project
The studies reported in this thesis set out to examine the molecular origins of ET, and in
particular to investigate the role of JAK2 V617F in the pathogenesis of the disorder and its
relationship to the concept of clonality in ET. One of the major assertions made in relation to
the 2008 WHO classification of MPNs has been examined, specifically that ET, like the other
MPNs, is a clonal, neoplastic disorder.
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The clinical features of a cohort of ET patients and their correlation with a range of molecular
characteristics have been analysed (Chapter 3). Regulation of JAK2 WT and V617F-positive
platelets in V617F-positive ET has been examined in Chapter 4, in order to establish whether
the V617F-positive platelets expand at the expense of WT platelets, as might be expected in a
neoplastic disorder. A further series of experiments, reported in Chapter 5, sought to elicit
evidence for more than one clonal population in V617F-positive ET, and thereby determine
whether acquisition of JAK2 V617F occurred more than once. Finally, inherited factors
predisposing to the development of V617F-positive ET, specifically the 46/1 haplotype, are
examined in Chapter 6.
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2 Materials and Methods
2.1 Sample preparation
2.1.1 Reagents
 Ammonium chloride (Sigma-Aldrich, Gillingham, UK)
 Calcium- and magnesium-free phosphate buffered solution (PBS) (Invitrogen, Paisley,
UK)
 Chloroform (VWR International Ltd, Lutterworth, UK)
 Double de-ionised water (ddH20)
 DTAB (dodecyl-trimethyl-ammonium bromide) (Sigma-Aldrich, Gillingham, UK)
 Dynal CD3 beads (Invitrogen, Paisley, UK)
 EDTA (ethylenediaminetetraacetic acid) (Sigma-Aldrich, Gillingham, UK)
 Ethanol 100% (VWR International Ltd, Lutterworth, UK)
 Ficoll-Paque™ PLUS (GE Healthcare, Buckinghamshire, UK)
 Foetal calf serum (FCS), sterile filtered (Invitrogen, Paisley, UK)
 Giemsa stain 0.4% w/v in buffered methanol solution, pH 6.9 (Sigma-Aldrich,
Gillingham, UK)
 May-Grünwald stain 0.25% w/v in methanol (Sigma-Aldrich, Gillingham, UK)
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 Plastic whole blood tube with spray-coated K2EDTA, 4mL (BD, Oxford, UK)
 RPMI-1640 medium with L-glutamine (Invitrogen, Paisley, UK)
 Sodium chloride (VWR International Ltd, Lutterworth, UK)
 Tris (Hydroxymethyl) methylamine (VWR International Ltd, Lutterworth, UK)
 TRIzol™ (Invitrogen, Paisley, UK)
2.1.2 Buffers
 DNA lysis buffer: 20g DTAB (final concentration 8%), 22g NaCl (final concentration 1.5
M), 25 mLs of 1M Tris Cl pH 7.8 (100 mM). Made up to 250mL with ddH20.
2.1.3 Purification of neutrophils, platelets and T-lymphocytes
Neutrophils, platelets and T-lymphocytes were purified from peripheral blood prior to DNA
and RNA extraction (Figure 2.1). Peripheral blood was collected into 4mL tubes containing
EDTA and centrifuged for 15 minutes at 200g at room temperature. The upper three-quarters
of the plasma layer was harvested as platelet-rich plasma, pooled and spun for 15 minutes at
2000g. The supernatant was discarded and the pellet washed in 10mL calcium- and
magnesium-free PBS containing 10mmol/L EDTA and centrifuged for 15 minutes at 2000g at
room temperature. The washing process was repeated once more and the resulting platelet
suspension counted using a Sysmex KX21N whole blood cell analyser (Sysmex, Milton Keynes
UK). Aliquots of 5x109 platelets were then centrifuged for 15 minutes at 2000g at room
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temperature and the supernatant was carefully removed. The pellet was resuspended in 1mL
TRIzol reagent by repeated pipetting and stored at -80°C for RNA extraction.
The sample remaining in each tube after removal of the platelet rich plasma, comprised mostly
of erythrocytes and leukocytes, was made up to 4mL with calcium- and magnesium-free PBS
containing 10mmol/L EDTA, mixed and centrifuged for 5 minutes at 2000g. The buffy coat,
comprised mostly of leukocytes, was recovered from each tube and pooled. The samples
remaining in the 4mL tubes were re-mixed, spun again for 5 minutes at 2000g, and any
additional buffy coat recovered and pooled with the first harvest. The resulting buffy coat
suspension was made up to 14mL with calcium- and magnesium-free PBS containing
10mmol/L EDTA, layered onto 12mL Ficoll-Paque™ PLUS and centrifuged for 20 minutes at
800g at room temperature, with minimum acceleration and braking. Mononuclear cells were
then harvested from the interface, resuspended in 15mL RPMI containing 2% FCS (RF2%), and
spun for 5 minutes at 800g at room temperature. The supernatant was carefully removed and
the pellet resuspended in 10mL RF2%.
The suspension was counted using the Sysmex analyser to obtain the total leukocyte count. T-
lymphocytes were then purified from the mononuclear cell suspension using anti-CD3-coated
magnetic beads (4x105 beads/µL suspended in PBS containing 0.1% bovine serum albumin,
BSA, and 0.02% sodium azide). For every 1x106 leukocytes in the mononuclear cell suspension,
2.5µL (1x106) of magnetic beads were used. These were first washed by adding them to 10mL
RF2% in a reaction tube, shaking the mixture, and placing the tube against a magnet for 3
minutes. Without removing it from the magnet, the tube was inverted to discard the
supernatant, leaving only the washed beads in the tube which was then removed from the
magnet. The mononuclear cell suspension was added to the washed beads, the mixture
shaken, and incubated for one hour at 4°C with end-over-end rotation to allow the beads to
bind the CD3-positive T-lymphocytes. Following this, the CD3-negative fraction was removed
by placing the tube against the magnet for 3 minutes then pouring off the supernatant by
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inverting the tube whilst holding it against the magnet. The CD3-positive cells and beads
remained in the tube and were resuspended in 10mL fresh RF2% and the process repeated
twice, to produce a suspension of purified T-lymphocytes (bound to the beads) in 10mL RF2%.
To allow morphological analysis of their purity, aliquots of approximately 50,000 T-
lymphocytes were diluted to a total volume of 300μL with RF2% and used to prepare 
cytospins. The cytospin slides were stained using the May-Grünwald Giemsa technique: slides
were placed in May-Grünwald stain for 5 minutes at room temperature, transferred to dilute
Giemsa stain (1:20 in ddH20) for 20 minutes at room temperature, then rinsed with ddH20 and
allowed to air dry.
For RNA extraction, aliquots of 5x106 T-lymphocytes were spun for 5 minutes at 300g at 4°C,
the supernatant removed, the pellet resuspended in 1mL TRIzol reagent by repeated pipetting,
and stored at -80°C. For DNA extraction, aliquots of 15x106 T-lymphocytes were spun for 5
minutes at 800g at room temperature, the supernatant removed, the pellet resuspended in
2.5mL RF2%, and 5mL DTAB lysis buffer added. The mixture was shaken and incubated for 5
minutes at 68°C then stored at -20°C for at least 12 hours prior to DNA extraction.
To obtain purified neutrophils, residual Ficoll-Paque™ PLUS was removed after the MNCs had
been harvested, the pellet disrupted by vortexing, resuspended in 2.5mL PBS and 22.5mL 0.8%
ammonium choride solution added to lyse red blood cells. The suspension was vortexed and
incubated on ice for 15 minutes, then spun for 5 minutes at 800g, the supernatant removed,
and the pellet resuspended in 10mL RF2%. The neutrophil suspension was counted using the
Sysmex analyser.
Cytospin slides of the purified neutrophils were prepared as described above for T-
lymphocytes. The purified neutrophils were stored in TRIzol reagent for RNA extraction and in
DTAB lysis buffer for DNA extraction, as described above.
Chapter 2
64
2.1.4 RNA extraction
Samples stored in TRIzol reagent were thawed at room temperature and 0.2mL chloroform
was added. The mixture was shaken vigorously, incubated at room temperature for 3 minutes,
and spun for 15 minutes at 12,000g at 4°C. The aqueous upper phase of the resulting mixture
was transferred to a tube containing 0.5mL isopropyl alcohol, shaken, incubated at room
temperature for 10 minutes, then spun for 10 minutes at 12,000g at 4°C to precipitate the
RNA. The supernatant was carefully removed and 1mL 75% ethanol added. The mixture was
vortexed, spun for 5 minutes at 7,500g at 4°C, the supernatant removed, and the RNA pellet
allowed to air-dry for 10 minutes then suspended in 500µL ddH20. RNA samples were stored at
-80°C.
2.1.5 Genomic DNA extraction
Samples stored in DTAB were thawed at room temperature and 7.2mL chloroform was added.
The mixture was shaken vigorously and spun for 15 minutes at 3000g at room temperature.
The aqueous upper phase of the resulting mixture was transferred to a tube containing 8mL
absolute ethanol, shaken, then spun for 5 minutes at 1000g at room temperature to
precipitate the DNA. The supernatant was carefully removed and 2mL 75% ethanol added. The
mixture was shaken, spun for 5 minutes at 1000g at room temperature, and the supernatant
removed. The DNA pellet was allowed to air dry for 15-20 minutes, then suspended in 50-
300μL ddH2O depending on the size of the pellet and incubated overnight at 4°C with rotation.
The DNA concentration was measured using a NanoDrop ND-1000 UV-Vis spectrophotometer
(Thermo Fisher Scientific, Wilmington, USA), and working dilutions of 50ng/μL made. All DNA 
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samples were stored at 4°C.
2.2 Molecular biology
2.2.1 Reagents
 Acetonitrile (Transgenomic Ltd, Glasgow, UK)
 Agarose (Bioline, London, UK)
 10x Bioline ammonium buffer (Bioline, London, UK)
 Bioline magnesium chloride 50mM (Bioline, London, UK)
 BIOTAQ™ DNA polymerase 5u/µL (Bioline, London, UK)
 Bovine serum albumin (BSA) 10mg/mL (New England Biolabs, Hitchin, UK)
 Bromophenol blue (VWR International Ltd, Lutterworth, UK)
 Carbenicillin (Invitrogen, Paisley, UK)
 N,N-Dimethylformamide ≥99.8% (Sigma Aldrich, Gillingham, UK) 
 DNA size standard – PA400 (Beckman Coulter UK Ltd., Buckinghamshire, UK)
 dNTPs 100mM each (Bioline, London, UK)
 Ethidium bromide 10mg/mL (Invitrogen, Paisley, UK)
 Glycogen 20mg/mL (Sigma Aldrich, Gillingham, UK)
 GoTaq® DNA polymerase 5u/µL (Promega, Madison, USA)
Chapter 2
66
 GoTaq® Flexibuffer (Promega, Madison, USA)
 GoTaq® magnesium chloride 25mM (Promega, Madison, USA)
 Luria-Bertani (LB) broth tablets (Sigma Aldrich, Gillingham, UK)
 Nusieve low melting point agarose (VWR International Ltd, Lutterworth, UK)
 Olignucleotide primers (Integrated DNA Technologies, Leuven, Belgium)
 Optimase® reaction buffer (Transgenomic Ltd, Glasgow, UK)
 Optimase® magnesium sulphate 25mM (Transgenomic Ltd, Glasgow, UK)
 Optimase® DNA polymerase (Transgenomic Ltd, Glasgow, UK)
 Orthoboric acid (VWR International Ltd, Lutterworth, UK)
 peqGOLD MicroSpin Cycle-Pure PCR Purification Kit (Peqlab, Sarisbury Green, UK)
 5x Phusion® HF buffer containing MgCl2 7.5mM (New England Biolabs, Hitchin, UK)
 Phusion® Hot Start DNA Polymerase 2u/µL (New England Biolabs, Hitchin, UK)
 QIAquick™ Gel Extraction Kit (Qiagen, Crawley, UK)
 Restriction enzymes and buffers (New England Biolabs, Hitchin, UK)
 Sample loading solution (SLS) (Beckman Coulter UK Ltd., Buckinghamshire, UK)
 SDS (sodium dodecyl sulphate) (Sigma Aldrich, Gillingham, UK)
 3M sodium acetate pH 5.2 (Sigma-Aldrich, Gillingham, UK)
 Superscript™ III First-Strand Synthesis SuperMix for qRT-PCR kit (Invitrogen, Paisley,
UK)
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 TOPO TA Cloning® Kit with One Shot® MAX Efficiency™ DH5α-T1R E. coli competent 
cells (Invitrogen, Paisley, UK)
 Tri-ethylene ammonium acetate (TEAA) (Transgenomic Ltd, Glasgow, UK)
 Tris (Hydroxymethyl) methylamine (VWR International Ltd, Lutterworth, UK)
 X-Gal (Sigma Aldrich, Gillingham, UK)
2.2.2 Buffers
 10x TBE (pH8.3), for 1 litre: Tris 108.9g, orthoboric acid 55.7g, EDTA 7.4g
 Loading buffer: 30% glycerol, 0.025% bromophenol blue in 1xTBE
2.2.3 Polymerase chain reaction (PCR)
Four different DNA polymerases were used in the PCR experiments reported in this thesis. The
general reaction conditions for each polymerase are described below, and variations from
these for specific situations are described in the appropriate chapters. For every DNA
polymerase, a master mix containing all necessary reagents except DNA template was
prepared and aliquoted according to the number of samples prior to the addition of DNA
template. Thermal cycling was performed using a DNA Engine Tetrad 2 Peltier Thermal Cycler
(BioRad Laboratories, Hemel Hempstead, UK) using a ramping speed of 1.0°C/S unless
otherwise specified.
All oligonucleotide primer sequences are listed in Appendix 1.
Chapter 2
68
2.2.3.1 BIOTAQ™ PCR
BIOTAQ™, a non-proofreading Taq polymerase, was used for the majority of the experiments
reported in this thesis which did not require an enzyme with 3’ to 5’ exonuclease proofreading
properties.
A master mix was prepared containing 1x reaction buffer [final concentrations: 16mM
(NH4)2SO4, 67mM Tris-HCl, 0.01% Tween-20], 1mM MgCl2, 0.5μM each oligonucleotide primer, 
0.2mM each dNTP, 0.05unit/μL polymerase, and made up to the desired volume with ddH20.
To this mix, 2.5ng/μL template DNA was added. Cycling conditions were 30 seconds 
denaturation at 95°C, 30 seconds primer annealing at a temperature specific to the primers
used, and 30 seconds primer extension at 72°C, repeated between 22 and 40 times, depending
on the nature of the PCR (see specific methods). A final step of 5 minutes at 72°C was included
to ensure complete extension of the PCR products.
2.2.3.2 GoTaq® Hot Start PCR
GoTaq® is also a non-proofreading Taq polymerase, but differs from BIOTAQ™ polymerase in
that it is bound to a proprietary antibody which inactivates it until the reaction mixture is
heated to 94°C or above for 2 minutes, whereupon its activity is restored (‘hot start’ activity).
This minimizes non-specific DNA amplification at lower temperatures. GoTaq® polymerase was
therefore used when BIOTAQ™ polymerase generated multiple non-specific PCR products.
A master mix was prepared containing 1x Promega flexibuffer (proprietary formulation), 2mM
MgCl2, 0.05unit/μL GoTaq® Hot Start polymerase, 0.5μM each oligonucleotide primer, 0.2mM 
each dNTP, and made up to the desired volume with ddH20. To this mix, 2.5ng/μL template 
DNA was added. Following an initial incubation for 2 minutes at 95°C to activate the
polymerase enzyme, between 22 and 35 cycles of PCR were performed, each cycle comprising
a 30 second denaturation step at 95°C, a 30 second primer annealing step at a temperature
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specific to the primers used, and a 45 second primer extension step at 72°C. After the last
cycle, a final step of 5 minutes at 72°C was included to ensure complete extension of the
primers.
2.2.3.3 Optimase® PCR
Optimase® is a DNA polymerase with 3’ to 5’ exonuclease proofreading activity which was
used when high-fidelity PCR amplification was required, most commonly to generate products
for analysis by denaturing high-performance liquid chromatography (dHPLC).
A master mix was prepared containing 1x reaction buffer (proprietary formulation), 1.5mM
MgSO4, 0.05unit/μL Optimase® polymerase, 0.5μM each oligonucleotide primer, 0.2mM each 
dNTP, and made up to the desired volume with ddH20. To this mix, 2.5ng/μL template DNA 
was added. Following an initial denaturation step of 5 minutes at 95°C, between 22 and 35
cycles of PCR were performed, each cycle comprising a 30 second denaturation step at 95°C, a
30 second primer annealing step at a temperature specific to the primers used, and a 60
second primer extension step at 72°C. After the last cycle, a final step of 5 minutes at 72°C was
included to ensure complete extension of the primers.
2.2.3.4 Phusion® PCR
Phusion® was used to generate PCR products from very low concentrations of template DNA
or cDNA (e.g. from old or degraded samples), especially when longer PCR products (>500bp)
were required. Like Optimase®, it is a proofreading polymerase, making it suitable for
applications such as dHPLC, and like GoTaq®, it has ‘hot start’ activity. It was generally used
when no satisfactory products could be obtained using one of the other DNA polymerase
enzymes.
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A master mix was prepared containing 1x HF buffer (proprietary formulation; contains MgCl2 at
a final concentration of 1.5mM), 0.02unit/μL Phusion® polymerase, 0.5μM each 
oligonucleotide primer, 0.2mM each dNTP and made up to the desired volume with ddH20. To
this mix, 2.5ng/μL template DNA was added. Following an initial denaturation/activation step 
of 2 minutes at 98°C, between 32 and 40 cycles of PCR were performed, each cycle comprising
a 42 second denaturation step at 98°C, a 42 second primer annealing step at a temperature
specific to the primers used, and a 60 second primer extension step at 72°C. After the last
cycle, a final step of 5 minutes at 72°C was included to ensure complete extension of the
primers.
2.2.4 Restriction enzyme digestion
Restriction enzymes were obtained from New England Biolabs. Genomic DNA or PCR products
were added to a mixture of the appropriate 1x reaction buffer, restriction enzyme, ddH20 and,
if necessary, 100μg/ml BSA, according to the manufacturer’s instructions, and incubated at the 
recommended temperature for 2-12 hours, according to manufacturer’s guidance.
2.2.5 Reverse-transcription PCR (RT-PCR)
Complementary DNA (cDNA) was generated from RNA by reverse transcription, using the
SuperScript™ III First-Strand Synthesis SuperMix for qRT-PCR kit. RNA concentration was
measured using the NanoDrop ND-1000 UV-Vis spectrophotometer, and 100ng-1μg of RNA 
was used as template. The RNA sample was made up to 8µL with ddH2O and added to a
mastermix containing 2µL RT enzyme mix (a proprietary formulation of SuperScript™ III
reverse transcriptase and RNaseOUT™ recombinant ribonuclease inhibitor) and 10µL 2x RT
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reaction mix (final concentration 5mM MgCl2, 1.25ng/µL random hexamers, 0.5mM dNTPs,
1.25µM oligo(dT)20 primers). The reaction mixture was mixed gently and incubated for 10
minutes at 25°C, followed by 30 minutes at 50°C, 5 minutes at 85°C, then chilled on ice.
Following the addition of 1µL E. coli RNaseH (2U/µL), the mixture was incubated for 20
minutes at 37°C. The resulting cDNA was stored at -80°C until needed and used in a 1 in 4
dilution as the template for PCR reactions.
2.2.6 Agarose gel electrophoresis
PCR products were visualised using agarose gels (1.5%-3.5%). Agarose (0.53-1.23g, depending
on desired gel concentration) was added to 35mL 1x TBE, dissolved by heating in a microwave
oven, and 3.5μL 1mg/mL ethidium bromide added. The gel was cooled, poured into a mould, 
allowed to set and immersed in 1x TBE containing 100ng/mL ethidium bromide running buffer.
PCR product or restriction enzyme digest was mixed with loading buffer (30% glycerol, 0.025%
bromophenol blue in 1xTBE), loaded into the wells and electrophoresed by the application of a
potential difference across the gel. The use of a DNA ladder allowed estimation of the PCR
product size. The gel was then placed on a UV transilluminator to visualise PCR products, and
digital images made.
2.2.7 Fragment analysis of PCR products and restriction enzyme digestion products
Fragment analysis was used to quantify the relative amount of multiple products generated by
PCR or following restriction enzyme digestion.
PCR was performed using one fluorescently-labelled primer and one unlabelled primer. The
DNA polymerase used varied according to the exact application, as did the number of cycles
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and the final concentration of each primer. Specific details are described in the appropriate
chapter. Where appropriate, PCR products underwent restriction enzyme digestion as
described in Section 2.2.4.
To perform fragment analysis, 2μL of the PCR or restriction enzyme digestion product were 
mixed with 0.5μL size standard and 38μL sample loading solution (deionised formamide), and 
run on the Beckman Coulter CEQ 8000 DNA Genetic Analysis System (Beckman Coulter UK Ltd.,
Buckinghamshire, UK). The instrument denatured the sample and separated the different PCR
products according to fragment length by capillary electrophoresis. Elution of each product
was detected by laser-induced excitation of its fluorescent label, and indicated by a peak at the
appropriate elution time on a graph generated by the supplied software. By reference to the
size standards, each product’s size was estimated by the software based on its elution time.
The area under the curve for each peak reflected the relative amount of each product, derived
by the software from the amplitude and duration of its fluorescence. The relative amount of
each product was calculated by expressing the area under the appropriate peak as a
proportion of the total area under all the peaks.
2.2.8 DNA sequencing
For DNA sequencing, PCR products were prepared and then purified using the peqGold micro-
spin cycle-pure kit. One volume PCR product was mixed with 10 volumes buffer CP (proprietary
formulation) then vortexed and the mixture applied to a PerfectBind DNA spin-column
assembled in a 2mL collection tube and spun for 2 minutes at 10,000g at room temperature.
The spin-column was transferred to a clean 1.5mL collection tube, 20µL DNA Elution Buffer
(proprietary formulation) applied to the column matrix and incubated for 5 minutes at room
temperature, then spun for 1 minute at 8,000g at room temperature to elute the purified PCR
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products into the collection tube. These were sequenced by the UCL Wolfson Institute for
Biomedical Research DNA sequencing service using an Applied Biosystems 3730xl 96-capillary
DNA analyser (Life Technologies, California, USA) with BigDye® 3.1 chemistry.
2.2.9 LB-carbenicillin culture medium and plates
For LB-carbenicillin culture medium, 12 LB medium capsules were dissolved in 500mL ddH20
and autoclaved, then cooled to approximately 60°C, and carbenicillin added to a final
concentration of 100μg/mL. For LB-carbenicillin-agar plates, 7.5g agar was added to the mix 
prior to autoclaving (final concentration 1.5% w/v); after the addition of carbenicillin the
medium was poured into Petri dishes, allowed to set for one hour, and stored at 4°C. Prior to
bacterial spreading, plates were incubated at 37°C for 30 minutes to dry, and spread with 40μL 
X-gal solution (40mg/mL X-gal in dimethylformamide), then incubated at 37°C for a further 30
minutes.
2.2.10 TA cloning
TA cloning allows individual PCR products to be analysed by ligating them into a plasmid which
is then transfected into competent bacteria and these are then cultured on LB-carbenicillin-
agar plates. Multiple, discrete bacterial clones are generated, each containing a PCR product.
The cloning studies reported in this thesis used the Invitrogen TOPO TA Cloning® Kit with One
Shot® MAX Efficiency™ DH5α-T1R E. coli. The plasmid vector in this kit has single 3’-thymidine
(T) overhangs, bound covalently to topoisomerase I, which allow efficient ligation of PCR
products generated using non-proofreading Taq polymerases as these add a single
deoxyadenosine (A) to the 3’ end of PCR products. Cloning was performed according to
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manufacturers’ instructions. Briefly, 1 to 4μL of fresh PCR product were added to 1μL salt 
solution and 1μL TOPO vector, made up with de-ionised water to 6μL, and incubated for 30 
minutes at room temperature. A vial of One Shot® Chemically Competent E. coli was thawed
on ice, 2μL of the ligated PCR product added, and incubated on ice for 30 minutes. Following 
incubation at 42°C for 30 seconds without shaking, the vial was transferred to ice, 250μL room 
temperature SOC medium added, and incubated at 37°C for 1 hour with shaking (200rpm).
Between 5μL and 50μL cell suspension was then spread on pre-warmed LB-agarose-
carbenicillin plates coated with X-gal (section 2.2.9), and the plates incubated at 37°C
overnight. Transformed colonies containing an inserted PCR product were identified by their
white or light-blue colour due to disruption of the lacZα gene in the pCR®2.1-TOPO® plasmid. 
Individual colonies were picked and expanded by incubation in LB-carbenicillin medium at 37°C
for 12 hours.
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3 Clinical and molecular characteristics of the ET
patient cohort
3.1 Introduction
Despite substantial improvements in our understanding of ET since it was first described over
75 years ago (Epstein and Goedel 1934), the diagnosis and management of the condition
remain challenging. Distinguishing between ET and other causes of thrombocytosis, such as
other MPNs, infection, bleeding, malignancy, iron deficiency, autoimmune inflammatory
disorders and hyposplenism, is often difficult and in many cases remains a process of
exclusion. Similarly, prognostication in ET can be challenging since ET is a heterogeneous
disorder and patients vary markedly in their clinical course. For some, ET represents a
relatively benign condition with a comparatively low risk of thrombosis and exerts little, if any,
effect on their life expectancy. For others, the disorder is associated with major morbidity –
such as life-threatening arterial and venous thromboses or haemorrhage – and premature
death. Since, in general, more aggressive disease justifies more intensive treatment, estimating
at diagnosis the risk of later complications is an essential part of deciding on appropriate
therapy. Considerable efforts have therefore been made to improve the diagnostic approach
to individuals with thrombocytosis, and then, in those with ET, to identify clinical and
pathological features which predict outcome.
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3.1.1 Diagnostic criteria for ET
Criteria for the diagnosis of ET were first proposed in 1975 by the PVSG (Berlin 1975). These
required the presence of a sustained platelet count exceeding 1000x109/L, a bone marrow
showing megakaryocytic hyperplasia without significant fibrosis or myelodysplasia, and the
absence of polycythaemia, CML, iron deficiency or a reactive cause for the thrombocytosis
such as infection, malignancy or an inflammatory process. Subsequent revisions of the PVSG
criteria have reduced the platelet threshold to 600x109/L (Table 3.1; Murphy et al, 1986;
Murphy et al, 1997). Despite claims that a threshold of 400x109/L would allow more ET
patients to be detected and treated (Sacchi et al, 2000), this cut-off was rejected, largely due
to concerns that some of the many patients with a reactive thrombocytosis of between
400x109/L and 600x109/L would be erroneously diagnosed with ET in the absence of a robust
means of distinguishing between the two conditions. Consequently the initial WHO diagnostic
criteria stipulated that patients must have a minimum platelet count of 600x109/L to be
diagnosed with ET (Jaffe 2001).
Table 3.1 PVSG Criteria for the diagnosis of ET
All seven criteria must be fulfilled to make a diagnosis of ET
1 Platelet count greater than 600 x 109/L
2 Haematocrit less than 40% or normal RBC mass
3 Stainable iron in the marrow or normal RBC mean corpuscular volume (If these measurements
suggest iron deficiency, PV cannot be excluded unless a trial of iron therapy fails to increase the
RBC mass into the polycythaemic range.)
4 No Philadelphia chromosome or BCR-ABL gene rearrangement
5 Collagen fibrosis of the bone marrow absent or less than one third of the biopsy area without
both marked splenomegaly and a leukoerythroblastic blood film
6 No cytogenetic or morphologic evidence for a myelodysplastic syndrome
7 No cause for a reactive thrombocytosis
From Murphy et al (1997)
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The discovery of JAK2 V617F and MPL mutations in approximately 50% and 5% respectively of
ET patients (Tables 1.7 and 1.8) had a significant impact on the diagnosis of ET. They both
facilitated the distinction between reactive thrombocytosis and ET and enabled identification
of a population of individuals with a mild thrombocytosis (below 600x109/L) who carried these
mutations and suffered the same thrombotic complications as ET patients with higher platelet
counts (Michiels et al, 2007). As a result, a reduction of the platelet threshold was once again
proposed (Tefferi et al, 2007) and on this occasion a lower value of 450x109/L was adopted by
the WHO in their revised 2008 criteria, shown in Table 1.1 (Swerdlow et al, 2008). The 2008
WHO classification requires the presence of MK hyperproliferation in the bone marrow, with
large, mature MKs and normal erythroid and myeloid precursors, and the exclusion of other
MPNs. Unlike previous criteria, it does not stipulate that reactive causes of a thrombocytosis
must be systematically excluded if a molecular marker (e.g. JAK2 V617F) is detected. The 2008
WHO classification is likely to become the most widely accepted diagnostic criteria for the
diagnosis of ET, and in the UK it has recently been incorporated into the British Committee for
Standards in Haematology guideline for the investigation of individuals presenting with a
thrombocytosis, although the diagnostic criteria in this guideline are subtly different from the
WHO ones in that they do not require that a bone marrow biopsy be performed if a molecular
marker is detected (Harrison et al, 2010).
3.1.2 Impact of clinical features at presentation on prognosis
In the 2008 WHO monograph, ET, along with the other conditions hitherto called
myeloproliferative disorders, was reclassified as a neoplasm (Swerdlow et al, 2008).
Nonetheless, in many patients – particularly older ones who comprise the majority of affected
individuals – the diagnosis of ET has little or no effect on life expectancy (Table 3.2). Bazzan et
al (1999) found that the life expectancy of older ET patients (>55 years at diagnosis) was
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similar to that of age-matched healthy controls, whereas that of younger patients was
shortened compared to controls. Although Mesa et al (1999) reported that the overall survival
of a small cohort of ET patients was poorer than that of age-matched controls, Passamonti et
al (2004) found that ET patients of all ages had a similar life expectancy to healthy controls.
Certainly, in the first 10 years following diagnosis, survival appears to be equivalent to controls
although it may be worse thereafter (Wolanskyj et al, 2006). The different findings of these
groups probably reflect differences in the composition of the patient cohorts they studied, and
a number of biological characteristics at diagnosis have now been identified which are
associated with inferior survival in ET (Table 3.2).
The most frequent complications observed in individuals with ET are thromboembolic, with a
historical rate of approximately 7% per patient-year following diagnosis (Cortelazzo et al,
1990), and a 10-year cumulative incidence (CI) of thrombosis of up to 42% (Wolanskyj et al,
2006), although this varies widely (see below). Treatment with cytoreductive agents has been
shown to reduce the rate of thromboembolic events in ET patients (see Section 3.1.4), but
there is concern that some of these agents may also increase the risk of leukaemic
transformation. For this reason, considerable efforts have been made to predict the relative
risks of thrombotic complications in order to select those patients who are most likely to
benefit from cytoreductive medications, and conversely to identify patients for whom such
treatment is not indicated (Table 3.3).
Two independent clinical risk factors – increasing age and prior history of thrombosis – are
now widely accepted to be associated with an increased rate of thromboembolic
complications in ET patients, although several other factors have also been proposed. In their
retrospective study of 100 ET patients, some of whom were treated with busulphan,
Cortelazzo et al (1990) observed that the average thrombotic rate in events per patient-year
varied markedly according to age: in individuals younger than 40 years it was 1.7%; in those
aged 40-60 years it was 6.3%; and in those older than 60 years it was 15.1%. The equivalent
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Table 3.2 Recent studies analysing life expectancy in ET
Reference n
Median
follow up
(years)
Median
survival
(years)
Risk factors
associated with
inferior survival
Overall survival compared to
aged-matched controls
(Bazzan et
al, 1999) 187 4.1
Not
reported None identified
Significantly worse for patients <55
years old at diagnosis: mortality
rate was 4.2x that of matched
controls, mostly due to
thrombosis. Note only 58% of
patients were on anti-platelet
agents
Life expectancy similar to controls
for patients > 55 years old at
diagnosis
(Passamonti
et al, 2004) 435 9.3 22.6
Prior thrombosis
Male sex Similar regardless of age
(Chim et al,
2005) 231
Not
reported 13
Age >60 at
diagnosis
Cigarette smoking
Not reported
(Wolanskyj
et al, 2006) 322 13.6 18.9
Age >60 at
diagnosis
Prior thrombosis
Diabetes mellitus
Cigarette smoking
WCC >15 at
diagnosis
Similar to controls in the first
decade after diagnosis, but
significantly worse thereafter
(Dan et al,
2006) 381 4.3
Not
reported
Age >60 at
diagnosis
Prior thrombosis
Similar to controls
(Gangat et
al, 2007) 605 7 18
Age >60 at
diagnosis
Prior thrombosis
Diabetes mellitus
Cigarette smoking
WCC >15 at
diagnosis
Anaemia
Not reported
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rate in a cohort of 200 haematologically normal controls was 1.2%. The thrombotic risk was
significantly higher than the controls in the oldest age group whereas in the two younger
categories the difference was not significant. A number of later reports also found that
increasing age was associated with an increased thrombotic risk (Besses et al, 1999; Carobbio
et al, 2007; Carobbio et al, 2008a; Shih et al, 2002; Wolanskyj et al, 2006) although none of
these had control arms and instead compared older ET patients with younger ones. Cortelazzo
et al (1990) also noted that ET patients who had had a prior thrombotic event were at
significantly higher risk of a subsequent thrombosis than those who had never had a
thrombosis (OR = 13, P < 0.0005), a finding corroborated by several other studies (Besses et al,
1999; Carobbio et al, 2007; Colombi et al, 1991b; Wolanskyj et al, 2006).
The role of vascular risk factors such as hypertension, diabetes mellitus (DM), hyperlipidaemia
and cigarette smoking in predicting the thrombotic risk in ET patients is uncertain. Whilst
Besses et al (1999) found that hypertension and hyperlipidaemia, but not DM or cigarette
smoking, were associated with an increased thrombotic rate, other studies have reported
contradictory results. Some have noted an increased thrombotic risk associated with cigarette
smoking alone (Jantunen et al, 2001), hypertension alone (Shih et al, 2002), or hypertension
and DM (Wolanskyj et al, 2006). Cortelazzo et al (1990) did not detect any association between
vascular risk factors and thrombotic risk.
Surprisingly, patients with the highest platelet counts seem not be at greatest risk of
thrombotic complications (Table 3.3). Indeed a recent study has suggested that moderately
elevated platelet counts (650-1000x109/L) are associated with the highest risk of thrombosis
(Carrobbio Blood 08), whereas patients with extreme thrombocytosis are most likely to suffer
haemorrhagic complications due to consumption of higher molecular-weight multimers of von
Willebrand factor (Budde et al, 1984; van Genderen et al, 1994; vanGenderen et al, 1996).
Recently, leukocytosis has been identified in a number of retrospective studies as a risk factor
for thrombosis (Barbui et al, 2009; Carobbio et al, 2008a; Carobbio et al, 2008b; Landolfi et al,
Chapter 3
83
2007; Wolanskyj et al, 2006), although other studies have suggested it is of more limited
prognostic value, being predictive only in younger patients (De Stefano et al, 2010), or of no
value at all (Gangat et al, 2009). Other proposed risk factors for thrombosis include leukocyte
activation and elevated haematocrit (Falanga et al, 2000; Wolanskyj et al, 2005).
Patients with ET are at increased risk of developing MF and AML compared to healthy controls,
athough the absolute risk remains low. The largest long-term follow-up study observed 435
patients (Passamonti et al, 2004) and found that the 15-year CI of developing MF and AML was
4% and 2% respectively, markedly lower than the incidence of thrombosis and solid tumours
(17% and 8% respectively). In a study of 386 patients, Palandri et al (2009a) reported the 10-
year CI of fibrotic and leukaemic transformation as 5% and 3% respectively, and Wolanskyj et
al (2006) reported equivalent figures of 4% and 1% in their study of 322 patients. Owing to the
rarity of these events, there is little data relating to the risk of fibrotic or leukaemic
transformation, although one study found that increasing age, anaemia, and a platelet count
exceeding 1000x109/L at diagnosis were associated with a higher incidence of leukaemic
transformation (Gangat et al, 2007).
3.1.3 Impact of molecular characteristics on prognosis
The role of molecular markers in predicting outcome in ET is less well-defined than in many
other haematological disorders. Nonetheless, a number have been proposed for use in
prognostication, specifically the presence of myeloid clonality by XCIP analysis, and JAK2 V617F
and MPL W505 mutational status.
XCIP analysis exploits the cellular mosaicism present in most females with regard to X-
chromosome inactivation to determine whether a cell population has arisen from a single
progenitor – i.e. whether the population is monoclonal (see Section 1.3.5). If all the constituent
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cells have inactivated the same X-chromosome, this is suggestive of a monoclonal population,
assuming there is no evidence of constitutional or age-related skewing. By contrast, if there is
a mix of inactivated X-chromosomes, this is suggestive of a polyclonal population. The XCIP
may also be predictive of outcome. Of the four studies which reported on the clinical
significance of the presence of a clonal myeloid population (Table 1.4), two observed that it
was associated with an increased thrombotic risk (Chiusolo et al, 2001; Harrison et al, 1999a).
It is worth noting, however, that in total these two studies reported 16 patients who suffered
thrombotic events, but in 14 of these (88%) the first event occurred at or prior to diagnosis;
consequently, these patients would be deemed high risk on clinical grounds alone, so whether
XCIP status provides additional useful prognostic information is uncertain.
Approximately 50% of ET patients carry the JAK2 V617F mutation (see Section 1.3.7), a finding
which has both facilitated the diagnosis of ET and prompted comparison between those
patients who harbour the mutation and those who do not. A number of studies have shown
that, compared to JAK2 WT ET patients, those who are V617F-positive tend to have higher
haemoglobin concentrations and lower platelet counts (Table 3.4). In these regards they more
closely resemble PV patients, who are almost invariably V617F-positive, than JAK2 WT ET
patients. It has, therefore, been argued that V617F-positive ET might represent a forme fruste
of PV. Loss of the full PV phenotype may be due to modifiers such as sex, iron stores,
erythropoietin levels, and the V617F mutant level (Campbell and Green 2006). PV is generally
believed to confer a higher thrombotic rate and poorer prognosis than ET (Cervantes et al,
2008; Passamonti et al, 2004) and the suggestion that V617-positive ET resembled it
immediately led to speculation that mutant-positive ET patients may have a worse outcome
than WT ones. Despite extensive research, it remains uncertain whether this is truly the case
(Table 3.5)
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A number of studies have suggested that, in ET, the presence of JAK2 V617F is associated with
an increased risk of thrombotic complications, either at diagnosis (Campbell et al, 2005), after
diagnosis (Kittur et al, 2007), or at any point (Cheung et al, 2006; Finazzi et al, 2007; Heller et
al, 2006; Ohyashiki et al, 2007) although in some reports the increased risk was confined to
younger patients (De Stefano et al, 2009) or those with mutant levels greater than 50%, which
are found in 2-6% of ET patients (De Stefano et al, 2009; Vannucchi et al, 2007). In the majority
of these studies, however, there was no evidence of an independent association between JAK2
mutation status and thrombotic risk once adjustment was made in multivariate analysis for
confounding factors, typically greater age and white cell count which are both associated with
V617F-positivity. Further, several studies have failed to find any association whatsoever
between JAK2 V617F-positivity and increased thrombotic complications (Alvarez-Larran et al,
2007; Caramazza et al, 2009; Wolanskyj et al, 2005).
A recent meta-analysis of 21 studies with 3150 ET patients concluded that the overall
thrombotic rate was higher in V617F-positive patients (OR 1.92, 95% CI 1.45-2.53), but did not
adjust for confounding factors, or distinguish between thrombotic events occurring prior to
presentation and those occurring thereafter (Lussana et al, 2009). Clearly, it is the risk of
future events which are most germane to management decisions at diagnosis, and whether
JAK2 V617F status influences this remains uncertain.
The clinical significance of the presence of MPL W515 mutations is difficult to evaluate due to
the small numbers of ET patients in whom they have been detected. The largest published
study found that, amongst 994 ET patients, 30 (3%) carried MPL W515 mutations and these
patients had an increased rate of arterial events at diagnosis and of microcirculatory
disturbance, but multivariate analysis was not attempted (Vannucchi et al, 2008a). Another
major study detected 32 patients with MPL mutations in a cohort of 776 patients (4%) and
reported an association between MPL mutations and an increased risk of venous events after
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entry into the study and death compared to JAK2 WT/ MPL WT patients but these associations
were lost after adjusting for age and prior history of thrombosis (Beer et al, 2008).
3.1.4 Risk stratification and therapy for ET patients
All patients with ET are routinely prescribed low-dose aspirin, which has been shown to reduce
the incidence of non-fatal thrombosis in PV (Landolfi et al, 2004), although it has never been
prospectively studied in ET. Aspirin may also relieve the vasomotor symptoms associated with
ET such as headaches and erythromelalgia (erythaema and a burning sensation of the hands or
feet). Other therapeutic interventions in ET include addressing concomitant vascular risk
factors such as hypertension, hyperlipidaemia, diabetes mellitus, obesity and smoking.
Cytoreductive medication is generally reserved for those patients at high risk of thrombotic or
haemorrhagic complications. Most national or international guidelines define high risk for
thrombosis as age greater than 60 years or a history of thrombotic events (Barbui et al, 2004;
Harrison et al, 2010; Tefferi 2008). Thrombotic events are generally deemed to include
myocardial infarction, angina pectoris, stroke, transient ischaemic attack, deep venous
thrombosis, pulmonary embolism, peripheral arterial thrombosis and retinal artery occlusion,
although severe erythromelalgia unresponsive to anti-platelet therapy may also be included
(Barbui et al, 2004). Patients at high risk of bleeding are those with a history of major
haemorrhage or who have extreme thrombocytosis, although the platelet threshold used for
implementation of cytoreduction varies between 1000 x109/L and 1500 x109/L (Barbui et al,
2004; Harrison et al, 2005; Harrison et al, 2010; Tefferi 2008).
It is unclear whether any ET patients who are younger than 60 years old and do not have a
prior history of thrombotic events or an extreme thrombocytosis would also benefit from
cytoreduction. The ‘intermediate risk’ arm of the MRC Primary Thrombocythaemia 1 (PT-1)
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Study is currently investigating the role of cytoreduction in patients aged 40-60 years without
high-risk features. Some experts have recommended that patients within this age group with
additional vascular risk factors such as diabetes or hypertension requiring therapy, familial
thrombophilic defects and leukocytosis should also be considered for cytoreductive therapy
(Barbui et al, 2004; Carobbio et al, 2008a; Harrison et al, 2005).
3.1.5 Choice of cytoreductive agent
The first-line of cytoreductive therapy is usually hydroxycarbamide (formerly called
hydroxyurea), which exerts its cytotoxic effects by inhibition of ribonucleotide reductase and
hence DNA synthesis, and has been shown to reduce the incidence of thrombotic
complications in ‘high-risk’ ET patients (Cortelazzo et al, 1995). Anagrelide, a newer agent, is a
phosphodiesterase inhibitor which selectively blocks megakaryocyte maturation without
affecting neutrophil production. It is licensed in the EU for the treatment of ET patients who
are intolerant of, or resistant to, hydroxycarbamide and is most commonly used when the
dose of hydroxycarbamide required to control the patients’ platelet counts renders them
neutropenic. Interferon alpha (IFNα) inhibits TPO-induced megakaryopoiesis by inducing SOCS-
1 expression, thereby suppressing proliferation of CFU-MKs and the more immature
pluripotent haemopoietic progenitors (Lengfelder et al, 1996), resulting in reduction of platelet
counts. Since it is not believed to be teratogenic, IFNα is the preferred treatment for ET 
patients requiring cytoreduction in pregnancy. Alkylating agents such as chlorambucil and
busulphan and radio-isotopes such as 32Phosphorus also have cytoreductive properties but are
now rarely used in the treatment of ET as they increase the rate of progression to acute
leukaemia, especially if used in combination with hydroxycarbamide (Finazzi et al, 2000;
Passamonti et al, 2004; Sterkers et al, 1998). By contrast, no intervention in ET has been
shown to reduce the risk of leukaemic transformation.
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The high risk arm of the PT-1 study compared cytoreductive agents in 809 ET patients at high
risk of thrombosis and found that hydroxycarbamide was superior to anagrelide in preventing
arterial events but less effective in preventing venous events. Hydroxycarbamide was also
associated with a lower incidence of myelofibrotic transformation, intolerable side effects and
serious bleeding (Harrison et al, 2005). For this reason, some experts recommend
hydroxycarbamide as the first-line cytoreductive agent in high-risk ET patients (Harrison et al,
2010; Tefferi 2008), although (unproven) concerns about the long-term leukaemogenic
potential of hydroxycarbamide mean that others favour anagrelide or IFNα for younger 
patients (Barbui et al, 2004; Emadi and Spivak 2009).
3.1.6 Aims
In this chapter, the clinical, haematological and molecular characteristics at disease
presentation of the cohort of ET patients used in subsequent studies have been analysed and
the results correlated with their clinical outcome.
3.2 Patients, materials and methods
3.2.1 Patient recruitment and sample collection
Patients were recruited from the University College Hospitals London Essential
Thrombocythaemia clinic and from haematology clinics in the UK between May 1996 and
January 2010, and provided written, informed consent in keeping with the Declaration of
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Helsinki. Prior to 2008, the 1986 PVSG Criteria (Murphy et al, 1986) were used for the
diagnosis of ET; from 2008 onwards, the WHO Criteria were used (Swerdlow et al, 2008).
Peripheral blood samples (approximately 25mL) were collected into EDTA and cell purification
performed as described in Section 2.1.1. For the majority of patients, neutrophil DNA and RNA,
T-lymphocyte DNA and RNA, and platelet RNA samples were prepared and stored in a tissue
bank. At the start of the research reported in this thesis, this tissue bank contained samples
from 114 ET patients. During the period of the research, samples from 19 new patients and
follow-up samples from 8 existing patients were added to the bank.
3.2.2 Clinical and demographic characteristics
Patients were assessed at diagnosis for the presence of splenomegaly, bleeding and
thrombotic manifestations (as defined in Section 3.1.4), and their blood counts recorded.
Where possible, patients were followed up to record the use of cytoreductive and anti-platelet
agent(s), the development of haemorrhagic or thrombotic complications, the onset of
myelofibrosis or acute myeloid leukaemia, or death.
Clinical and blood count data was obtained from a departmental clinical database created
prior to the start of this research for 59 patients, although in some cases the data here was
incomplete, and from medical case notes for 62 patients. For 12 patients no presentation
clinical or blood count data was available.
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3.2.3 JAK2 V617F status
Patient neutrophil DNA was screened for the presence of JAK2 V617F using PCR to amplify
exon 14 of the JAK2 gene followed by restriction enzyme digestion with AflIII to distinguish
between wild-type and mutant alleles (Figure 3.1) as previously published (Gale et al, 2007). All
oligonucleotide primer sequences are listed in Appendix 1.
Figure 3.1 Method for PCR of JAK2 exon 14 followed by AflIII digestion to
distinguish between JAK2 WT and V617F alleles
Bold indicates V617F mutation site, underlining indicates location of mismatch (T>C) introduced by
primer. *AflIII recognition site is ACGTG
BIOLINE™ PCR was performed as described in Section 2.2.3.1 using primers flanking the JAK2
V617F mutation site in exon 14. Since no restriction enzymes were available which could
discriminate between WT and mutant-positive PCR products directly, a mismatched forward
primer, JAK2ex14/(MM)F, was designed. This introduced a mismatch immediately upstream of
the mutation site to create a recognition site for AflIII which would cut the WT allele whilst
leaving the mutant allele uncut. Using this mismatched forward primer and an intronic reverse
primer, JAK2ex14/R, a 157bp PCR product spanning the mutation site in exon 14 was
amplified. Thirty-five cycles of PCR were performed with an annealing temperature of 60°C,
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and PCR products were separated by agarose gel electrophoresis (2% gel) and visualised by UV
transillumination.
A digestion mix was then prepared containing 5 units AflIII enzyme, 1x manufacturer’s buffer 3
and 100μg/mL bovine serum albumin (BSA), made up to 3μL with ddH2O, and to this 7μL PCR 
product was added and incubated for 6 hours at 37°C. Following 3.5% agarose gel
electrophoresis, digestion products were visualised by UV transillumination. AflIII cut the wild-
type allele to 129bp and 28bp but did not cut the mutant allele (157bp).
Screening for JAK2 V617F had already been performed for 114 patients at the start of the
research reported in this thesis, and was performed for a further 19 patients during the course
of this research.
3.2.4 JAK2 V617F mutant level quantification in neutrophil gDNA
JAK2 exon 14 PCR and AflIII digestion was performed as described in Section 3.2.3, except that
a fluorescently-labelled exonic reverse primer (JAK2ex14/RF) was used. Only 30 cycles of PCR
were performed in order to minimise the formation of heteroduplex products, since they
would not be cut by AflIII and would therefore mimic homoduplex V617F-positive products.
Denaturation, annealing and extension times were 60 seconds in each cycle. Following
digestion with AflIII, 2µL of each product underwent fragment analysis as described in Section
2.2.7. The wild-type and the mutant peaks were at 129bp and 157bp respectively. Mutant
allele level was calculated by expressing the area under the 157bp peak as a proportion of the
total area under both peaks. Each sample was analysed three times and the mean value of the
three results calculated.
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JAK2 mutant level analysis had already been performed for 42 patients prior to the start of the
research reported in this thesis, and was performed for a further six patients during the course
of this research.
3.2.5 X-chromosome inactivation pattern (XCIP) analysis
In order to determine an XCIP, it is necessary to distinguish between the two X-chromosomes
and between the active and the inactivated X-chromosome (Figure 3.2). To distinguish
between the two X-chromosomes, the subject must be heterozygous for a polymorphic X-
chromosome gene which is known to be differentially methylated on the active and inactive X-
chromosomes. In these studies, the human androgen receptor gene, HUMAR, was studied,
since it is heterozygous in 90% of females (Allen et al, 1992), with different alleles
distinguishable on the basis of size. This is due to the presence of a highly polymorphic variable
number tandem repeat (VNTR) sequence of 11-31 trinucleotide (CAG) repeats in the first exon
of the HUMAR gene.
The active and inactive chromosomes are distinguished on the basis of differential methylation
using a methylation-sensitive restriction enzyme (HpaII) followed by PCR. Since the inactivated
HUMAR allele is methylated, subjecting the DNA to digestion with HpaII will cut the active
(unmethylated) allele just upstream of the VNTR region. If PCR is then performed using primers
located outside the cutting site, only the intact inactive (methylated) allele will be amplified. If
some cells in a population inactivate one X-chromosome and others inactivate the other X-
chromosome, two different-sized PCR products will be generated, assuming the individual is
heterozygous at the HUMAR locus. The relative amount of the two products is proportional to
the relative degree of methylation of the two alleles within the cell population, and can be
quantified by fragment analysis by calculating the areas under the corresponding peaks.
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Figure 3.2 Principle of XCIP analysis using HUMARA
The HUMAR allele on the left is methylated (indicated by M), whereas the HUMAR allele on the right is
not. Methylation-sensitive digestion with HpaII leaves the methylated allele intact (left) but cuts the
unmethylated allele (right). PCR with primers which anneal outside the methylation sites allows efficient
amplification of the intact allele (left), whereas the cut allele is not amplified (right).
VNTR indicates variable number tandem repeat
However, the relative amounts of the final PCR products does not depend solely on the
amount of each allele present in the template DNA following HpaII digestion. If equal amounts
of two different-sized alleles are used as template in the same PCR, the smaller allele may be
preferentially amplified if a large number of cycles is used (Walsh et al, 1992). For this reason,
only 22 cycles of PCR were performed (Gale et al, 1996). Furthermore, in order to identify and
control for any preferential amplification of the smaller allele due to its size rather than
differential methylation, the PCR was performed twice for every DNA sample: in one, HpaII-
digested DNA was used as template, in the other non-HpaII digested DNA was used. In the
latter, equal amounts of the two PCR products were expected. The results from the two PCRs
were then compared and the effect of the HpaII digestion was determined. In this way the
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degree of methylation of each HUMAR allele in the original sample was calculated. This
analysis was performed on both neutrophil and T-cell DNA to evaluate methylation in myeloid
cells and lymphoid cells respectively. The latter are not believed to be involved in MPNs and
were therefore used to reflect the patient’s constitutional XCIP.
Methylation-sensitive digestion: Two reactions were set up, one with and one without HpaII.
For the former, 4L gDNA was added to a reaction mixture containing 2.5 units RsaI, 12.5 units
HpaII, 1x manufacturer’s buffer 1, in a total reaction volume of 5L. For the second reaction,
2L gDNA was added to a reaction mixture containing 2.5 units RsaI, 1x manufacturer’s buffer
1, and made up to a total reaction volume of 5L with ddH2O. RsaI was included in both
reactions as it cut the genomic DNA outside the primer annealing sites, regardless of
methylation status, and thereby improved PCR efficiency. Both reactions were incubated at
37°C overnight.
PCR: A PCR reaction mix was prepared containing 1x Promega buffer, 0.2mM each dNTP,
1ng/L each HUMAR primer (HUMAR/U, a fluorescently-labelled forward primer, and
HUMAR/D, an unlabelled reverse primer), and made up to 14L with ddH2O. This was added to
the digest products, followed by a drop of mineral oil and incubated at 95°C for 5 minutes.
Samples were then held at 85°C whilst Taq polymerase mixture (1 unit Promega aTaq made up
to 1L with ddH2O) was added, then 22 cycles PCR performed (45 seconds 95°C, 45 seconds
68°C, 30 seconds 72°C) followed by a final extension of 15 minutes at 72°C. PCR products (2L
each) were then analysed by fragment analysis as described in Section 2.2.7.
Calculation of X-chromosome inactivation status: For polymorphic individuals, two major peaks
were expected – one which represented the shorter HUMAR allele, A, and one which
represented the longer HUMAR allele, B (Figure 3.3). In addition, each major peak frequently
had one or more ‘slippage’ peaks, each being smaller than the major peak in 3bp increments,
caused by Taq slippage during the PCR, and the area of the largest slippage peak was added to
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the corresponding major peak. Using the fragment analysis software, the total area of alleles A
and B was calculated for the reaction without HpaII (A– and B– respectively) and for the
reaction containing HpaII (A+ and B+ respectively). The relative percentage inactivation of allele
A (%A) and allele B (%B) is given by the following equations:
%A =
(A+/ A−)
(A+/ A-) + (B+/ B−) and %B = (B+/ B−)(A+/ A-) + (B+/ B-)
Figure 3.3 Fragment analysis chromatogram of HUMARA PCR products from a
single patient
Chromatograms of PCR products from neutrophil gDNA which has undergone restriction enzyme
digestion in the absence (left) and presence (right) of HpaII.
In each chromatogram, the major peaks representing the shorter and longer HUMAR alleles are labelled
A and B respectively. A number of smaller slippage peaks are visible to the left of the corresponding
major peak. For each allele the area of the largest slippage peak was added to that of the corresponding
major peak (as bracketed) for use in the HUMARA calculation.
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XCIP analysis data was already available for 94 patients at the start of the research reported in
this thesis, and was performed for a further 11 patients during the course of this research.
3.2.6 MPL mutation screening
Mutations in MPL most commonly occur in exon 10 and affect residue W515. MPL exon 10 was
therefore screened for the presence of mutations by denaturing HPLC.
3.2.6.1 Generation of a MPL W515L-positive control by site-directed mutagenesis
A mutant-positive control sample was generated by site-directed mutagenesis (Figure 3.4).
Two short-length W515L-positive products were generated from normal control gDNA
template using mismatched primers MPLW515L/F and MPLW515L/R (Figure 3.4A). A 149bp
MPL W515L-positive PCR product was amplified using primers MPLex10/F, which annealed just
upstream of MPL exon 10, and MPLW515L/R, and a 130bp MPL W515L-positive PCR product
was amplified using primers MPLex10/R2, which annealed just downstream of MPL exon 10,
and MPLW515L/F (Figure 3.4B). These two products were generated in separate reactions,
using 35 cycles of BIOTAQ™ PCR as described in Section 2.2.3.1, and an annealing temperature
of 60°C. The two PCR products were electrophoresed on a 1.5% low-melting point agarose gel,
visualised by UV transillumination, cut out from the gel and purified using the QIAquick Gel
Extraction Kit (Qiagen, Crawley, UK) as per manufacturers’ instructions.
Equal volumes of each purified PCR product were then mixed together. A 252bp W515L-
positive PCR product was amplified by BIOTAQ™ PCR using 1L of the PCR product mixture as
template in a 20L total reaction volume with primers MPLex10/F and MPLex10/R2, an
annealing temperature 60°C and 25 cycles of PCR. Other conditions were as described in
Section 2.2.3.1. The 252bp W515L-positive PCR product was then purified using the PEQLab
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A
B
Figure 3.4 Site-directed mutagenesis to create a MPL W515L-mutant positive
control
A. Genomic sequence of part of MPL exon 10 (codon 515 in bold), showing WT forward and reverse
strands, and the two mismatched primers which introduce the G>T substitution (mismatch
underlined)
B. Generation of mutant-positive product
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Gold PCR purification kit, according to manufacturers’ instructions, and the presence of the
W515L mutation confirmed by direct sequencing.
Mutant levels are reported to be relatively low in ET, with a median value of approximately 15-
25% for both JAK2 V617F (Vannucchi 08; Girodon 08) and MPL W515K/L (Beer 08; Jones 10). In
order to ensure that the screening technique was sufficiently sensitive to identify the majority
of mutant-positive samples, a positive control with a low MPL W515L level (approximately
10%) was included with every run. This control was produced by mixing nine volumes of WT
gDNA with one volume of the 252bp W515L-positive PCR product of an equal concentration. In
order to equalise the concentrations of the W515L-positive PCR product and the WT gDNA, the
former was diluted in ddH2O (1 in 10, 1 in 100, 1 in 1000, 1 in 10,000). The dilution which was
closest in concentration to the WT gDNA was identified by using each one, as well as WT
gDNA, as template in a MPL exon 10 PCR. An Optimase® PCR was performed using conditions
as specified in Section 2.2.3.3, with primers spanning MPL exon 10, MPLex10/F3 (forward) and
MPLex10/R2 (reverse). A ‘touchdown’ PCR technique was used, based on manufacturer’s
recommendations, which involved using an initial annealing temperature 7°C above the mean
melting temperature of the two primers (65°C), and gradually reducing the annealing
temperature with successive cycles: two cycles, Ta=72°C; two cycles, Ta=71°C; two cycles,
Ta=70°C; three cycles, Ta=69°C; 13 cycles, Ta=68°C; 13 cycles, Ta=66°C.
Visual inspection of the PCR products by UV transillumination following agarose gel
electrophoresis revealed that the 1 in 10,000 dilution of the W515L-positive PCR product and
the WT gDNA generated similar strength products. WT gDNA and the 1 in 10,000 dilution of
the W515L-positive product were therefore mixed together in a 9:1 ratio to generate the 10%
(approximately) MPL W515L-positive control.
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3.2.6.2 Screening for MPL exon 10 mutations using dHPLC
The Transgenomic WAVE® system (Transgenomic Ltd, Glasgow, UK) of dHPLC was used to
screen for mutations of MPL exon 10. This technique exploits differences in the physical
properties of heteroduplex and homoduplex PCR products to detect the presence of somatic
mutations. Heteroduplex products are generated in a PCR when the template DNA contains a
mixture of WT and mutant alleles. One strand of the heteroduplex product contains the WT
allele and the other contains the mutant allele (or rather its complement). This mismatch
introduces instability into the PCR product, and consequently the two strands are less strongly
bound together at this site than at the equivalent site in homoduplex PCR product which is
composed of two perfectly complementary DNA strands, either both WT or both harbouring
the same mutation. Denaturing the PCR product by heating it to 95°C then allowing it to re-
anneal at progressively lower temperatures maximises heteroduplex formation.
In dHPLC, the PCR products are pumped through a polystyrene-divinylbenzene copolymer
column at a temperature which has been calculated to partially denature them. The
denaturation profile of a PCR product depends on its sequence and can be predicted using the
manufacturer’s Navigator software. The partially-denatured products bind to the column and
are eluted off by progressively increasing concentrations of acetonitrile. Since the DNA strands
of the heteroduplex product are less strongly bound than those of the homoduplex product,
they will be elute off the column earlier. A UV detector generates a chromatogram based on
the timing and intensity of DNA elution. The presence of heteroduplex products are therefore
detectable as a peak arising before the main homoduplex peak.
In order to screen the cohort of ET patients for MPL exon 10 mutations, a 226bp fragment
spanning MPL exon 10 was amplified using an Optimase® PCR as described in Section 3.2.6.1
and analysed by dHPLC. PCR products were electrophoresed on a 2% agarose gel and
visualised by UV transillumination, then denatured by incubation for 5 minutes at 95°C and
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slowly cooled: 1 minute at 93.5°C, and then 1 minute at progressively lower temperatures in
1.5°C increments down to 39.5°C. Denatured products were run on the Transgenomic WAVE®
instrument at 62.5°C and 65.8°C, which were the optimal column temperatures for partial
denaturation of the amplicon, calculated using Transgenomic Navigator software (Figure 3.5).
Samples with abnormal WAVE patterns were further analysed by direct sequencing of MPL
exon 10. MPL exon 10 PCR products were generated as described in Section 3.2.6.1, purified
using the peqGold micro-spin cycle-pure kit, and sequenced by the UCL Wolfson Institute for
Biomedical Research DNA sequencing service (Section 2.2.8) using primers MPLex10/3F and
MPLex10/R2.
Figure 3.5 Theoretical melting curves of MPL exon 10 PCR product generated by
Transgenomic Navigator software
A 226bp PCR product amplified from gDNA using primers MPLex10/F3 (forward) and MPLex10/R2
(reverse) is shown, with the predicted helical fraction after running on the dHPLC instrument at 62.5°C
and 65.8°C.
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3.3 Results
3.3.1 Overall results and analysis by clinical risk factors at presentation
The clinical and demographic characteristics of the 133 patients studied are shown in Table
3.6. Of the 133 patients, 28 (21%) were male. At diagnosis, the median age was 48 years (range
8-84 years), 34 patients were aged 60 or over, and the median platelet count was 805x109/L
(range 453-4875 x109/L). At the time of analysis (February 2010), the median time since
diagnosis was 12.6 years (range 0.7-31.4). Follow-up data was available on 104 patients and 29
patients were lost to follow-up. The median patient age at the time of analysis was 62.8 years
(range 24.6-97.8). Eighty-two patients (78% of those evaluable) received cytoreductive
medication during follow-up.
Overall, 37 patients (36% of those evaluable) had a thrombotic episode, of whom 20 had
suffered a thrombosis prior to diagnosis, 11 post diagnosis, and six suffered thromboses both
pre and post diagnosis. The 37 patients who had a thrombosis (at any stage) were significantly
older at diagnosis than those who did not (53 versus 44 years; P=0.03, t-test), but had similar
presenting blood counts: median platelets 819 versus 802x109/L; haemoglobin 13.6 versus
13.9g/dL; white cell count 9.5 versus 9.2 x109/L (Table 3.7). There was no significant
association between suffering a thrombosis prior to or at diagnosis and suffering one after
diagnosis (P=0.10, Fisher’s exact test). Six patients (6%) had haemorrhagic complications. Six
patients (6%) transformed to MF, of whom one later developed AML and died, one underwent
a stem cell transplant, one was awaiting a transplant at the time of analysis and three were
lost to follow up. Six patients died (6%), one due to AML, one pneumonitis, one gliobastoma
multiforme, one dementia, and two unknown causes.
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Table 3.6 Clinical and demographic characteristics of ET patients included in
study
Data available
n Value
Total patients 133
Sex, n (% of total*) 133
Male 28 (21%)
Female 105 (79%)
Median age at presentation, years (95% CI) 121 48.0 (43.4-50.0)
Median platelet count at presentation, x 109/L (95% CI) 117 805 (874-1073)
Median haemoglobin at presentation, g/dL (95% CI) 77 13.7 (13.3-14.0)
Median white cell count at presentation, x 106/L (95% CI) 50 9.4 (9.3-11.63)
Median time since diagnosis, years (95% CI) 121 12.6 (12.1-14.7)
Palpable splenomegaly, n (% of total*) 80 7 (9%)
Cytoreductive therapy†, n (% of total*) 104
None 22 (21%)
Hydroxycarbamide 70 (67%)
Anagrelide 20 (19%)
Interferon-alpha 12 (12%)
Other (32P, chlorambucil or busulphan) 7 (7%)
Complications, n (% of total*) 104
Thrombosis prior to or at presentation 26 (25%)
Thrombosis post-presentation 17 (16%)
Thrombosis (at any stage)‡ 37 (36%)
Bleeding (at any stage) 6 (6%)
Death (all causes) 6 (6%)
Myelofibrotic transformation 6 (6%)
Leukaemic transformation 1 (1%)
* Where percentages of the total are shown, these are the percentage of the number of patients for
whom data on that parameter was available.
† Patients are counted for each therapy used and so may appear more than once.
‡ Six patients had thromboses both pre- and post diagnosis
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Table 3.7 Effect of presenting age and blood counts on occurrence of thrombosis
at any stage
Presenting variable* No thrombosis Thrombosis
P-value
(t-test)
n Median (95% CI) n Median (95% CI)
Age, years 84 44 (40.0-48.6) 37 53 (47.8-56.5) 0.03
Haemoglobin, g/dL 45 13.9 (13.3-14.3) 32 13.6 (12.8-14.0) 0.3
White cell count, x109/L 29 9.2 (8.9-11.2) 21 9.5 (8.7-13.4) 0.4
Platelet count, x109/L 81 802 (870-1143) 37 819 (796-1011) 0.3
* The presenting age and blood counts were only available for a proportion of patients (see Table 3.6)
3.3.2 Analysis by XCIP status
During the research reported in this thesis, XCIP analysis was performed on samples from 10
patients, of whom two were uninterpretable due to constitutional skewing, and two were not
informative at the HUMAR locus. Of the six patients with interpretable XCIPs, three (50%) had
clonal myelopoiesis (i.e. greater than 75% expression of one allele, a difference between
neutrophil and T-cell XCIP of greater than 20%, and patient age less than 65 years) and three
(50%) had polyclonal myelopoiesis. Data was available for a further 92 patients from analysis
performed prior to the start of the research reported in this thesis. Overall, therefore, XCIP
results were available for 102 of the 105 female patients in the study. No PCR products were
obtained in the remaining three patients.
In 36 of the 102 patients, XCIP results were not interpretable, either due to age (n=21) or
constitutional skewing (n=15), and in four more patients they were not informative at the
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HUMAR locus, leaving 62 patients with evaluable XCIPs. Of these, 38 (61%) were polyclonal,
and 24 (39%) were clonal (Table 3.8). Clonal patients tended to be younger at presentation
than polyclonal patients, 35.5 versus 43.0 years, although the difference was not quite
significant (P=0.06, t-test). The median presentation platelet count was higher in clonal
patients than polyclonal patients, 950 versus 780x109/L, and this difference just reached
statistical significance (P=0.05, t-test). The median presenting haemoglobin, 12.6 versus
13.7g/dL, was similar in the two groups (P=0.51, t-test).
Table 3.8 Clinical and demographic characteristics of patients studied according
to their XCIP status
Clonal Polyclonal P-value
Total patients, n (% of evaluable patients) 24 (39%) 38 (61%) -
Median age at presentation, years (95% CI) 35.5 (29.4-43.1) 43.0 (39.0-50.9) 0.06
Median platelet count at presentation, x 109/L
(95% CI) 950 (804-1617) 780 (717-965) 0.05
Median haemoglobin at presentation, g/dL
(95% CI) 12.6 (11.8-14.2) 13.7 (12.7-14.1) 0.5
Median time since diagnosis, years (95% CI) 13.4 (11.0-17.5) 11.7 (10.3-14.0) 0.2
Cytoreductive therapy, n (% of evaluable
patients*)
No 2 (12%) 5 (17%)
1.00
Yes 15 (88%) 24 (83%)
Complications, n (% of evaluable patients*)
Thrombosis prior to or at presentation 7 (47%) 6 (21%) 0.09
Thrombosis post-presentation 3 (20%) 3 (10%) 0.4
Thrombosis (at any stage)† 8 (53%) 8 (28%) 0.1
Bleeding (at any stage) 0 1
Death (all causes) 1 1
Myelofibrotic transformation 3 0
Leukaemic transformation 1 0
* Clinical data was available for 15 clonal patient and 29 polyclonal patients
† Three patients had thromboses both pre- and post-presentation (two with clonal XCIP and one with
polyclonal XCIP)
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The rate of thrombotic events was higher in clonal patients than in polyclonal patients, both
prior to presentation and overall, but this difference did not reach statistical significance (47%
versus 21%, P=0.09; and 53% versus 28%, P=0.11, Fisher’s exact test). There was no difference
in the rate of thrombosis after presentation, 20% versus 10% (P= 0.39, Fisher’s exact test).
3.3.3 Analysis of JAK2 V617F status
During the research reported in this thesis, 20 ET patients were screened for the presence of
the JAK2 V617F mutation, of whom ten (50%) were mutant-positive. There was no difference
in median age at presentation in mutant-positive patients compared to WT ones (53 years
versus 48 years, P=0.43, t-test), in the median presenting platelet count (734x109/L versus 788
x109/L, P=0.51, t-test), or the rate of thrombotic complications (50% versus 30%, P=0.65,
Fisher’s exact test). The median mutant level in the V617F-positive patients was 15% (range
5%-21%).
JAK2 V617F screening had been performed for a further 113 patients prior to the start of the
research described in this thesis. In total, therefore, data was available for 133 ET patients, of
whom 55 (41%) were mutant-positive (Table 3.9). JAK2 mutant levels were available in 48
V617F-positive patients (in the other seven patients no PCR products were obtained), and in
these the median mutant level was 17% (range 5-100%). Patients who harboured the JAK2
V617F mutation were significantly older than those who were JAK2 WT, median age 53.0
versus 39.5 years (P<0.0001, t-test). Mutant-positive patients also had a significantly lower
presenting platelet count, median 772 versus 950x109/L, (P = 0.011, t-test) and a significantly
higher presenting haemoglobin, 14.2g/dL versus 13.0g/dL (P=0.0002, t-test).
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Table 3.9 Clinical and demographic characteristics studied according to JAK2
status
Data available
n
(JAK2 WT : V617F)
JAK2 WT* JAK2 V617F† P-value
Total patients 133 78 (58%) 55 (41%) -
Sex 133(78 : 55)
Male 16 (21%) 12 (22%) 1.00
Female 62 (79%) 43 (78%) 1.00
Median age at
presentation, years
121
(69 : 52)
39.5
(36.4-45.0)
53.0
(50.4-59.0) <0.0001
Median platelet count at
presentation, x 109/L
117
(68 : 49)
950
(937-1264)
772
(747-871) 0.011
Median haemoglobin at
presentation, g/dL
77
(35 : 42)
13.0
(12.4-13.4)
14.2
(13.8-14.7) 0.0002
Median white cell count
at presentation, x 106/L
50
(18 : 32)
10.0
(8.9-13.1)
9.0
(8.8-11.6) 0.52
Median time since
diagnosis, years
121
(69 : 52)
12.5
(11.6-14.9)
12.7
(11.6-15.6) 0.770
Palpable splenomegaly 80(36 : 44) 3 (9%) 4 (10%) 1.00
Cytoreductive therapy 104(53 : 51)
None 14 (26%) 8 (16%)
Hydroxycarbamide 30 (57%) 40 (78%)
Anagrelide 14 (26%) 6 (12%)
Interferon alpha-2a 4 (8%) 8 (16%)
Other (32P, busulphan
or chlorambucil) 5 (9%) 2 (4%)
Cytoreductive therapy 104(53 : 51)
No 14 (26%) 8 (16%)
0.231
Yes 39 (74%) 43 (84%)
Continuous variables are shown using median (95% confidence intervals), P-values using the t-test.
Categorical variables are shown using n (percentage of total), P-values using Fisher’s exact test.
* Where percentages are given, these represent the percentage of the total number of JAK2 WT
patients for whom data for that parameter was available (shown in second column)
† Where percentages are given, these represent the percentage of the total number of JAK2 V617F
patients for whom data for that parameter was available (shown in second column)
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Table 3.9 Clinical and demographic characteristics studied according to JAK2
status – continued
Complications 104(53 : 51)
Thrombosis prior to
or at presentation 10 (19%) 16 (31%) 0.256
Thrombosis post-
presentation 6 (11%) 11 (22%) 0.191
Thrombosis (at any
stage)‡ 14 (26%) 23 (45%) 0.099
Bleeding (at any
stage) 6 (11%) 2 (4%)
Death (all causes) 0 (0%) 6 (12%)
Myelofibrotic
transformation 3 (6%) 3 (6%)
Leukaemic
transformation 0 (0%) 1 (2%)
‡ Four JAK2 V617F-positive patients and two JAK2 WT had thromboses pre- and post diagnosis
There was no difference in sex-distribution, median follow up, prevalence of splenomegaly or
usage of cytoreduction between the two groups. There was no difference in the incidence of
thrombotic complications pre- or post-presentation. Although, the incidence of thrombosis at
any time did appear higher in the V617F-positive group than in the JAK2 WT group, 45% versus
26%, the difference did not reach statistical significance (P= 0.1, Fisher’s exact test). Patients
who had had a thrombosis (at any time) did, however, have a significantly higher mean mutant
level than those who did not have a thrombosis, 11% versus 5% (P=0.02; t-test).
Mutant levels greater than 25% have been associated with a particularly high thrombotic risk
(Antonioli et al, 2008; Carobbio et al, 2009). Of the 37 patients who had a thrombosis, six
(16%) had mutant levels greater than 25%, compared to three (5%) of the 67 patients who did
not have a thrombosis (P<0.0001, Fisher’s exact test).
All six patients who died were JAK2 V617F-positive, resulting in a significantly higher mortality
rate in the V617F-positive group, 12% versus 0% (P=0.01, Fisher’s exact test).
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3.3.4 Correlation between XCIP status and JAK2 mutational status
Of the 22 JAK2 V617F-positive patients with an interpretable XCIP, 16 (73%) had a polyclonal
XCIP and six (27%) had a clonal XCIP. Of the 40 JAK2 WT patients with an interpretable XCIP, 22
(55%) had a polyclonal XCIP and 18 (45%) had a clonal XCIP. There was no association between
XCIP status and JAK2 genotype (P=0.19, Fisher’s exact test).
An analysis was performed to determine whether, in female V617F-positive patients, the size
of the mutant-positive population could account for the difference between the T-cell and
neutrophil XCIP. This analysis was based on the assumption that the mutant-positive
population was clonal and all of its member cells therefore shared the same inactivated X-
chromosome carrying either allele A or B. Scott et al (2006) have reported that in ET, mutant-
positive cells are heterozygous for the mutation. Therefore, if a patient has a particular mutant
level (x%), the percentage of mutant-positive cells (y%) will be double this and the remainder
will be WT (z%). Thus y = 2x, and z = 100-2x.
Using the constitutive (i.e. T-cell) XCIP of AT% : BT%, the predicted neutrophil XCIP is given by
one of two possibilities depending on whether allele A or B is inactivated in the mutant-
positive population. If allele A is inactivated, the predicted neutrophil XCIP (A%:B%) = [(y/100)
x 100] + [(z/100) x %AT] : [(z/100) x %BT]. If allele B is inactivated, the predicted neutrophil XCIP
(A%:B%) = [(z/100) x %AT] : [(y/100) x 100] + [(z/100) x %BT].
Using this calculation, the two possible neutrophil XCIPs were predicted for each patient,
allowing for the inactivation of either the A or the B-allele in the mutant-positive population.
The two predicted neutrophil XCIPs were then compared to the actual neutrophil XCIP
observed in each patient, and the one which was closer to the observed value was identified to
allow the likely inactivated X-chromosome of the mutant-positive clone to be determined.
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This analysis has already been published for 20 of the patients reported in this thesis (Gale et
al, 2007) and demonstrated that the difference between the observed neutrophil XCIP and the
closer of the two predicted ones ranged between 0% and 17% – i.e. in every case the
difference was within the limit of technical variation (20%) for this technique, indicating that
the size of the mutant-positive population could indeed account for the difference between
the T-cell and neutrophil XCIP. This analysis was then performed for the two V617F-positive
female patients included in this thesis who had not previously been reported and revealed that
difference between the observed and the predicted neutrophil XCIP was 14% in one patient
and 27% in the other (Table 3.10).
Table 3.10 JAK2 V617F-positive patients with an interpretable XCIP: the effect of
mutant level on neutrophil clonality status
Patient ClonalityStatus*
Neutrophil
XCIP
T-cell
XCIP
%
V617F†
%
V617F+
cells‡
Predicted Neutrophil XCIP§ %
Difference
(observed –
predicted)
A% B% A% B%
if A clone if B clone
A% B% A% B%
1 C 100 0 69 31 7% 14% 73 27 59 41 27
2 P 73 27 72 28 26% 52% 87 13 35 65 14
* C indicates clonal, P indicates polyclonal
† In neutrophil DNA
‡ Assumes heterozygous mutant status in all cells
§ Calculated using ‘y’ to represent the percentage of mutant-positive cells and ‘z’ to represent the
percentage of WT cells, based on a T-cell XCIP of AT%:BT%, and the following equations: if the A allele
is inactivated in the clone the predicted neutrophil XCIP (A%:B%) = [(y/100) x 100] + [(z/100) x %AT] :
[(z/100) x %BT]; if the B allele is inactivated in the clone the predicted neutrophil XCIP (A%:B%) =
[(z/100) x %AT] : [(y/100) x 100] + [(z/100) x %BT].
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3.3.5 MPL exon 10 mutation screening
PCR for MPL exon 10 was performed in 133 patients. PCR products were obtained for 131 of
these and analysed by dHPLC. The 10% W515L-positive control was distinguishable from the
wild-type control using a column temperature of both 62.5°C and 65.8°C (Figure 3.6).
Interpretable WAVE chromatograms were obtained for 126 patients. Clearly abnormal
chromatograms were observed in three (2%) of these patients– two females and one male. All
three cases were JAK2 WT and represented 4% of JAK2 WT patients. Direct sequencing of
these samples demonstrated mutations in MPL exon 10 in all three cases. One case of MPL
W515K and two of MPL W515L were detected and in all three cases the height of mutant peak
was smaller than that of the WT one on the sequencing chromatogram (Figure 3.7). For two
further patients the WAVE chromatogram was equivocal but in these cases there was no
evidence of mutations in MPL exon 10 on sequencing.
Figure 3.6 dHPLC chromatogram traces of MPL exon 10 PCR products amplified
using normal control DNA and a 10% W515L-positive control as template
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Figure 3.7 dHPLC chromatogram traces and corresponding direct sequencing
chromatogram traces of samples with MPL W515 mutations
Codon 515 is boxed on the sequencing traces; vertical arrows indication loci of point mutations
3.4 Discussion
The data in this chapter address the clinical, laboratory and molecular characteristics of a
cohort of 133 ET patients studied in our institution, and their relationship to outcome. Overall,
the cohort of patients reported in this thesis was broadly similar to those reported by most
published studies in terms of presenting characteristics and clinical course. The median age at
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presentation, at 48 years, was slightly lower than the average reported in recent studies which
is 54 years (Table 3.4), possibly as a result of referral bias to UCH which provides tertiary level
specialist care for patients with haematological disorders. Consequently surrounding district
hospitals may have preferentially referred younger patients who might be perceived to benefit
most from expert management. Females represented 79% of the ET patients; this female
preponderance is typical of most published series, although it is perhaps more marked than
generally reported (59% of patients; Table 3.4) and it is likely that this reflected the active
recruitment by the department of female patients specifically for XCIP analysis. The median
presenting haemoglobin and white cell count in our cohort were similar to those reported by
most other studies (13.7g/dL versus 14.0g/dL and 9.4 x109/L versus 9.5x109/L respectively), but
the median platelet count was lower than that generally observed (805x109/L versus
905x109/L). The reason for this is unclear.
The incidence of thrombotic complications at or prior to presentation (25%) was similar to that
reported by other groups: 22% in Bellucci et al (1986) and 19% in Passamonti et al (2004). The
median duration since diagnosis for the group was 12.6 years, during which time 16% of
patients suffered thrombotic complications. This is compatible with the 15-year cumulative
thrombotic risk of 17% reported by Passamonti et al (2004) and the 18% rate of thrombosis
observed by Tefferi et al (2001) during a median follow-up of 9.2 years. In the cohort studied
here, patients who suffered a thrombosis were on average older at diagnosis than those who
did not (53 versus 44 years old; Table 3.7) but both groups had similar presenting platelet
counts, which is in keeping with the majority of published studies (Table 3.3).
The rates of leukaemic and myelofibrotic transformation during follow-up (1% and 5%
respectively) were also similar to published data. Passamonti et al (2004) reported the rates of
leukaemic and myelofibrotic transformation were both 5% at 15 years post-diagnosis, whilst
equivalent figures at 10 years post-diagnosis were reported by Palandri et al (2009a) as 1% and
4% respectively, and by Wolanskyj et al (2006) as 3% and 5% respectively.
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Sixty-two of the 105 female patients in the study had an interpretable XCIP, and of these 24
(39%) were clonal (Table 3.8), a slightly lower proportion than that reported in most published
studies (range 43% to 69%, overall mean 62%; Table 1.4). It is notable, however, that with one
exception (Teofili et al, 2002) all the studies which reported a clonal XCIP rate greater than
55% did not control for the possibility of constitutional skewing by analysing T-cell XCIPs.
Consequently, some of the patients they classified as having acquired myeloid skewing might
have had constitutional skewing, meaning the true figure may have been lower.
The finding that patients with clonal myelopoiesis had significantly higher presenting platelet
counts than those with polyclonal myelopoiesis (median 950x109/L versus 780x109/L; P=0.05)
has been previously reported (El-Kassar et al, 1997), although it was not observed by Chiusolo
et al (2001) or Shih et al (2002). Of the 44 patients with interpretable XCIPs and clinical follow-
up data studied in this thesis, 21 have previously been reported by Harrison et al (1999a), who
did not find any association between presenting platelet count and XCIP (median 722x109/L in
clonal patients versus 778x109/L in polyclonal patients, P=0.92). This discrepancy presumably
reflects the different characteristics of the 23 patients reported here who were not included in
the 1999 study.
A near-significant trend to younger age in clonal patients compared to polyclonal ones (35.5
versus 43.0 years, P=0.06) was noted in the cohort reported in this thesis. It is possible,
however, that this trend may simply have reflected the exclusion from the analysis of 21
women with clonal XCIPs who were older than 65 on the grounds of possible age-related
skewing. If these 21 patients are grouped together with the 24 women with clonal XCIPs who
were 65 or younger, the median age of this combined group was no different to that of the
polyclonal group (56 versus 43 years, P=0.25). As discussed above, Harrison et al (1999a) have
previously reported on nearly half of the evaluable patients studied in this thesis and did not
identify any difference in age between the clonal and polyclonal patients (48 versus 40 years,
P=0.55). The other three studies which examined this issue produced conflicting data: Shih et
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al (2002) reported that patients with a clonal XCIP were significantly younger at presentation
than those with a polyclonal XCIP, whereas el-Kassar et al (1997) observed the reverse, and
Chiusolo et al (2001) did not identify any association between XCIP and age at diagnosis. There
does not appear to be, therefore, a clear relationship between XCIP and age at presentation.
In the cohort examined in this thesis, the overall rate of thrombotic events was higher in
patients with a clonal myeloid XCIP than those whose XCIP was polyclonal, but this was not
statistically significant (53% versus 28%, P=0.11). Harrison et al (1999a) had previously
reported on many of the patients included in this thesis and found that clonal myelopoiesis
was associated with a significantly higher thrombotic rate than polyclonal myelopoiesis (60%
versus 15%, P=0.04). Whilst the results from these two analyses appear contradictory, the
difference between them was of borderline statistical significance (P=0.05, Fisher’s exact test).
This slight difference may have been due to the relatively high thrombotic rate in the
polyclonal patient group reported in this thesis compared to that reported in any of the other
comparable studies (Table 3.11), which may have occurred by chance. It may also reflect minor
methodological variations between the studies. For instance, angina was regarded in this
thesis as a thrombotic episode, in keeping with current standard practice (Barbui et al, 2004;
Harrison et al, 2005), but in some of the previous studies it was not.
Chiusolo et al (2001) observed a significantly higher thrombotic rate amongst clonal patients
than polyclonal ones (41% versus 7%, P=0.04), and Shih et al (2002) reported a non-significant
trend towards an increased thrombotic rate in patients with a clonal XCIP (33% versus 7%,
P=0.07). By contrast, el-Kassar et al (1997) found no such association (32% versus 21%,
P=0.70), although they grouped haemorrhagic and thrombotic complications together, making
direct comparison with the other studies difficult. Individually these studies are too small to
convincingly demonstrate an association between myeloid XCIP status and thrombotic risk.
However, if the data from the four studies is combined (excluding the data from Harrison et al,
1999a), then there is more robust evidence that thrombotic risk is significantly higher in
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patients with clonal myelopoiesis (38% for patients with a clonal XCIP versus 18% for patients
with a polyclonal XCIP, P=0.008; Table 3.11).
Table 3.11 Summary of studies examining association between myeloid XCIP
status and thrombotic rate
Reference
Median
follow-
up,
months
Polyclonal XCIP Clonal XCIP Significant
association
between XCIP
and thrombosis?
Total
n
Thrombotic
complications
n (% of total)
Total
n
Thrombotic
complications
n (% of total)
(El-Kassar et
al, 1997)
45 14 3 (21%)* 19 6 (32%)*
No
P=0.70
(Harrison et
al, 1999a)
73 13 2 (15%) 10 6 (60%)
Yes
P=0.04
(Chiusolo et
al, 2001)
36 15 1 (7%) 17 7 (41%)
Yes
P=0.04
(Shih et al,
2002)
45 15 1 (7%) 33 11 (33%)
No
P=0.07
Reported in
this thesis
151 29 8 (28%) 15 8 (53%)
No
P=0.11
Overall † 84‡ 73 13 (18%) 84 32 (38%)
Yes
P=0.008
Includes only the four studies which allow the criteria described in Section 1.3.5 to be applied and which
included data on thrombotic complications. All P-values derived using Fisher’s exact test
* Includes both thrombotic and haemorrhagic complications (this study did not distinguish between
them)
† Data from Harrison et al (1999a) is excluded from the overall analysis since all the patients reported
in this study are included in the cohort reported in this thesis
‡ Weighted according to size of study
Of the 133 patients in the cohort, 55 (41%) were JAK2 V617F-positive, with a median mutant
level of 17%. Both these findings are in keeping with those reported by the majority of
published studies, in which the overall prevalence of JAK2 V617F is 53% and the median
mutant level is 22% (Tables 1.7 and 3.12). At presentation, JAK2 V617F-positive patients had
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lower median platelet counts than JAK2 WT ET patients (772x109/L versus 950x109/L, P=0.011),
higher median haemoglobin concentrations (14.2g/dL versus 13.0g/dL, P=0.0002), and were
older (53.0 versus 39.5 years, P<0.0001). These associations between JAK2 mutant status and
presenting characteristics have also been reported by most published studies (Table 3.4), and
have led to the hypothesis that mutant-positive ET patients have a phenotype that lies
somewhere between JAK2 WT ET and PV (Campbell and Green 2006). Some studies have
suggested that JAK2 V617F-positive patients have higher presenting white cell counts than WT
patients (Campbell et al, 2005; Kittur et al, 2007; Pardanani et al, 2010), but this was not
observed in the cohort reported here (9.0 versus 10.0, P=0.52), nor was there any difference in
the prevalence of splenomegaly.
In the cohort studied here, those patients who were JAK2 V617F-positive did not have a
greater thrombotic rate than WT ones, whether at diagnosis (31% versus 19%, P=0.26), during
follow-up (22% versus 11%, P=0.19), or overall (45% versus 26%, P=0.10). The published data
are conflicting and suggest that any effects of JAK2 V617F on thrombotic risk are modest
(Table 3.5) and this cohort may, therefore, have been too small to detect them. Nonetheless, it
is noteworthy that patients who suffered a thrombosis had a higher mean mutant level than
those who did not (11% versus 5%, P=0.02). In absolute terms, however, this difference (6%) is
small and may not indicate a true biological difference between the two groups. It may,
instead, reflect the presence of a few individuals with high mutant levels in the group of
patients who had a thrombosis. According to a number of recent studies, patients with mutant
levels greater than 50%, seen in 2%-6% of ET patients, have a significantly increased
thrombotic risk compared to all other ET patients (De Stefano et al, 2009; Vannucchi et al,
2007), and two groups have observed the same phenomenon in patients with mutant levels
above 25% (Antonioli et al, 2008; Carobbio et al, 2009). Of the 104 patients reported in this
thesis for whom clinical follow-up data was available, the proportion of patients with a mutant
level greater than 25% was significantly higher in the 37 patients who had a thrombosis than in
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the 67 who did not (16% versus 5%, P<0.0001). It appears, therefore, that the thrombotic risk
may be related to the presence of high mutant levels rather than simply the presence or
absence of JAK2 V617F, and this may account for the lower thrombotic rate in ET patients
compared to PV patients, who more frequently harbour high mutant levels. One study has
even suggested that at equivalent mutant levels the thrombotic risk is similar in the two
disorders (Carobbio et al, 2009).
The mortality rate was significantly higher in the V617F-positive group, but since the majority
of deaths were not related to haematological causes, this is likely to have been coincidence.
No published studies have reported any similar association between JAK2 mutational status
and mortality, though Vannucchi et al (2007) did find that the 2% of ET patient who had a
V617F mutant level greater than 50% did have an increased rate of myelofibrotic
transformation.
MPL W515 mutations were detected in only three of the patients reported in this thesis,
accounting for 2% of all patients and 4% of JAK2 WT patients, figures similar to those of other
studies (Table 1.8). None of them suffered thrombotic complications either prior to or
following presentation, but the small patient numbers precluded meaningful interpretation of
these findings. Of the three MPL W515-positive patients, one had a clonal neutrophil XCIP, one
was male, and one was uninterpretable on the grounds of constitutive skewing.
No association between JAK2 V617F and XCIP clonality was observed. This is surprising since, if
V617F-positive cells are clonal, a higher rate of XCIP clonality might be expected in V617F-
positive patients than in WT patients. In fact the opposite was true, although the difference
was not significant: the proportion of patients with clonal myelopoiesis was 27% in the V617F-
positive group compared to 45% in the JAK2 WT one, P=0.19. These findings are in keeping
with those of Levine et al (2006) who compared XCIP clonality and V617F mutant levels in PV,
ET and MF. Whereas a correlation between clonality and mutant level was demonstrated in
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PV, no such correlation was detectable in ET and MF. The apparent absence of correlation
between mutant level and clonality in ET may relate the lower mutant levels usually reported
in ET compared to PV (Table 3.12). The smaller mutant-positive population in ET would,
therefore, be expected to exert a more modest effect on the overall myeloid clonality than in
PV. Since the XCIP approach to clonality analysis has a limit of technical variation of 20%, it
may not be sufficiently sensitive to detect such subtle effects.
An earlier study from our group has examined the relationship between the size of the
mutant-positive population and T-cell XCIP in determining the neutrophil XCIP (Gale et al,
2007). Using the assumptions that mutant-positive cells are heterozygous for V617F and
clonal, and therefore inactivate the same X-chromosome, this study calculated two possible
resulting neutrophil XCIP values, depending on whether the clonal population was assumed to
inactivate the ‘A’ or ‘B’ HUMAR alleles. In all 20 patients studied, one of the two calculated
neutrophil XCIPs was within the limit of technical variation for the assay (20%) of the observed
neutrophil XCIP. In the studies reported in this thesis, this analysis was performed for a further
two patients: in one the closer of the two calculated neutrophil XCIPs was 14% different than
the observed value, in the other it was 27% (Table 3.10). In the second individual, the observed
neutrophil XCIP was 100%:0%, whereas the closer of the calculated values was 73%:27%,
based on a T-cell XCIP of 69%:31% and the assumption that the mutant-positive population,
which represented 14% of myeloid cells, inactivated the A-allele. In this patient the V617F-
positive population could not account for the difference between the T-cell and neutrophil
XCIPs, implying that the clonal population was larger than mutant-positive one. One possible
explanation for this is that the V617F-positive clonal population is derived from a larger, JAK2
WT one, in keeping with a pre-JAK2 event in this individual.
Overall, in 21 of the 22 patients, the neutrophil XCIP could be predicted from their mutant
level and T-cell XCIP, within the technical limits of the assay. It therefore appears that in the
majority of ET patients, the size of the mutant-positive population can account for the
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difference between the T-cell and neutrophil XCIP, even if the mutant-positive population is
too small to achieve a neutrophil XCIP which fulfils the criteria for clonality. The size of the
mutant-positive population required to achieve a clonal neutrophil XCIP depends on the T-cell
XCIP and the X-chromosome which is inactivated in the mutant-positive population. For
instance, in a patient whose T-cell XCIP is 60%:40%, if the mutant-positive population
inactivates the A allele, a mutant level of 25% is needed to generate a clonal neutrophil XCIP
(80%:20%) based on the calculation described in Section 3.3.4. However, if it inactivates the B
allele a level of 33% is required for a clonal neutrophil XCIP (20%:80%). In the cohort reported
in this thesis, five patients with interpretable XCIPs had mutant levels of at least 25%, of whom
four had evidence of clonal myelopoiesis. The fifth patient (Table 3.10, patient 2) in this group
had a mutant level of 26%, yet her T-cell and neutrophil XCIPs were very similar (72%:28% and
73%:27% respectively).
It is notable that the majority of patients with a clonal XCIP studied in this thesis were JAK2 WT
(18 out of 24 patients, 75%). This would indicate that these 18 individuals harboured a myeloid
clone, large enough to affect the overall neutrophil XCIP, which was due to a somatic mutation
other than JAK2 V617F. One of these harboured a MPL W515K mutation, but in the other 17
no mutations were detected.
In summary, the majority of the clinical and laboratory characteristics of the cohort of patients
studied in this thesis were similar to those reported in most published studies, as were the
observed differences between JAK2 V617F-positive and JAK2 WT patients with regard to
haemoglobin level, platelet count and age. XCIP status appeared not to predict the incidence
of vascular complications, though when the data was combined with that from other studies a
significant association was observed. Whilst JAK2 status was not associated with thrombotic
risk, the JAK2 mutant level was. There was no association between the presence of JAK2 V617F
and clonal myelopoiesis as determined by XCIP analysis. This observation may have been due
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to the XCIP technique’s lack of sensitivity to small clones, and conversely to the presence of
V617F-negative patients with clonal myelopoiesis who are likely to harbour other mutation.
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4 JAK2 V617F-positive and JAK2 WT thrombopoiesis
in ET
4.1 Introduction
Although JAK2 V617F is present in a large proportion of patients with the three major MPNs,
the mutant level has consistently been reported to be lower in ET than in PV or MF (Table
3.12). A number of studies have suggested that, in ET, V617F -positive neutrophils represent
only a minority of the total neutrophil population and that this proportion remains stable over
many years (Antonioli et al, 2010; Besses et al, 2010; Gale et al, 2007; Girodon et al, 2008;
Theocharides et al, 2008). This implies that JAK2 V617F-positive and JAK2 WT granulopoiesis
stably co-exist in ET patients for prolonged periods, which differs from erythropoiesis in PV,
where low EPO levels lead to suppression of JAK2 WT erythroid cells and selection of EPO-
hypersensitive V617F-positive erythroid cells (Dupont et al, 2007).
The stable co-existence of mutant-positive and JAK2 WT granulopoiesis in ET is not typical of a
neoplastic disorder and may simply be a feature of analysing neutrophils, rather than the more
biologically-relevant platelets. The nature of this relationship between V617F-positive and
JAK2 thrombopoiesis is, therefore, unclear and will be investigated in this chapter.
4.1.1 The long-term stability of the V617F-positive population in ET
Three of the seminal studies which first reported on the occurrence of JAK2 V617F in MPNs
observed that transfection of Ba/F3 cells with the mutant JAK2 gene resulted in these cells
becoming hypersensitive to EPO and IL-3 (James et al, 2005; Kralovics et al, 2005; Levine et al,
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2005). Kralovics et al (2005) went on to demonstrate that, in the presence of serum, V617F-
transfected cells showed increased survival and proliferation compared to JAK2 WT-
transfected ones. In view of this, the V617F-positive myeloid cells in patients with ET might be
expected to outgrow the JAK2 WT ones and eventually to represent the majority of the
myeloid population, as they do in PV and Philadelphia-positive cells do in CML (Dubé et al,
1984aa; Dubé et al, 1984b). There is convincing evidence, however, that this is not the case.
A number of studies have examined the V617F mutant level in the three major MPNs (Table
3.12). Although the mutant level varies widely in individual ET patients, the overall median
level for all the published studies is only 22% (range of medians 6%-47%), and significantly
lower than that observed in either PV or MF (overall medians 49% and 47% respectively). In ET
the percentage of myeloid cells carrying the mutation is likely to be double the mutant level,
based on the data from Scott et al (2006). They genotyped haemopoietic colonies from 17
V617F-positive ET patients and found that in every case a mix of JAK2 WT-homozygous and
V617F-heterozygous colonies was present, but no patient harboured V617F-homozygous
colonies. Although Dupont et al (2007) and Pardanani et al (07 2007) subsequently reported
occasional V617F-homozygous haemopoietic colonies in small numbers of ET patients, it is
likely that in most ET patients, the vast majority of V617F-positive cells are heterozygous for
the mutation. Based on the overall median mutant level in ET of 22%, this implies that on
average fewer than half of myeloid cells carry the mutation.
One possible explanation for the relatively low mutant level in ET is that the condition
represents an early phase in the V617F-positive MPN spectrum and that PV and MF, in which
the mutant levels are significantly higher, are later stages of the same disorder. It is possible
that over time the mutant population outgrows the WT one leading to a change from ET to PV
or MF. In support of this hypothesis, there is evidence from murine models that increasing the
V617F-to-WT ratio changes the MPN phenotype. Tiedt et al (2008) generated a transgenic
murine model in which expression of V617F in haemopoietic cells was controllable by Cre-lox
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recombination and showed that when WT expression exceeded mutant expression, a
thrombocytosis resulted whereas when mutant levels were greater than WT levels,
polycythaemia was observed.
Mutant levels in ET, however, appear not to increase with time, according to a number of
published studies. Gale et al (2007) sequentially analysed mutant levels in 19 V617F-positive
ET patients over a median follow-up of 47 months. In 18 of these the mutant level remained
stable during follow-up, within the limits of technical variation, including five patients who had
not received cytoreductive therapy, suggesting that the stability of the mutant level was not
due to treatment. Four subsequent studies, whilst primarily examining the effect of
hydroxycarbamide therapy on mutant levels, have included untreated patients, with similar
conclusions. Theocharides et al (2008) observed that in six untreated ET patients, mutant
levels increased by a mean of 9% over a median follow-up of 26 months, which was considered
to be within the limits of technical variation. Similarly, Girodon et al (2008) found no significant
change in mutant levels in nine untreated ET patients during a median follow-up of 16 months,
and Antonioli et al (2010) reported that in 24 untreated ET patients, followed for a median of
24 months, the median mutant level rose from 27% to 31%, which again was not significant.
Finally, Besses et al (2010) observed a small but non-significant rise in mutant levels in 24
untreated ET patients over a median follow-up of 48 months, from a median of 26% to 29%. In
summary, there is no evidence that mutant levels in ET do rise over time, even in the absence
of cytoreductive therapy, or that the mutant-positive myeloid population outgrows the JAK2
WT one. Instead a steady state appears to exist, with no further advantage for the JAK2-
mutated cells, although the reason for this remains unclear.
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4.1.2 JAK2 V617F mutant levels in neutrophils and platelets
A second possible explanation for the relatively low mutant levels in ET is that this is a feature
of analysing neutrophils rather than platelets or MKs. The majority of studies which have
examined the issue have quantified mutant levels in neutrophils since these are abundant in
the peripheral blood and are therefore the easiest myeloid cells to analyse. In ET, however, the
most striking abnormality is in megakaryopoiesis and thrombopoiesis and therefore the
mutant levels in MKs and platelets are perhaps more relevant than those in neutrophils.
Because peripheral blood platelets contain no detectable DNA, quantification of their JAK2
mutant level requires RNA analysis, and this has been done relatively infrequently.
Two studies did find that, in ET, mutant levels were higher in platelet RNA than in neutrophil
DNA, suggesting that there may be differences in JAK2 mutant levels in different myeloid
lineages (Bellosillo et al, 2007; Moliterno et al, 2006). It is likely, however, that some patients
in both studies had received treatment with cytoreductive agents, which have been reported
to reduce mutant levels (Girodon et al, 2008; Kiladjian et al, 2008; Larsen et al, 2009).
Consequently it remains uncertain whether V617F-positive platelets represent the majority of
the platelet population in mutant-positive ET and the low mutant levels reported by the
studies in Table 3.12 are an artefact of studying neutrophils, or whether mutant levels in
platelets and neutrophils are similar.
Determining whether, in ET, V617F-positive and JAK2 WT thrombopoiesis genuinely co-exist in
a stable, long-term equilibrium has profound implications for our understanding of ET, since
neoplastic conditions are usually characterised by an expansion of the abnormal population at
the expense of the normal one.
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4.1.3 Aims
The studies reported in this chapter set out to quantify JAK2 V617F levels in neutrophils and
platelets from a cohort of 10 patients with untreated ET in order to establish whether there
was a difference in mutant levels between the two lineages, and to investigate the relative
sizes of the V617F-positive and the JAK2 WT platelet populations.
4.2 Patients, materials and methods
4.2.1 JAK2 V617F mutant levels quantification in neutrophil and platelet RNA
Peripheral blood samples were collected from 10 ET patients prior to the initiation of
cytoreductive therapy which might affect mutant levels. Each patient’s platelet count at the
time of collection was known. Neutrophils and platelets were purified as described in Section
2.1.3, RNA extracted as described in Section 2.1.4, and cDNA was generated using the
SuperScript™ III First-Strand Synthesis SuperMix for qRT-PCR kit as described in Section 2.2.5.
BIOTAQ™ PCR was then performed as described in Section 2.2.3.1 to amplify a 169bp fragment
covering the mutation site in exon 14, using a 1 in 4 dilution of this cDNA as template. The
primers used were JAK2ex14/(MM)F and an exon 15 fluorescently-labelled reverse primer
(JAK2ex15/RF), both at a final concentration of 0.25μM. Only 30 cycles of PCR were performed 
in order to minimise the formation of heteroduplex products, since they would not be cut by
AflIII and would therefore mimic V617F-positive product. Denaturation, annealing and
extension times were 60s in each cycle, with an annealing temperature of 61°C.
Following AflIII digestion (as described in Section 3.2.3.1) the uncut mutant allele was
identified by fragment analysis as a peak at 169bp, whilst the WT allele was cut to 28+141bp,
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though only the 141bp peak was visible as a peak since the 28bp fragment had no fluorescent
label. As described in Section 3.2.4, the mutant level was calculated by expressing the area
beneath the mutant peak as a percentage of the total area beneath both peaks. In every case,
each sample was analysed three times and the mean value for all three runs calculated.
4.2.2 Calculation of the numbers of V617F-positive and WT platelets
The mutant levels in platelet RNA (%Mut) and the total platelet count (PLTT) at the time of
sampling were used to calculate the number of mutant-positive platelets (PLTM), based on the
assumption that all the latter platelets were heterozygous for the mutation (Scott et al, 2006),
using the following equation:
PLTM = PLTT × 2(%Mut÷100).
The difference between the total and the mutant-positive platelet count represents the WT
platelet count.
4.3 Results
4.3.1 Mutant allele levels in neutrophil DNA and RNA and platelet RNA
The median V617F mutant level in samples from 10 ET patients obtained prior to cytoreductive
therapy was 15% (range 11%-27%) in neutrophil gDNA and 21% (range 12%-31%) in neutrophil
RNA (Figure 4.1). There was no significant difference in mutant levels between the two groups
(P=0.07, paired t-test). In eight patients, the mutant level was higher in neutrophil RNA than in
gDNA (range 2% to 17% higher), whereas in two patients the reverse was observed (2% and
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10% higher in neutrophil gDNA than in RNA). In the patient whose mutant level was 10%
higher in neutrophil gDNA than in RNA (27% versus 17%) there was no evidence of sample
transposition, and the quantification assay was repeated with similar results. If this patient’s
values were excluded, the median mutant level was significantly higher in neutrophil RNA than
in gDNA (21% versus 14%, P=0.01, paired t-test).
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Figure 4.1 JAK2 V617F mutant levels in neutrophil DNA and RNA, and platelet
RNA in 10 ET patients
The median mutant level in platelet RNA was 27% (range 20-39%), significantly higher than in
neutrophil gDNA and neutrophil RNA (P=0.001 and P=0.002 respectively, paired t-test). The
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mutant level was higher in platelet RNA than in neutrophil RNA in every patient (range 2% to
18% higher), and higher than in neutrophil gDNA in 9 of the 10 patients (range 6% lower to
22% higher). The one exception was the patient described in the paragraph above (mutant
level in neutrophil gDNA 27% versus 21% in platelet RNA).
4.3.2 Calculation of WT and mutant platelet counts
Using the equation described in Section 4.2.3, the WT and mutant-positive platelet counts
were calculated for the 10 ET patients investigated (Figure 4.2A). The median total, WT, and
mutant-positive platelet counts were 745×109/L (range 489-1023x109/L), 303×109/L (range
218-426×109/L), and 410×109/L (range 263-798×109/L) respectively. There was no difference
between the median WT and mutant platelet counts (P=0.11, t-test; Figure 4.2B). In five
patients the WT platelet count was higher than the mutant-positive platelet count, and in the
other five it was lower.
In all 10 patients the WT platelet count was above the lower limit of normal for the laboratory
(150×109/L) and in two patients it was above the upper limit of normal (400×109/L). There was
no correlation between mutant level and total platelet count (r2=0.325, P=0.085; Figure 4.3A),
between total platelet count and WT platelet count (r2=0.003, P=0.87, Figure 4.3B), or
between mutant platelet count and WT platelet count (r2=0.30, P=0.10, Figure 4.3C).
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Figure 4.2 Calculation of JAK2 wild-type and V617F-positive platelets in 10 ET
patients
A. The whole bar represents the total platelet count at the time of testing. The open bar indicates the
WT platelet count, and the filled bar the V617F-positive platelet count. The figure above the bar is
the percentage of JAK2 V617F-mutant positive platelets calculated from the mutant level in platelet
RNA. The dashed horizontal lines indicate the normal range in our laboratory.
B. Comparison between WT and mutant platelets for each patient. The dashed horizontal lines
indicates the median value for each group.
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Figure 4.3 Correlation between platelet counts and JAK2 V617F mutant level
4.4 Discussion
JAK2 mutant levels in V617F-positive ET patients are usually low, and on average fewer than
half of their neutrophils carry the mutation. Moreover, mutant levels in these patients usually
remain stable over many years. These observations are not keeping with the evidence that
acquisition of JAK2 V617F confers a proliferative advantage on affected cells but may simply be
a consequence of analysing neutrophils, rather than the biologically more relevant platelets.
The studies reported in this chapter, therefore, set out to investigate whether mutant levels in
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neutrophils and platelets differ in ET, and to examine the effect of the presence of a mutant-
positive platelet population on the size of the JAK2 WT one.
Mutant levels were quantified in neutrophil gDNA and RNA, and platelet RNA from 10
untreated ET patients. The results indicate that, whilst median V617F levels were similar in
neutrophil gDNA and RNA (15% and 21% respectively, P=0.07), the median level in platelet
RNA (27%) was higher than in both neutrophil gDNA and RNA (P=0.001 and P=0.002
respectively). Nonetheless, the difference between the median level in neutrophil RNA and
platelet RNA of 6% is, in absolute terms, small – especially in view of the technical variation for
the assay of 10% (Gale et al, 2007). Considering the patients individually, all 10 had mutant
levels which were higher (by between 2% and 18%) in platelet RNA than in neutrophil RNA
and, with one exception, than in neutrophil gDNA (by between 7% and 22%). The sample from
the patient whose mutant level was higher in neutrophil gDNA than in both other samples was
checked and re-analysed; whilst there was no evidence of sample transposition, this could not
be verified absolutely. If this patient’s results are excluded, mutant levels were significantly
higher in neutrophil RNA than in neutrophil gDNA (21% versus 15%, P=0.01), but the other
comparisons were unaffected.
These observations are in keeping with those of Moliterno et al (2006) who found that in 13 ET
patients the median mutant level was significantly higher in platelet RNA than in neutrophil
gDNA than in (42% versus 22%, P=0.001). The difference in median mutant level between the
platelet RNA and neutrophil gDNA, 20%, was more marked than that observed in the cohort
studied in this chapter, 12%, but since the number of patients receiving cytoreduction was not
reported, it is difficult to compare the two studies. A larger study of 43 mutant-positive ET
patients by Bellosillo et al (2007) also found a higher median mutant level in platelet RNA than
in neutrophil RNA (13% versus 10%, P = 0.02). In this study approximately one-third of the ET
patients were receiving cytoreductive therapy at the time of sampling, which might account
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for the relatively low overall mutant levels compared to the majority of other studies (Table
3.12).
Whilst the data presented in this chapter does suggest that in ET the mutant level in platelets
is higher than in neutrophils, the actual figure of 27% is still considerably lower than the
median reported by most studies for neutrophils in PV or MF (Table 3.12). If V617F-positive
cells are usually heterozygous for the mutation in ET, as Scott et al (2006) suggest, this implies
that on average approximately half of the platelets are mutant-positive and half are JAK2 WT.
These data therefore appear to confirm the notion that in ET the V617F-positive populations
(both neutrophils and platelets) do not rapidly outgrow their WT counterparts, but seem to co-
exist, typically representing 40-60% of the neutrophils and platelets in the peripheral blood.
To further explore the relationship between JAK2 WT and mutant-positive platelets in ET, the
number of WT and mutant-positive platelets at diagnosis were calculated for each of the 10 ET
patients, based on platelet counts and simultaneous mutant levels quantified from samples
taken prior to cytoreductive therapy. The overall median WT platelet count was similar to the
median mutant platelet count (303×109/L versus 410×109/L, P=0.11; Figure 4.2B), and in no
patient was the WT platelet count below the lower limit of normal. In two patients the WT
platelet count (401×109/L and 426×109/L) was marginally above the upper limit of normal for
this laboratory (400×109/L) (Figure 4.2A). Moreover, there was no correlation between mutant
level and platelet count (Figure 4.3A), nor any evidence that the WT platelet count fell as the
total platelet count or mutant-positive platelet count increased (Figures 4.3B and 4.3C).
The fact that production of JAK2 WT platelets was not suppressed in the presence of a
thrombocytosis caused by mutant-positive platelets suggests that the regulation of
thrombopoiesis generally (i.e. of both JAK2 WT and V617F-positive platelets) is defective in ET.
One possible mechanism for this relates to the role of c-Mpl in the normal homeostatic
feedback pathway for thrombopoiesis (see Chapter 1). Thrombopoiesis is principally regulated
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by plasma levels of the c-Mpl ligand, TPO, which, in the absence of an inflammatory stimulus,
vary inversely with platelet count in haematologically normal individuals. Clearance of TPO is
mediated by its internalisation and degradation by platelets and megakaryocytes via c-Mpl.
Impaired c-Mpl expression in ET has been reported by several groups (Harrison et al, 1999b;
Kralovics et al, 2003; Li et al, 2000) and this may account for the elevated TPO levels often seen
in the disorder (Table 1.2). Moreover, JAK2 V617F may play a role in the impaired expression
of c-Mpl. Moliterno et al (2006) observed an inverse correlation between mutant levels and
platelet c-Mpl expression in ET, suggesting that the abnormal JAK2 molecule may interfere
with expression of the receptor and therefore lead to impaired TPO clearance. They also noted
that c-Mpl platelet expression was similarly impaired in JAK2 WT ET patients, and concluded
that in these cases a different molecular mechanism was responsible for the abnormal
receptor expression.
It is, therefore, possible that impaired c-Mpl expression results in disruption of the normal
thrombopoietic feedback system and is responsible for the lack of suppression of JAK2 WT
platelets in the presence of a V617F-positive population and thrombocytosis. As a
consequence, despite the presence of a thrombocytosis, there is sufficient circulating TPO to
stimulate the remaining WT megakaryocytes to produce WT platelets in normal numbers. Over
time, even if the absolute number of V617F-positive MKs and platelets were to increase, their
defective c-Mpl expression would render them unable to clear TPO in the normal way, and WT
thrombopoiesis would therefore be unaffected.
Mutant levels in PV are markedly higher than in ET, and this may in part relate to the
regulation of erythropoiesis which is mediated by EPO. EPO levels are controlled by a quite
different mechanism than that of TPO: elevated haemoglobin levels result in suppression of
renal EPO production, and thereby downregulate bone marrow erythroid activity. In PV, EPO
levels are usually suppressed (Johansson et al, 2002; Mossuz et al, 2004), and correspondingly
little WT erythropoiesis would be expected. JAK2 V617F-positive erythroid progenitors are,
Chapter 4
141
however, hypersensitive to EPO (Dupont et al, 2007) and would therefore be able to
proliferate despite the low EPO levels. Defective TPO clearance might account for the
persistence of WT thrombopoiesis at normal levels in V617F-positive ET; it does not, however,
explain why mutant levels in neutrophil DNA, which is what most studies have measured, from
ET patients are relatively low and remain so over prolonged follow-up.
An alternative hypothesis to explain the persistence of relatively low mutant levels in ET in
both platelets and neutrophils is that the degree of expansion of the V617F-positive
population depends on the molecular background on which the mutation arises, since this
could affect the relative proliferative advantage which acquisition of the mutation confers. If
JAK2 V617F occurred in an individual whose myeloid progenitors already possessed an
unusually high proliferative rate – whether due to hereditary or acquired factors – the V617F-
positive progenitor might possess a lesser growth advantage compared to JAK2 WT
progenitors than if it arose in a completely haematologically normal individual. The
subsequent expansion of its progeny would be less marked and, since the JAK2 WT
myelopoiesis is more proliferative than normal it would not necessarily be suppressed by the
V617F-positive myelopoiesis.
The possible nature of such a pre-existing ‘hyper-proliferative’ tendency remains largely
speculative, but there is evidence for a pre-JAK2 V617F event, at least a proportion of ET cases.
Kralovics et al (2006) identified six ET patients whose neutrophil mutant level was less than
25% (i.e. fewer than 50% of granulocytes carried the mutation), who had evidence for
monoclonal haemopoiesis by XCIP analysis or using a cytogenetic marker (del20q). This, they
concluded, indicated that in a proportion of MPD patients JAK2 V617F had arisen on a
background of clonal haemopoiesis due to a prior somatic mutation. In keeping with this, one
of the patients reported in Chapter 3 of this thesis was found to have a clonal population
which was larger than the V617F-positive one.
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Further evidence for a possible pre-JAK2 event came from data from Campbell et al (2006a)
and Theocharides et al (2007) who observed that in the majority of V617F-positive ET cases
which transformed to AML, the leukaemic blasts were WT. They found no evidence for mitotic
recombinations, deletions or point-mutations, which could account for the loss of V617F from
a V617F-positive progenitor, and concluded that in some cases at least, it was more likely that
the blasts had arisen from a pre-JAK2 clonal population.
Alternatively, the speculative pre-JAK2 abnormality might be inherited. Pardanani et al (2008)
found that at three different JAK2 SNPs, there was a strong association between one allele and
PV, and the other allele and ET. The three SNPs were all in linkage disequilibrium with specific
JAK2 haplotypes, and it was suggested that the phenotype-determining allele may lie within
these haplotypes. There is also evidence that the variation in haematological parameters in
normal individuals may be determined by hereditary factors. In a study of nearly 14,000
individuals, Soranzo et al (2009) identified 22 SNPs which were associated with full blood count
variability, including four which were associated with variation in platelet counts. Acquisition
of JAK2 V617F in an individual who harboured an inherited tendency to have a high-normal
platelet count might be enough to result in a thrombocytosis, and simultaneously deprive the
mutant-positive cells of the marked proliferative advantage required to dominate
haemopoiesis.
In conclusion, the data presented here suggest that, whilst JAK2 V617F levels are higher in
platelets than neutrophils in ET, this difference is, in absolute terms, small. Further, it appears
that in V617F-positive ET, WT thrombopoiesis is not suppressed by the presence of a V617F-
positive population, and the mutant-positive progenitors do not rapidly outgrow their WT
counterparts, contrary to what may be expected in a neoplastic disorder. This raises the
question of whether ET is necessarily a clonal neoplasm, which is considered further in the
following chapter.
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5 Testing for more than one JAK2 V617F-positive
population in patients with mutant-positive ET
5.1 Introduction
In 2008, the WHO reclassified what had hitherto been called myeloproliferative disorders as
myeloproliferative neoplasms (Swerdlow et al, 2008). This change in terminology served to
emphasize the belief that these were neoplastic diseases which arose as a consequence of
clonal expansion of haemopoietic progenitors (Tefferi and Vardiman 2008). Central to this view
of the nature of MPNs was the perception that the acquisition of a number of somatic
mutations, most commonly affecting JAK2 exons 12 and 14 (V617F) and MPL exon 10, is critical
to the pathogenesis of these neoplasms.
Parallels between the Philadelphia-negative MPNs and CML, and their respective
constitutively-activated tyrosine kinases were soon drawn and the role of JAK2 V617F in the
Philadelphia-negative MPNs was equated to that of BCR-ABL in CML. ET and PV were likened
to CML in chronic phase, MF to accelerated-phase CML, and the leukaemic transformation of
all 3 Philadelphia-negative MPNs to the blast crisis phase of CML (Campbell and Green 2006).
Conceptualising the Philadelphia-negative MPNs in this way was intellectually appealing since
it allowed a rationalised classification of all 4 major MPNs. Moreover, it implied that the
advances in the understanding of CML which followed the discovery of BCR-ABL might be
rapidly emulated in the V617F-positive MPNs, facilitating the development of novel, targeted
therapies. However, classifying ET as a clonal neoplasm akin to chronic-phase CML ignores
marked differences in the natural history of the two disorders, and comparing JAK2 V617F to
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BCR-ABL as the pathogenic mutation overlooks several fundamental differences between the
two molecular abnormalities.
5.1.1 Is V617F-positive ET a clonal neoplasm initiated by JAK2 V617F?
Four observations suggest that V617F-positive ET is not analagous to chronic-phase CML, and
that JAK2 V617F does not play the same pathogenic role in ET that BCR-ABL does in CML. First,
ET does not clinically behave as a neoplastic disease. The mortality associated with ET is low
and is usually due to a thrombotic event. In the absence of leukaemogenic medications the
rate of malignant transformation is low – approximately 1-3% over 10 years – and the median
survival is between 15 and 25 years (Passamonti et al, 2004; Passamonti et al, 2008; Wolanskyj
et al, 2006). By contrast in untreated CML there is a 25% per annum risk of transformation to
acute leukaemia (Champlin and Golde 1985) and a median survival of less than 5 years
(Cervantes and Rozman 1982).
Second, in the small proportion of ET patients who do develop acute leukaemia, the malignant
clone is often V617F-negative even when the preceding ET was V617F-positive (Campbell et al,
2006a; Theocharides et al, 2007), whereas in CML loss of Philadelphia-positivity is not
observed following leukaemic transformation – indeed BCR-ABL expression usually increases
(Elmaagacli et al, 2000; Gaiger et al, 1995). Campbell et al (2006a) studied four V617F-positive
MPN patients who developed AML (two ET and two PV), and observed that in three cases the
blast cells were JAK2 WT, although the mechanism for this was unclear. If the blasts were
derived from a V617F-positive progenitor, mitotic recombination might explain the loss of the
V617F mutation. This was, however, considered unlikely for two reasons. Firstly, in one of the
three patients reported, the pre-AML V617F-positive granulocytes carried cytogenetic
abnormalities – del20q and t(1;9) – which were not detectable in the blast cells, suggesting
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that the blast cells were not derived from the V617F-positive ones. Secondly, in two patients,
the blast cells were shown by microsatellite analysis to be heterozygous for two chromosome
9p SNPs, located either side of the JAK2 gene, suggesting that the blasts cells had not
undergone mitotic recombination. Consequently, the authors speculated on the existence of a
pre-JAK2 clonal population from which both the V617F-positive MPN cells and the JAK2 WT
blasts had arisen. Theocharides et al (2007) also reported that the majority of V617F-positive
MPN patients who developed AML had JAK2 WT blasts, found in nine out of 14 interpretable
cases. Again, microsatellite analysis did not suggest the occurrence of mitotic recombination,
but interestingly in one patient the V617F-positive MPN granulocytes and the JAK2 WT blasts
shared a common cytogenetic abnormality (del11q), which was interpreted by the authors as
in keeping with a pre-JAK2 transformed population. By implication, therefore, JAK2 V617F was
not the initiating event in MPN, at least in these individuals.
Third, in V617F-positive ET patients, the mutant-positive population is usually small and
remains stable over many years. The median mutant level observed in neutrophil DNA in our
patient cohort (17%) was similar to that reported by most published studies (overall median
22%; Table 3.12), and implies that on average approximately 30-40% of myeloid cells carried
the mutation (see Chapter 4). In the majority of ET patients, the V617F level remains stable for
many years (Gale et al, 2007; Theocharides et al, 2008) and, as demonstrated in the previous
chapter, JAK2 WT thrombopoiesis is not suppressed by the presence of a mutant-positive
population. This is very different to the situation in CML where the cytogenetically normal
progenitors are suppressed, and the Philadelphia-positive progenitors expand rapidly to
constitute more than 99% of dividing myeloid precursors (Dubé et al, 1984a; Dubé et al,
1984b).
Finally, most studies examining XCIPs in ET have reported that a proportion, on average 40%,
of patients have polyclonal, or at least oligoclonal, myelopoiesis (Table 1.4). Even in JAK2
V617F-positive ET patients, haemopoiesis is frequently poly- or oligoclonal and there is no
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correlation between V617F-positivity and clonality (Antonioli et al, 2005; Levine et al, 2006). In
our cohort, 72% of V617F-positive ET patients with an interpretable XCIP had a polyclonal
pattern, compared to 55% of JAK2 WT patients. Taken together, these four observations
suggest that V617F-positive ET is not necessarily a clonal neoplasm in the mould of CML but is
instead a more complex, heterogeneous disorder.
5.1.2 JAK2 V617F and clonality in ET
Of the observations presented above, the lack of association between the presence of JAK2
V617F and myeloid clonality is perhaps the most surprising, since detection of a cell population
carrying an acquired mutation is usually assumed to indicate the presence of a clonal disorder.
One possible explanation for this observation, discussed in Chapter 3, is that in ET the mutant
population is often too small to affect the overall myeloid clonality status. Nonetheless, an
association between high mutant levels and myeloid clonality might still be expected, yet
Levine et al (2006) demonstrated that in ET no such association exists, whereas in PV it does. It
is also notable that in one patient discussed in Chapter 3 (Table 3.10, patient 2), T-cell and
neutrophil XCIPs were nearly identical (72%:28% and 73%:27% respectively), despite a mutant
level of 26%.
An alternative explanation is that, in some ET patients the V617F-positive population is not
monoclonal and therefore does not necessarily result in myeloid clonality even in the presence
of high mutant levels. This idea is not in keeping with conventional views of the role of somatic
mutations in haematological disorders and implies that the V617F-positive population is
derived from more than progenitor, each of which has acquired the mutation independently.
Individual MPN patients have occasionally been reported to harbour more than one MPN-
associated mutation. Pardanani et al (2006) studied 1182 MPN patients and identified six
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individuals (0.5% of the cohort), including two with ET, who had both JAK2 V617F and MPL
W515 mutations. Of these six patients, two had MPL W515L and W515K mutations as well as
JAK2 V617F. Beer et al (2009; Jones et al, 2009; Olcaydu et al, 2009) described 13 MPN
patients with two different genetic lesions, including five ET patients, four with JAK2 V617F
and MPL W515L, one with JAK2 V617F and del20q. They used colony analysis to investigate the
clonal relationship of the different mutant-positive populations and found that in seven of the
13 patients, including all five ET patients, some colonies carried one mutation, others carried
the second mutation, but none was positive for both. They inferred from this that there were
two or more distinct clones. They also noted that the frequency of patients with biclonal
disease – seven out of approximately 1000 patients screened (0.7%) – was much greater than
would be expected by chance and speculated about the existence of either an inherited or an
environmental factor which predisposed to acquisition of these genetic abnormalities.
There is increasing evidence that some individuals have a hereditary predisposition to develop
JAK2 V617F-positive MPNs (discussed in detail in Chapter 6). Moreover, the data presented in
Chapter 4 suggests that in most mutant-positive ET patients, JAK2 WT myelo- and
thrombopoiesis is not suppressed by the mutant-positive population, indicating the long-term
persistence of WT myeloid progenitors. If these JAK2 WT cells are particularly susceptible to
acquisition of JAK2 V617F, multiple mutant-positive clones might result. It is therefore feasible
that the mechanism which predisposed these individuals to acquire JAK2 V617F in the first
place may impart a tendency to do so repeatedly.
The suggestion that in ET there may be several co-existing independent V617F-positive clones,
rather than one dominant one, is contentious since it implies that the disorder is oligoclonal.
The obstacle to examining this hypothesis is finding a means to identify multiple occurrences
of the same mutation. To overcome this, two different approaches have been adopted. One
technique uses an informative A/G SNP, rs2230724 located in exon 19 of the JAK2 gene, to
identify the JAK2 allele (maternal or paternal) on which the mutation has arisen; the presence
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of the mutation on both alleles in a single individual would be indicative of more than one
mutational event. The other technique uses XCIP analysis to determine whether mutant-
positive haemopoietic colonies from a single individual share a common clonal origin.
5.1.3 Aims
The experiments reported in this chapter aimed to investigate the hypothesis that in V617F-
positive ET, multiple mutant-positive independent clones exist.
5.2 Patients, materials and methods
5.2.1 Patient selection
The possibility that more than one V617F-positive population exists in mutant-positive ET
patients was initially investigated using a JAK2 SNP, rs2230724, and a PCR-restriction enzyme
digestion-PCR approach to identify the allele on which the mutation had arisen. This involved
generating a PCR product spanning both the JAK2 V617F mutation site (exon 14) and the SNP
locus (exon 19). Since exons 14 and 19 are too far apart to allow a PCR product spanning both
the mutation and SNP loci to be amplified from gDNA (8.0Kb), cDNA was used (798bp product).
For analysis using this technique, therefore, patients had to be V617F-positive and
heterozygous for the exon 19 SNP, and have cDNA available.
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5.2.2 Determining JAK2 status
5.2.2.1 Screening for JAK2 V617F using gDNA
PCR for JAK2 exon 14 and restriction enzyme digestion with AflIII was used to screen DNA for
the V617F mutation as described in Section 3.2.3.
5.2.2.2 Screening for JAK2 V617F using cDNA
To screen cDNA for the V617F mutation (see Section 5.2.4), a similar PCR and restriction
enzyme digest technique to that described in Section 3.2.3 was used, except that a reverse
primer which annealed to exon 15 was used (JAK2ex15/R; Figure 5.1A). A 169bp fragment
spanning exon 14 was amplified using BIOTAQ™ PCR with primers JAK2ex14/(MM)F and
JAK2ex15/R. Thirty-five cycles of PCR were performed using an annealing temperature 61°C.
PCR products were then digested with AflIII using 7μL PCR product in a reaction mixture 
containing 5 units AflIII enzyme, 1x manufacturer’s buffer 3 and 100μg/mL BSA, made up to a 
10μL total reaction volume with ddH20 and incubated for 6 hours at 37°C. AflIII cut the WT
allele to 28 and 141bp whilst the mutant allele remained uncut (169bp). Digestion products
were separated by agarose electrophoresis (3% gel) and visualised by UV transillumination.
5.2.3 JAK2 exon 19 SNP (rs2230724) genotyping
5.2.3.1 Exon 19 SNP genotyping using gDNA
Patient T-cell gDNA was genotyped for the JAK2 exon 19 A/G SNP by PCR and restriction
enzyme digestion. T-cell, rather than neutrophil, gDNA was used to avoid interference by
possible acquired loss of homozygosity of chromosome 9 in myeloid cells. A 214bp fragment
covering JAK2 exon 19 and part of the flanking introns was amplified by PCR using BIOTAQ™
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A
B
Figure 5.1 Schematic representation of the technique used to determine the JAK2
exon 19 SNP (rs2230724) genotype of V617F positive-mutant alleles
A. Genomic structure of JAK2 gene showing primers used.
B. PCR-restriction enzyme digestion-PCR technique used to determine the JAK2 exon 19 SNP genotype
of JAK2 V617F mutant-positive alleles using cDNA
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polymerase as described in Section 2.2.3.1, with primers JAK2ex19/F and JAK2ex19/R (Figure
5.1A), an annealing temperature of 60°C and 35 cycles of PCR, using 50ng of T-cell gDNA as
template per reaction. Following this, a digestion mixture was prepared containing 5 units
BstNI enzyme, 1x manufacturer’s buffer 2 and 100μg/mL BSA, made up to 5µL with ddH20, and
to this 5µL PCR product was added and incubated for 2 hours at 60°C. Digestion products were
separated by agarose electrophoresis (3% gel) then visualised by UV transillumination. BstNI
cut the G-allele to 93 and 121bp but did not cut the A-allele (214bp).
5.2.3.2 Exon 19 SNP genotyping using cDNA
To genotype cDNA for the exon 19 SNP (see Section 5.2.4), a 235bp fragment was amplified
using BIOTAQ™ PCR as described in Section 2.2.3.1, with exonic primers JAK2ex18/F and
JAK2ex20/R. Thirty-five cycles of PCR were performed using an annealing temperature 62°C.
PCR products were then digested with BstNI using 7μL PCR product in a reaction mixture 
containing 5 units BstNI enzyme, 1x manufacturer’s buffer 2 and 100μg/mL BSA, made up to a 
10μL total reaction volume with ddH20 and incubated for 2 hours at 60°C. BstNI cut the G-
allele to 108 and 127bp whilst the A-allele remained uncut (235bp).
5.2.4 JAK2 exon 19 SNP (rs2230724) genotyping of V617F-positive alleles by PCR-
restriction enzyme digestion-PCR
JAK2 V617F-positive patients who were heterozygous for SNP rs2230724, and for whom cDNA
was available, were investigated for the presence of more than one V617F-positive population
using a PCR-restriction enzyme-PCR technique (Figure 5.1B).
cDNA was generated from neutrophil RNA by reverse transcription using the SuperScript™ III
First-Strand Synthesis SuperMix for qRT-PCR kit as described in Section 2.2.5. A 798bp
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fragment covering JAK2 exons 14-20 was then amplified from neutrophil cDNA using BIOTAQ™
polymerase, as described in Section 2.2.3.1, with primers JAK2ex14/(MM)F and JAK2ex20/R,
and 1µL cDNA diluted 1 in 4 in ddH2O as template. Thirty-eight cycles of PCR, each of 60
seconds at 95°C, 60 seconds at 62°C, 90 seconds at 72°C were performed, followed by a final 5
minute extension at 72°C. Products were visualised on 2% agarose gel containing ethidium
bromide.
Products were digested with BsaAI to cut the WT but not the mutant allele. AflIII could not be
used for this digestion due to the presence of an AflIII site common to both WT and mutant
alleles which would destroy the ability to re-amplify the mutant products. For the digestion, a
reaction mixture was made up containing 5 units BsaAI enzyme and 1x manufacturer’s buffer
3, made up to 5µL with ddH20, and to this 5µL PCR product was added. The mixture was
incubated for 6 hours at 37°C.
This digest was then used as template for a second round of PCR. Undiluted digests were too
concentrated to yield interpretable second-round PCR products and a range of dilutions of the
digests in ddH20 was therefore made (1 in 50, 1 in 250, 1 in 1,000 and 1 in 10,000). For the
second round of PCR, 1 µL of each dilution was used as template. As in the first round PCR, a
798bp fragment spanning exons 14-20 was amplified using BIOTAQ™ polymerase with primers
JAK2ex14/(MM)F and JAK2ex20/R. Thirty-two cycles of PCR were performed, each of 60
seconds at 95°C, 60 seconds at 62°C, 90 seconds at 72°C, followed by a final 5 minute
extension at 72°C.
The final stage of the process was to determine the JAK2 V617F status and exon 19 SNP
genotype of the resulting 798bp PCR product, by PCR and restriction enzyme digestion as
described in Sections 5.2.2.2 and 5.2.3.2 respectively. For both PCRs, a 1 in 100 dilution of the
second-round PCR product was used as template.
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5.2.5 JAK2 exon 19 SNP genotyping of V617F-positive alleles by TA cloning
In the process described above, incomplete BsaAI digestion of the WT first-round PCR
products, even if minor, would result in some WT allele amplification in the second-round PCR.
Consequently it is possible that the JAK2 exon 19 SNP genotyping performed in the final step
of the process might be from a mix of WT and mutant-positive alleles, and would therefore be
misleading.
To overcome this, the exon 19 SNP genotype of V617F-positive alleles was studied by TA
cloning using the Invitrogen TOPO TA Cloning® Kit (Figure 5.2). For the five patients studied,
cDNA was generated from neutrophil RNA as described in Section 5.2.4; cDNA was also
generated from platelet RNA for two of the five patients, and from RNA obtained from CD34-
positive cells for one patient. Using 1 in 4 dilutions of the cDNA as template, a 798bp fragment
spanning JAK2 exons 14-20 was amplified by BIOTAQ™ PCR, as described in Section 5.2.4. The
entire 20µL PCR product obtained from each reaction was run on a 1.5% low-melting point
agarose gel, visualised by UV transillumination and cut out from the gel. Gel-purification of the
PCR products was necessary to remove the primers which interfered with subsequent
reactions. The gel fragment containing the PCR product was melted by warming to 60°C.
Depending on the strength of the original band as assessed visually, between 1 and 4µL of the
molten gel was used in the ligation step of the TA cloning process which was performed
according to manufacturer’s instructions (see Section 2.2.10). Bacterial clones were grown on
LB-agar-carbenicillin plates coated with X-gal and transformed clones containing the JAK2 exon
14-20 PCR product were identified by their white or light-blue colour. These were picked and
expanded by incubation in 50μL LB medium containing carbenicillin at 37°C overnight. 
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Figure 5.2 Schematic representation of the TA cloning technique used to
determine the JAK2 exon 19 SNP (rs2230724) genotype of JAK2 V617F
mutant-positive alleles using cDNA
The JAK2 V617F status of individual clones was determined by PCR and restriction enzyme
digestion (Section 5.2.2.2) using 1µL bacterial suspension in the 20µL PCR mix as template.
Prior to the first cycle of PCR, the reaction mix was incubated for 2 minutes at 95°C to lyse the
bacteria. V617F-positive clones were then genotyped for the JAK2 exon 19 SNP by PCR and
restriction enzyme digestion (Section 5.2.3.2), again using 1µL bacterial suspension in the 20µL
PCR mix as template and a 2 minute 95°C bacterial lysis step prior to the first PCR cycle.
5.2.6 Using a JAK2 intron 14 SNP (rs12343687) to genotype V617F-positive alleles
Whilst this work was underway, data on several previously unrecognised JAK2 SNPs was
published (Jones et al, 2009; Kilpivaara et al, 2009; Olcaydu et al, 2009), including one in intron
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14 which was sufficiently close to the V617F locus to allow a 482bp PCR product spanning both
sites to be amplified from gDNA. The patients who had been studied using the exon 19 SNP
were therefore investigated using the intron 14 SNP to establish whether RNA and gDNA-
based approaches gave concordant results. The process described in Sections 5.2.4 and 5.2.5
was therefore repeated but here the JAK2 intron 14 SNP, rs12343687 (C/T), was studied
instead of the JAK2 exon 19 SNP.
5.2.6.1 Genotyping patients for intron 14 rs12343687 SNP status
In order to identify which of the patients studied in Sections 5.2.4 and 5.2.5 were heterozygous
for the intron 14 SNP, a 164bp fragment spanning this SNP was amplified using primers
JAK2ex14/F2 and JAK2ex14/(MM)R (Figure 5.3A). The reverse primer introduced a mismatch
immediately downstream of the SNP to create a recognition site so that BsaAI would cut
products with the C allele whilst leaving the T-allele products uncut. T-cell gDNA was used as
template and 35 cycles of BIOTAQ™ PCR were performed as described in Section 2.2.3.1, with
an annealing temperature of 59°C. Products were run on a 2% agarose gel and visualised by UV
transillumination. Digestion with BsaAI was then performed: a reaction mix was made up
containing 4 units BsaAI enzyme and 1x manufacturer’s buffer 3, made up to a 4μL ddH20, and
to this 4µL PCR product was added and the mixture incubated for 4 hours at 37°C. Products
were run on a 3% agarose gel and visualised by UV transillumination. BsaAI cut the C allele to
31 and 133bp whilst the T allele remained uncut (164bp).
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A.
B.
Figure 5.3 Schematic representation of JAK2 exons 14 and 15 showing primers
used to genotype V617F-positive alleles using intron 14 SNP
(rs12343687)
A. Genomic structure of JAK2 exons 14 to 15 showing primers used.
B. PCR-restriction enzyme digestion-PCR technique used to determine the JAK2 intron 14 SNP genotype
of JAK2 V617F mutant-positive alleles using gDNA
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5.2.6.2 JAK2 intron 14 SNP genotyping of V617F-positive alleles by PCR-restriction enzyme
digest-PCR
Neutrophil gDNA from patients who were heterozygous for rs12343687 was then studied using
a similar PCR-restriction enzyme digest-PCR technique to that described in Section 5.2.4 except
that a 482bp fragment was amplified covering the JAK2 exon 14 mutation site and the
rs12343687 SNP in intron 14 (Figure 5.3B). A first round PCR was performed using GoTaq® DNA
polymerase, primers JAK2ex14/(MM)F and JAK2ex14/(MM)R, 35 cycles of PCR at an annealing
temperature of 59°C. PCR products were digested using AflIII as described in Section 3.2.3
which cut the WT allele so that only mutant-positive PCR products were re-amplified in a
second round of PCR. Conditions for the second round PCR were identical to those used in the
first-round PCR but with 1µL of the digest diluted 1 in 20 as template. The JAK2 V617F status of
the second-round PCR products was then determined using the PCR-restriction digestion
technique described in Section 5.2.2.1, followed by determination of their rs12343687 status
as described in Section 5.2.6.1.
5.2.6.3 JAK2 intron 14 genotyping of V617F-positive alleles by TA cloning
TA cloning was performed in three patients, using the same approach to that described in
Section 5.2.5 except that competent bacteria were transformed with the 482bp PCR product
which spanned the JAK2 exon 14 mutation site and rs12343687 in intron 14. This was amplified
from neutrophil gDNA using primers JAK2ex14/(MM)F and JAK2ex14/(MM)R as described in
Section 5.2.6.2. V617F-positive clones were identified by PCR and restriction enzyme digestion
as described in Section 5.2.2.1 and the rs12343687 allele present in these clones was
determined as described in Section 5.2.6.1. For both PCRs, 1µL bacterial suspension was added
to the 20µL PCR mix as template and prior to the first cycle of PCR, the reaction mix was
incubated for 2 minutes at 95°C to lyse the bacteria.
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5.2.7 X-chromosome inactivation analysis of erythroid burst-forming units (BFU-Es)
To establish whether V617F-positive haemopoietic progenitors shared a common clonal origin,
BFU-Es were cultured from mononuclear cells (MNCs) from patients with mutant-positive ET.
JAK2 V617F-positive BFU-Es were then identified and analysed to determine their inactivated
X-chromosome.
5.2.7.1 Culturing BFU-Es from peripheral blood
To minimise contamination all processing except centrifugation was performed in a laminar air
flow cabinet. Approximately 30mL peripheral blood was collected in EDTA and centrifuged for
15 minutes at 200g at room temperature and the platelet-rich plasma was removed. The buffy
coat of the remaining sample was then harvested and MNCs purified by Ficoll-Hypaque density
centrifugation as described in Section 2.1.3. They were resuspended in 15mL RPMI containing
10% FCS (RF10%) and spun for 5 minutes at 800g at room temperature. The supernatant was
removed, the pellet resuspended in 5mL RF10% and the resulting MNC suspension was
counted using a Sysmex KX21N whole blood cell analyser.
MACS HSC-CFU media complete with Epo (Miltenyi Biotec, Bisley, UK) was thawed at 37°C and
divided into 2.5mL aliquots. To each aliquot, an appropriate volume of the MNC suspension
was added to generate the following dilutions: 0.5x105 cells/mL, 1.0x105 cells/mL, 2.0x105
cells/mL and 4.0x105 cells/mL. At least four aliquots at each concentration were made up. Each
aliquot was vortexed and gently layered into a single well of a 6 well tissue-culture plate using
a 5mL syringe and kwill, ensuring no air bubbles were introduced into the media.
Approximately 3mL sterile PBS was added to the spaces between the wells, to prevent
dehydration of the media, and each plate was incubated at 37°C in a humidified atmosphere
containing 4% CO2.
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After 14 days, each well was inspected under a dissecting microscope and BFU-Es identified.
Single, discrete BFU-Es were harvested into 200µL PBS using a sterile fine-tip pastette and
centrifuged at 2000g for 5 minutes at room temperature. The supernatant was removed and
to each pellet 43µL TNE lysis buffer (10mM Tris-HCl, 400mM NaCl, 2mM EDTA) was added.
Samples were incubated on ice for 2 minutes, and 5µL 10% SDS and 1µL 20mg/mL proteinase K
added. Samples were then vortexed, incubated at 56°C for one hour and placed at -20°C for at
least 12 hours. After thawing, DNA was extracted by the addition of 1µL glycogen, 5µL 3M
sodium acetate and 150µL absolute ethanol, followed by centrifugation at 14,000g for 15
minutes at room temperature. The supernatant was removed, 200µL 75% ethanol added, and
the sample spun at 14,000g for 5 minutes at room temperature. The supernatant was again
removed, the DNA pellet allowed to air dry and resuspended in 15µL ddH20.
5.2.7.2 Identification of V617F-positive colonies
JAK2 V617F-positive colonies were identified by amplification refractory mutation system
(ARMS) PCR technique using the methodology of Jones et al (2005; Figure 5.4). This single-step
technique allowed more rapid analysis of large numbers of colonies than the PCR and
restriction enzyme digestion described in Section 5.2.2. Since mutant-positive colonies were
expected to be heterozygous for V617F, with a mutant level of 50%, a high-sensitivity
technique was not required. For this PCR, four primers were used in order to generate three
possible products – a 463bp common (control) product, a 229bp WT product, and a 279bp
mutant product. Two common intronic primers were used, both at 1μM: a forward primer 
(JAK2ex14/ARMS/FO) located in intron 13, upstream of the mutation site, and a reverse primer
(JAK2ex14/ARMS/RO) located in intron 14, downstream of the mutation site. These two
primers generated the 463bp common product regardless of the presence of V617F. In
addition, a WT-specific forward primer (JAK2ex14/ARMS/FW) was used at 0.5μM, which only 
annealed to the WT JAK2 sequence and together with JAK2ex14/ARMS/RO generated the
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229bp WT product. Finally, a V617F-specific reverse primer (JAK2ex14/ARMS/RM) was used at
0.5μM, which, in the presence of V617F and JAK2ex14/ARMS/FO, generated the 279bp mutant
product. GoTaq® PCR was performed as described in Section 2.2.3.2 except for the use of the 4
primers at the specified concentrations, with 1µL colony DNA as template. Thirty-two cycles of
PCR were performed, with an annealing temperature of 60°C, and products electrophoresed
and visualised as before.
A.
B.
Figure 5.4 JAK2 exon 14 ARMS PCR to detect V617F (based on Jones et al, 2005)
A. Schema for PCR showing JAK2 exons 14 and 15, the four primers used, and the three possible
products
B. Agarose gel (2%) showing the three possible products in four V617F-positive ET patients with known
mutant levels (indicated at the bottom of the gel), and one JAK2 WT control (‘WT’). ‘Neg’ indicates
negative control and ‘ladder’ indicates Bioline Hyperladder 4.
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5.2.7.3 Inactivated X-chromosome analysis of V617F-positive colonies
The inactivated X-chromosome of V617F-positive colonies was determined using a modified
HUMARA technique (Section 3.2.5). A digestion mixture containing 12.5 units HpaII, 2.5 units
RsaI and 1x manufacturer’s buffer 1 was prepared and made up to 2.5µL with ddH2O. To this
mix 2.5µL colony DNA was added and the mixture incubated overnight at 37°C. A PCR product
spanning the VNTR sequence in the first exon of the HUMAR gene was then amplified. A
reaction mix containing 1x manufacturer’s flexibuffer, 0.2mM each dNTP, 1ng/µL each
HUMARA primer and 1 unit GoTaq® Hot Start polymerase was prepared, made up to 15µL with
ddH20, and added to the 5µL digestion mix. Twenty-five cycles of PCR were performed, using
an annealing temperature of 68°C, and a final extension of 72°C for 15 minutes. Cycling
conditions were as described in Section 2.2.3.2.
PCR products were then analysed by fragment analysis, as described in Section 2.2.7, in order
to determine the inactivated HUMAR allele. Since all cells in each colony were descended from
a single cell, all would be expected to inactivate the same HUMAR allele. Consequently, only a
single primary peak was expected on fragment analysis. The presence of more than one
primary peak implied the presence of either two separate colonies or incomplete enzyme
digestion, and such results were repeated and excluded if persistent.
5.3 Results
5.3.1 JAK2 exon 19 SNP (rs2230724) genotyping in haematologically normal
controls and ET patients
A cohort of 114 haematologically normal controls, 111 ET patients and 26 PV patients was
screened to determine the rs2230724 genotype (AA, AG or GG). There was no difference in the
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distribution of SNP genotypes in ET patients, regardless of mutational status, or in PV patients
compared to normal controls (Table 5.1). However, when compared to the expected genotype
frequency based on HapMap European population data, there was a significant excess of A-
alleles in ET patients overall, V617F-positive ET patients, and PV patients (P<0.001, P= 0.03 and
P=0.04 respectively, Chi-square).
5.3.2 JAK2 exon 19 SNP genotyping of V617F-positive alleles using SNP rs2230724
Twenty-three V617F-positive ET patients were heterozygous for rs2230724, and of these 11
had cDNA available. Samples from these 11 patients were therefore screened for more than
one V617F-positive population, initially using the PCR-restriction enzyme digestion-PCR
technique. PCR products were visualised by agarose gel electrophoresis. Inspection of the gel
revealed that adequate first-round and second-round PCR products were amplified in 10 of the
11 patient samples studied; in the remaining patient (Table 5.2, patient E10) both PCR
products were too weak to allow accurate genotyping for V617F and the exon 19 SNP.
In the 10 samples where good PCR products were obtained, re-amplification of only mutant-
positive and not WT alleles in the second-round PCR was confirmed by exon 14 PCR and AflIII
digestion (Figure 5.5A). SNP genotyping of the second round PCR products from nine of the 10
patients showed a mixture of A and G alleles (Figure 5.5B) with only one patient (patient E1,
lane 3) showing only A alleles. This patient had a relative mutant level of 100%, consistent with
the presence of chromosome 9pLOH. The relative A:G allele proportions, as determined by
visual estimation of the two bands (Figure 5.5B), varied in the other nine patients (Table 5.2).
In six patients, the mutation arose principally on the A-allele (Table 5.2, patients E2,E3,E6, E8,
E9 and E10), in three it arose principally on the G-allele (patients E4, E7 and E11), and in one
patient the distribution between the two alleles was approximately equal (patient E5). This
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suggested that JAK2 mutations were present on both chromosomes in most of the patients
studied.
To ensure that these results were not due to incomplete BsaAI digestion of the WT PCR
product, which would mimic the mutant product, full-length PCR products covering the V617F
mutation and the SNP (exons 14-20) were TA cloned using neutrophil cDNA from five of these
patients. V617F-positive clones were identified and the exon 19 SNP present in these clones
determined. Between 29 and 33 V617F mutant-positive clones were genotyped from each
sample. In each case, both allele A and allele G clones were detected (Table 5.2, patients E7-
E11). In three cases, the majority of clones had allele A: 82%, 76% and 77% of clones
respectively in patients E8-E10. In one case allele A and G clones were approximately equal
(patient E7, 41% A clones), and in the remaining case there were more allele G clones (patient
E11, 23% A clones). In all these individuals, the results from the TA cloning approach mirrored
those from the PCR-restriction enzyme digest-PCR approach (Table 5.2).
Platelet samples from two patients gave comparable results to the neutrophil samples: 82%
and 78% allele A clones respectively in neutrophils and platelets from patient E8; 77% and 72%
from patient E9. Neutrophil samples taken from the same patient 23 months apart (patient E9)
were analysed and gave comparable results with 77% and 87% allele A clones respectively.
RNA from a purified bone marrow CD34+ sample was also available from this patient and
yielded similar results to the neutrophil sample, 78% allele A clones.
Of the 26 V617F-positive PV patients studied, ten were heterozygous at the exon 19 SNP and
cDNA was available for five of these. Neutrophil cDNA samples from these five patients were
screened using the PCR-restriction enzyme digestion-PCR technique for the presence of more
than one mutational event. In all five cases, the V617F-positive alleles were associated with a
single exon 19 SNP allele (allele A in every case; Figure 5.6).
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Figure 5.5 JAK2 exon 19 SNP genotype analysis of V617F mutant alleles in 11 ET
patients
A. Gel showing AflIII restriction enzyme digest of 14/(MM)F + 15/R PCR products amplified from the
798bp second-round PCR product. WT products were cut (28+141bp), V617F mutant-positive
products remained undigested (169bp).
B. Gel showing BstNI restriction enzyme digest of 18/F + 20/R PCR products amplified from the 798bp
second-round PCR product. Exon 19 SNP allele G products were cut (108+127bp), but allele A
products remained undigested (235bp).
Un=no restriction enzyme added. WTc = wild-type control. Gc=allele G control.
Breaks within a single panel indicate spliced lanes from a single run
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Figure 5.6 JAK2 exon 19 SNP genotype analysis of V617F mutant alleles in 5 PV
patients
A. Gel showing AflIII restriction enzyme digest of 14/(MM)F + 15/R PCR products amplified from the
798bp second-round PCR product. WT products were cut (28+141bp), V617F mutant-positive
products remained undigested (169bp).
B. Gel showing BstNI restriction enzyme digest of 18/F + 20/R PCR products amplified from the 798bp
second-round PCR product. Exon 19 SNP allele G products were cut (108+127bp), but allele A
products remained undigested (235bp).
Un=no restriction enzyme added. WTc = wild-type control. Gc=allele G control.
5.3.3 JAK2 intron 14 SNP genotyping of V617F-positive alleles using SNP rs12343687
DNA samples from the 11 ET patients investigated in Section 5.3.2 were genotyped for the
intron 14 SNP (rs12343687). Six were heterozygous for the intron 14 SNP and could therefore
be assessed for the presence of more than one V617F-positive population by PCR-restriction
enzyme digestion-PCR or TA cloning. Using the former technique, in all six cases the second-
round PCR amplified only V617F-positive PCR products (Figure 5.7A) and these mutant-positive
products contained a mix of C and T alleles at SNP rs12343687 (Figure 5.7B). In one patient
(E3), the mutation arose principally on the C allele, in two patients (E7 and E11) it arose
principally on the T allele, and in three patients (E5, E6 and E9) the distribution between the
two alleles was approximately equal.
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For three patients, the 482bp PCR product spanning the mutation site and the intron 14 SNP
was TA cloned. In two of these (Table 5.2, patients E3 and E7), the results from these
confirmed the results from the PCR-digest-PCR technique – i.e. mutant-positive clones were a
mix of C and T alleles at the intron 14 SNP. For patient E3, both the PCR-restriction enzyme
digest-PCR and the TA cloning approach indicated that JAK2 V617F had arisen principally on
the C allele, and in patient E7 both techniques indicated that the mutation arose principally on
the T allele. However, in one (patient E9) only one intron 14 SNP allele (C) was associated with
V617F-positive clones even though the PCR-digest-PCR technique suggested that the mutation
arose on both the C and T alleles (Figure 5.7B).
Figure 5.7 JAK2 intron 14 SNP (rs12343687) genotype analysis of V617F mutant
alleles in 6 ET patients
A. Gel showing AflIII restriction enzyme digest of 14/(MM)F + 14/R PCR products amplified from the
482bp second-round PCR product. WT products were cut (28+129bp), V617F mutant-positive
products remained undigested (157bp).
B. Gel showing BsaAI restriction enzyme digest of 14/F2 + 14/(MM)R products amplified from the
782bp second-round PCR product. Intron 14 SNP allele C products were cut (31+133bp), but allele T
products remained undigested (164bp).
Un=no restriction enzyme added. WTc = wild-type control. Cc=allele C control.
Breaks within a single panel indicate spliced lanes from a single run
These results were then compared with those obtained using the exon 19 SNP (rs2230724) for
the six patients for whom data for both SNPs was available. In two patients (E7 and E11) in
whom the mutation arose principally on the T allele at the intron 14 SNP, it arose principally on
the G allele at the exon 19 SNP. Conversely, in the single patient (E3) in whom the mutation
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arose principally on the C allele of the intron 14 SNP, it arose principally on the A allele at the
exon 19 SNP, and in one patient (E5) the mutation was equally distributed between the two
alleles at both SNPs. In two further patients (E6 and E9), however, the mutation was
distributed equally between both intron 14 SNP alleles but arose preferentially on the A allele
at the exon 19 SNP.
5.3.4 Genotyping of peripheral blood erythroid burst-forming units (BFU-Es)
Freshly-collected peripheral blood from female V617F-positive ET patients was required for
this assay. Of the eighteen appropriate patients under active follow-up, six were available to
provide samples and erythroid colonies from these six individuals were cultured and analysed
(Table 5.3). The mutant level in these patients varied between 5% and 35%, implying that
approximately 10% to 70% of the myeloid cells were mutant-positive, assuming that all
mutant-positive cells were heterozygous for the mutation (Scott et al, 2006). Two of the six
patients (E8 and E12) had polyclonal neutrophil XCIPs, two had clonal ones (E13 and E14), and
two had uninterpretable ones – one due to age (E6) and one due to constitutional skewing
(E7).
For each of the six patients studied, between 53 and 192 colonies were harvested and
underwent JAK2 V617F mutation screening. There was a significant correlation between the
V617F mutant level in neutrophil DNA and proportion of mutant-positive colonies for the six
patient samples (P=0.04, r2=0.71). Patients E6 and E7 had the highest mutant level, in keeping
with 70% and 46% of their cells being mutant-positive respectively, and the greatest
proportion of their colonies were V617F-positive, 98% and 35% respectively (Table 5.3).
Patient E13 had the lowest mutant level, equivalent to 10% mutant-positive cells, and the
lowest proportion of mutant-positive colonies, 4%. The other three patients had intermediate
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values for both the mutant levels and the proportion of erythroid colonies which were mutant-
positive.
Table 5.3 Summary of XCIP analysis of V617F-positive BFU-Es from 6 ET patients
* Assumes V617F-positive cells are heterozygous for the mutation
The inactivated HUMAR allele for every V617F-positive colony was analysed. In a proportion of
colonies it could not be established due to the presence of more than one peak on fragment
analysis, indicating contamination by another colony. For this reason the number or colonies
with a HUMARA result was generally smaller than the number of V617F-positive colonies
identified (Table 5.3). In five of the six patients, all the mutant-positive colonies from a single
patient inactivated the same HUMAR allele – the A allele in two patients (E7 and E13), and the
B allele in three patients (E6, E8 and E14). In one patient (E12), however, five (38%) of the 13
V617F-positive colonies inactivated the A allele, and eight (62%) inactivated the B allele. The
neutrophil and T-cell XCIPs in this patient were both 31%:69%.
Three of these six patients (E6-E8) had been investigated using TA cloning and found to have
more than one V617F-positive population (Section 5.3.2). All three of these patients appeared
to have the same inactivated X-chromosome in V617F-positive erythroid colonies.
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5.3.5 Calculation of neutrophil XCIP based on T-cell and BFU-E XCIPs and mutant
levels
The calculation described in Section 3.3.4 uses the T-cell XCIP and V617F mutant levels to
generate two different neutrophil XCIPs, depending on which X-chromosome is inactivated in
the V617F-positive population. The data presented in Table 5.3 allows the inactivated X-
chromosome of the mutant-positive populations to be deduced from the XCIP of the BFU-Es,
and the calculation can therefore be refined as follows:
Predicted neutrophil XCIP (A%:B%) = [(y/100 x AC) + (z/100 x %AT)] : [(z/100 x %BT) + (y/100 x
BC)]
where y is the percentage mutant-positive cells, z is the percentage WT cells, the T-cell XCIP is
AT%:BT%, and the ratio of inactivated A to B alleles in the V617F-positive colonies is AC:BC.
This calculation generates only a single predicted neutrophil XCIP, which was compared to the
observed value (Table 5.4). For the six cases studied the median difference between the
predicted and the observed neutrophil XCIP values was 12% (range 2-17%).
5.4 Discussion
The experiments reported in this chapter have investigated the possibility that there is more
than one JAK2 V617F-positive population in mutant-positive ET patients. Two different JAK2
SNPs were exploited in order to identify the allele on which the V617F mutation had arisen,
initially using a PCR-restriction enzyme digestion-PCR technique and then confirmed by TA
cloning. Erythroid colonies were subsequently cultured from PB MNCs from V617F-positive
female ET patients and mutant-positive colonies analysed to determine the inactivated X
chromosome in order to investigate whether they shared a common clonal origin.
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The results indicate that, in this small cohort of mutant-positive ET patients, the majority had
evidence for more than one V617F-positive myeloid population. In 10 of the 11 patients
studied the V617F mutation had arisen on both JAK2 alleles. This implies that, in these
individuals, the mutation was acquired on at least two different occasions. Because there are
only two possible alleles on which the mutation could arise, it is impossible to determine the
exact number of times the mutation has been acquired, except that it must have been more
than once. Poisson statistics suggest that there is likely to be more than two independent
mutational events in most cases: if there were just two events in a single individual, the
probability of that person acquiring each event on different alleles is 0.5, and therefore on
average only about half of the 11 individuals would be expected to harbour V617F on different
alleles. In fact 10 of the 11 cases studied had biallelic acquisition of V617F, and the probability
of this occurring by chance if each individual acquired the mutation just twice is small – equal
to 11/211 or 0.005. This suggests that the majority of the patients studied had more than two
mutational events. By contrast, in all five PV patients there was no evidence for more than one
mutational event.
In six ET patients, the mutation arose principally on the A-allele (Table 5.2, patients E2,E3,E6,
E8, E9 & E10), in three it arose principally on the G-allele (patients E4, E7 & E11), and in one
patient the distribution between the two alleles was approximately equal (patient E5). In the
two patients in whom platelet or CD34+ cell cDNA was analysed (patients E8 and E9), the A:G
ratio was comparable in these cells to that obtained in neutrophils. Likewise, analysis of
samples from the one patient (E9) at separate time points yielded equivalent results. This
suggests that the A:G ratio is similar regardless of cell lineage studied, which is compatible with
the idea of the mutational events occurring in a multipotent progenitor, and that it remains
stable over time.
The findings from the experiments using the JAK2 intron 14 SNP (rs12343687) supported these
conclusions. In the six patients who were heterozygous for this SNP, the PCR-restriction
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enzyme digest-PCR technique showed that mutant-positive alleles were associated with a mix
of C and T alleles. Data from the TA cloning approach was in keeping with the acquisition of
JAK2 V617F on both alleles in two of the three patients studied (E3 & E7; Table 5.2). In one
patient, however, (E9; Table 5.2) the mutant-positive clones carried only A-alleles at the intron
14 SNP, even though the PCR-restriction enzyme digest-PCR technique suggested a mix of
mutant-positive alleles. The reason for this discrepancy is unclear, but may be due to chance
since only 14 mutant-positive clones were analysed.
Data from haplotype analysis (see Chapter 6) suggests that the C allele at rs12343687 and the
A allele at rs2230724 are both part of the 46/1 haplotype. In keeping with this, the patient (E3)
who predominantly acquired V617F on the C allele at rs12343687 also predominantly acquired
the mutation on the A allele at rs2230724. Conversely, the two patients (E7 and E11) who
predominantly acquired V617F on the T allele at rs12343687 also predominantly acquired the
mutation on the G allele at rs2230724. On patient (E5) appeared to acquire the mutation
equally on both alleles for both SNPs investigated. In two patients (E6 and E9) the two SNPs
gave discordant results – in both cases the SNP rs12343687 data suggested that the mutation
was acquired equally on both alleles whereas the SNP 2230724 data indicated preferential
acquisition of the mutation on the A allele.
Overall, these results strongly suggest that ET patients may acquire JAK2 V617F more than
once. This is not the first evidence for the existence of multiple mutant-positive myeloid
populations in MPN patients. Pardanani et al (2008) and Beer et al (2009) both reported that
approximately 0.5-1% of MPN patients harboured more than one MPN-associated mutation
(see Section 5.1.2). However, the data reported in this chapter goes further and suggests that
the majority (10 of 11 patients studied, 91%) of ET patients have more than one V617F-
positive population.
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Data from Olcaydu et al (2009) supports the assertion that MPN patients may have more than
one V617F-positive population, although they observed a markedly lower prevalence of this
phenomenon. In their seminal study reporting the existence of a haplotype associated with
acquisition of JAK2 V617F, they analysed a PCR product spanning both the mutation site and
the intron 14 SNP by allele-specific PCR and observed that V617F preferentially arose on the
46/1 haplotype allele (93 of 109 patients, 85%). In three cases (3%), however, the mutation
appeared to have arisen on both alleles. The authors concluded that there was evidence for
more than one V617F events in a minority of MPN patients. They speculated that the true
prevalence was likely to be greater than 3% since patients in whom all the mutations had
arisen on the same allele would appear to have just a single mutational event using this
technique.
This does not, however, explain the marked difference between the proportion of patients
with biallelic JAK2 V617F mutations reported by Olcaydu et al (2009) and that observed in our
cohort – 3% and 91% respectively. It may be in part due to differences in the patient cohort. Of
the five PV patients reported in this thesis, none had evidence for more than one V617F-
positive event, and it may be that the frequency of this phenomenon is lower in PV than in ET.
Consequently, the presence of PV patients in the Olcaydu et al (2009) series might have
reduced the apparent frequency of biallelic mutations. Since the composition of their MPN
cohort is not reported, this cannot be verified.
Another suggested explanation for this difference is that the apparent proportion of patients
with biallelic mutations in our cohort was exaggerated by PCR artefact due to use of relatively
high PCR cycle numbers, resulting in template switching during PCR extension and the
generation of chimeric DNA molecules (Beer et al, 2010b). They argued that the true
prevalence of more than one V617F event in ET is 5-10%. Although this is a possibility, if the
findings presented in this chapter were due to random PCR error, it is improbable that two
different samples, either from two different lineages or two separate time points, from the
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same patient would consistently yield similar A:G ratios whilst samples from different patients
produced different ones. Moreover, in all five PV patients studied JAK2 V617F was present only
on one allele (the A-allele), despite using identical methodology.
Regardless of the precise figure, it is apparent that a proportion of ET patients have more than
one V617F-positive myeloid population. This does not, however, prove that the disorder is
truly polyclonal, since all the mutant-positive populations may be derived from a pool of
clonally-related progenitors which were themselves derived from a single transformed
precursor, implying the existence of a pre-V617F event. In this case, in female patients all the
V617F-positive cells would share a common inactivated X-chromosome. Alternatively, the
mutant-positive cells may be derived from ‘normal’ polyclonal progenitors, implying that
acquisition of JAK2 V617F was the initial pathogenic event, and the disorder is truly oligo- or
polyclonal. In this case the V617F-positive cells would not necessarily share a common
inactivated X-chromosome. For this reason, establishing the clonal relationship of the V617F-
positive cells was particularly important in providing an insight into the pathogenesis of the
disease.
XCIP analysis of V617F-positive BFU-Es was performed in six patients. In one patient 38% of
colonies inactivated one X-chromosome whilst 62% of colonies inactivated the other – a ratio
which was similar to the patient’s constitutional XCIP (31%:69%). It therefore appears that in
this patient the mutation arose independently in more than one clonally unrelated progenitor.
Results from the other five patients suggested that in these cases all the V617F colonies
inactivated a single X-chromosome, in keeping with the progenitors which acquired JAK2
V617F being phylogenetically related and therefore the progeny of a single transformed
precursor. It is also possible, however, they were not clonally related and simply shared a
common inactivated X-chromosome by chance. The chance of two unrelated progenitors
sharing the same inactivated X-chromosome will depend on the patient’s constitutional (i.e. T-
cell) XCIP – for instance in patient E7 (Table 5.3), whose T-cell XCIP was 82%:18%, the chance
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of the mutation arising in two unrelated progenitors which both inactivate the A-allele is
approximately (82%)2 i.e. 67%. Given the relatively small number of colonies with XCIP results
(between 3 and 37), it is possible that in some cases the colonies shared the same inactivated
X-chromosome by chance.
If the inactivated X-chromosome observed in the V617F-positive colonies is taken to reflect the
overall XCIP of the mutant-positive population, it can be used to predict the neutrophil XCIP of
these six patients, based on the T-cell XCIP and the size of the mutant-positive population, as
described in Section 5.3.5 (Table 5.4). In every case, the difference between the expected and
the observed neutrophil XCIP was within the technical limits of the HUMARA (20%). This is in
keeping with one of the conclusions drawn in Chapter 3 – that the neutrophil XCIP is a function
of the T-cell XCIP, the mutant level, and the XCIP of the mutant-positive population – but
refines it by accommodating the possibility that the V617F-positive cells may not necessarily all
inactivate the same X-chromosome, as in patient E12.
Whilst it is not possible to draw firm conclusions from such a small cohort, the data suggests
that at least some patients may harbour more than one V617F-positive population which are
not clonally related and have arisen from polyclonal progenitors, although in the majority the
mutant-positive populations are phylogenetically related and derived from a single
transformed precursor. Studies in larger numbers of patients are required to confirm these
observations.
These finding are compatible with those of Beer et al (2009) who determined the XCIP of the
mutant-positive colonies in three female patients that carried two distinct mutant populations,
either V617F and MPL W515, or V617F and a JAK2 exon 12 mutation. They observed that in
two, including one ET patient, the colonies carrying different mutations inactivated different X-
alleles, proving that in these two patients the two clones had arisen independently and were
not from a shared founder clone. Mutant-positive colonies from the third patient all expressed
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the same X-chromosome. This would suggest that the sequence of mutational events varies
between patients.
In keeping with this, studies which have attempted to determine the timing of acquisition of
V617F in relation to other mutations have come to contradictory conclusions. Some published
reports have suggested that JAK2 V617F is primarily a secondary molecular event in MPN.
Levine et al (06 2006) reported that in 23% of V617F-positive ET patients, the clonal myeloid
population based on XCIP analysis was larger than the V617F-positive one. They argued that
this implied the presence of a pre-JAK2 clone, from which the JAK2 V617F-population was
derived. Kralovics et al (2006) came to the same conclusion, also by comparing XCIP and V617F
data, as did Delhommeau et al (2009) but using a different method. Delhommeau et al (2009)
employed haematopoietic colony analysis to determine the sequence of mutational events in
five patients with JAK2 V617F-positive TET2-mutated MPN, including one case of ET. In all five
cases, they detected TET2-mutated haemopoietic colonies which were JAK2 WT, but they did
not identify any V617F-positive, TET2 WT colonies. They interpreted this as evidence that in
these patients acquisition of TET2 mutations preceded acquisition of JAK2 V617F. Similarly
Beer et al (2010a) identified an individual with post-ET AML who had both MPL-mutated and
V617F-positive populations, each of which was shown to be derived from a common TET2-
mutated clone.
There is, however, evidence that JAK2 V617F may precede other molecular abnormalities.
Colony analysis by Schaub et al (2009) suggested that in three of nine MPN patients with both
JAK2 V617F and del20q, including 2 ET patients, V617F preceded del20q, whereas in two
patients the reverse was true. In the remaining four cases there was evidence for multiple
del20q and 9pLOH events, and the sequence was uncertain. The same group subsequently
investigated eight patients with V617F-positive, TET2-mutant MPN and found that in four
patients the TET2 mutation appeared to arise first, in two patients V617F arose first, and in the
remaining two patients there were two distinct populations each carrying a single mutation
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(Schaub et al, 2010). Saint Martin et al (2009) also identified a single PV patient who appeared
to have acquired JAK2 V617F prior to TET2 mutations.
Taken together, these reports emphasise the heterogeneity of the molecular pathogenesis of
V617F-positive ET, and that the role of the mutation in the disorder is not straightforward. This
concept is in keeping with the main finding from the experiments presented in this chapter –
that a large proportion of ET patients have more than one V617F-positive population, and that
in some patients these populations are clonally distinct whereas in others they are likely to be
phylogenetically related. It thus appears that whilst some patients have a monoclonal mutant-
positive population, others have an oligoclonal population with more than one independent
V617F-positive clone. This latter situation is reminiscent of paroxysmal nocturnal
haemoglobinuria (PNH). Multiple clones, each with a different mutation in the
phosphatidylinositol glycan anchor (PIGA) gene, are seen in some PNH patients, and the extent
to which the clones expand varies widely among patients (Parker 2007).
PNH is generally considered to be a benign disorder and shares a number of key characteristics
with V617F-positive ET. In both conditions, the expansion of mutant-positive clones is limited
and the peripheral blood is a relatively stable mosaic of normal and abnormal cells, the most
common serious complications are thrombotic, and transformation to AML occurs more
frequently than in haematologically normal individuals but is nonetheless uncommon (Parker
2007). Consequently some patients with JAK2 V617F may have a benign disorder, and the
presence of the mutation should not invariably be taken to indicate the presence of a
malignant neoplasm.
These findings raise two further questions. If the mutation does arise repeatedly in V617F-
positive ET patients, why does the mutant level remain stable, often for many years; and what
causes a specific mutation which is not observed in normal controls to occur repeatedly in
some individuals?
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Addressing the first question, it is not known why repeated acquisition of JAK2 V617F
mutations in WT progenitors does not result in a progressive increase in the mutant level. One
possibility is that the V617F-positive progenitors have a limited lifespan, resulting in an
equilibrium in which the size of the V617F-positive population is determined by the rate at
which old mutant-positive progenitors die and new ones arise. Alternatively, there may be
some limit on the total size of the mutant-positive population, governed perhaps by the
proliferative advantage conferred by JAK2 V617F compared to its JAK2 wild-type counterparts.
If JAK2 V617F is a second event and arises in pre-transformed progenitors, those JAK2 WT
progenitors which are also part of the pre-transformed clone may have a proliferative or
survival advantage compared to truly normal progenitors. The relative advantage of acquiring
JAK2 V617F might then be less marked than if it were acquired on a normal background, and
expansion of V617F-positive cells would be correspondingly slower. In this way it is possible
that the nature of the pre-JAK2 mutation determines the size of the stable V617F-positive
population, and therefore the disease phenotype (ET or PV). The second question, why a
specific mutation should occur repeatedly in some individuals, is even more intriguing but
there is increasing evidence for an inherited predisposition to developing V617F-positive
MPNs. The observation that PV patients and those with V617F-positive ET had a significant
excess of A-alleles at the JAK2 exon 19 SNP (Table 5.1) suggested an association between these
disorders and this SNP. In fact, this SNP is part of a wider MPN-associated haplotype, a subject
which is explored in detail in the next chapter.
In conclusion, the findings presented in this chapter suggest that some, and possibly most,
patients with JAK2 V617F-positive ET have more than one mutant-positive population. In many
cases these appear to be clonally related and may therefore have arisen from a larger clonal
population, but in at least some cases they are unrelated and may indicate that JAK2 V617F
has been acquired by a number of polyclonal haematopoietic progenitors. This is compatible
with other studies which have indicated that ET is a heterogeneous disease, and suggests that
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the role of JAK2 V617F in the pathogenesis of ET is complex and not directly analogous to that
of BCR-ABL in CML. Finally, these results show that at least some V617F-positive ET patients
have an oligoclonal disorder, in keeping with its benign clinical course, and more generally they
indicate that the presence of an acquired mutation in a haematological disorder does not
necessarily imply the presence of a malignant disease.
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6 Investigations into the 46/1 haplotype
6.1 Introduction
Inherited causes of thrombocytosis which show classical Mendelian inheritance are well
described but uncommon (Table 1.3). Moreover, they do not behave like sporadic ET, since
individuals with these conditions typically develop a polyclonal thrombocytosis at an early age,
do not manifest the increased risk of thrombotic and leukaemic complications seen in the
sporadic variant, and very rarely harbour the mutations associated with sporadic ET (Skoda
2009; Teofili et al, 2007). There is, however, increasing evidence that at least a proportion of
patients with sporadic ET have an inherited predisposition to develop the disorder. This
chapter will examine this phenomenon and investigate possible underlying mechanisms.
6.1.1 Familial clustering of ET
Familial clustering of individuals with classical, adult-onset ET and other MPNs has been
repeatedly described (Brubaker et al, 1984; Fickers and Speck 1974; Janssen et al, 1990) but
was for many years regarded as a rare phenomenon of questionable significance. It was
thought that, whilst this might have suggested the existence of a genetic or environmental
factor which predisposed to the development of MPNs in a small number of cases, it may
equally well have been due to chance (Perez-Encinas et al, 1994). A recent Swedish Registry
study (Landgren et al, 2008), however, has convincingly demonstrated that this clustering is
unlikely to be due to chance. This study determined the relative risk (RR) of developing an
MPN for 24,577 first-degree relatives of 11,039 MPN patients, compared to 99,542 first-degree
relatives of 43,550 haematologically normal matched controls. The overall RR was 5.6 times
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greater in relatives of MPN patients compared to relatives of controls, although it varied
depending on the MPN subtype of the proband. First degree relatives of ET patients had a RR
of 6.8 compared to control relatives of developing an MPN, not necessarily ET, but this figure
was 4.9 and 2.7 for relatives of PV and MF patients respectively. Relatives of ET patients were
at greatest risk of developing ET (RR = 8.0) but also had an increased risk of developing PV (RR
= 5.4), whilst relatives of PV patients had a similar risk of developing both PV and ET (RR = 6.0
and 5.4 respectively).
Familial clustering of MPN cases, therefore, appears to occur more frequently than would be
expected by chance, but the mechanism for this is unknown. Moreover, the majority of MPN
cases do not arise in familial clusters and it is possible that the clustered cases represent a
different disease than the much commoner sporadic ones, with a different pathogenesis. A
number of recent reports, however, suggest that this is not the case and that MPN patients
within family clusters frequently harbour the same genetic mutations as those with the
sporadic disorder.
Bellanné-Chantelot et al (2006) screened 46 ‘MPN families’ – defined as having at least two
members, mostly first-degree relatives, diagnosed with MPN – for the presence of JAK2 V617F.
They found that in 6 families the mutation was not detectable in any individual, in 22 families
all affected individuals carried the mutation, and most significantly, in 18 families some
affected individuals carried the mutation whilst others did not. This last finding suggested that
JAK2 V617F was not a prerequisite for development of MPN, even in patients with V617F-
positive relatives. Furthermore, in those family members with V617F-positive MPN, the
mutation was detectable in myeloid cells but, with one exception, not in their lymphoid cells.
None of their haematologically normal relatives harboured the mutation. This would suggest
that the mutation was acquired rather than constitutional. Combined with the observation
that in some families only a proportion of members with an MPN carried JAK2 V617F, this
might imply the existence of a heritable factor which predisposed to acquisition of several
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mutations, including JAK2 V617F, which in turn contributed to development of the MPN.
Another group subsequently reported similar findings in their study of 10 Italian MPN families
investigated with regards to JAK2 V617F status (Rumi et al, 2006). They observed that in four
families some, but not all, of the affected individuals carried JAK2 V617F, and in the V617F-
positive individuals the mutation was confined to myeloid cells. Of the 11 informative female
MPN patients studied using XCIP analysis, eight had clonal haemopoiesis, of whom seven were
V617F-positive.
The similarity between cases of sporadic MPN and those occurring within family clusters was
further highlighted by a later study which reported on 458 patients with apparently sporadic
MPN (Rumi et al, 2007). Detailed investigation of family members revealed that 35 (8%) of
these 458 patients in fact had a relative with an MPN. The natural history of the disorder was
similar regardless of whether or not the patient had an identifiable relative with MPN. Of note,
second-generation patients appeared to develop the disorder significantly earlier than first-
generation ones and exhibited telomere shortening, indicative of disease anticipation. As
noted in the previous studies, in some families only a proportion of MPN patients were JAK2
V617F-positive.
In summary, there is increasing evidence for the existence of a mechanism which confers an
inherited susceptibility to acquiring MPN-associated mutations such as JAK2 V617F in the
familial MPN clusters. Because sporadic MPN shares a number of clinical and molecular
characteristics with MPN occurring in familial clusters, such a mechanism may be common to
both variants. One possibility is that in the familial variant there is a germline mutation in an
unknown gene which results in a tendency to acquire further genetic events, and that this
mutation is acquired in the truly sporadic condition. Since mutations in TET2 occur in up to
17% of sporadic MPN patients (Delhommeau et al, 2009; Tefferi et al, 2009), and often
precede JAK2 V617F in patients who harbour both mutations, and because TET2 is believed to
be a tumour suppressor gene, inherited mutations in this gene were proposed as a mechanism
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for familial MPNs (Saint-Martin et al, 2009). However, two studies have failed to support the
suggestion that germline mutations in TET2 underlie the familial occurrence of MPN (Olcaydu
et al, 2010; Saint-Martin et al, 2009).
6.1.2 The 46/1 haplotype
Currently, therefore, no single mutation has been found to convey an increased risk of
acquiring MPN-associated mutations. Instead, there is evidence that a specific haplotype
within the JAK2 gene may do so, at least in sporadic MPN. Three initial studies reported an
association between this haplotype and V617F-positive MPNs, though it was unclear whether
the haplotype also predisposed to V617F-negative MPNs (Jones et al, 2009; Kilpivaara et al,
2009; Olcaydu et al, 2009). All three studies, published simultaneously, arrived at similar
conclusions using different approaches.
Jones et al (2009) set out to investigate whether JAK2 V617F arose in association with a
particular JAK2 haplotype by studying six JAK2-spanning SNPs (Figure 6.1): rs7864782 (A/G),
rs10758669 (A/C), rs7046736 (A/C), rs1234241 (G/C), rs10974947 (A/G) and rs 2031904 (A/G).
They selected 142 MPN patients who were heterozygous for these SNPs and had a mutant
level greater than 50%, which was taken to indicate the presence of 9pLOH. They predicted
that 9pLOH should result in preferential amplification of the SNP allele which was in cis with
the mutant allele. By determining the allelic ratios at each SNP using pyrosequencing, they
established the SNP allele sequence on which the mutation had arisen. In 109 (77%) of the 142
patients studied, the mutation had been acquired in cis with one particular haplotype,
characterised by the SNP allele sequence ACAGGG at the six loci studied.
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They then analysed the Wellcome Trust Case Control Consortium (WTCCC) SNP data from
1,500 UK blood donors and concluded that, in these haematologically normal controls, a 280kb
linkage disequilibrium (LD) block existed spanning JAK2 and two neighbouring genes, INSL4
and INSL6. Within this block, 92 JAK2 haplotypes were apparent and one of these, designated
number 46, had the allele sequence ACAGGG at the six SNPs initially studied. Another
haplotype, number 1, had five of these six alleles at the same loci. Jones et al (2009) focused
on a total of 20 JAK2 SNPs, and at 19 of these, haplotypes 1 and 46 were mutually identical and
were therefore referred to jointly as the 46/1 haplotype. This combined haplotype
represented 24% of the WTCCC cohort. Using C/G SNP rs12340895, which was not one of the
six SNPs originally investigated but was in complete LD with the 46/1 haplotype, they
determined the haplotype frequency amongst a larger cohort of MPN patients and
haematologically normal controls. The G allele, which tagged the 46/1 haplotype at
rs12340895, was over-represented in PV and V617F-positive ET patients, and in one of the two
groups of V617F-negative ET patients studied. Using allele-specific PCR, they then amplified a
fragment spanning V617F and rs12343867, a C/T SNP located in JAK2 intron 14, which was also
in LD with 46/1. Sixty-six patients who were heterozygous for both the mutation and the SNP
were investigated and in 49 (74%) cases the mutation arose in cis with the C allele, which
tagged the 46/1 haplotype. They concluded that the 46/1 haplotype predisposed to the
development of V617F-associated MPNs, either by increasing the somatic mutation rate at this
locus (the ‘hypermutability’ hypothesis) or by enhancing the selective advantage of the
mutation when acquired in the presence of it (the ‘fertile ground’ hypothesis).
Olcaydu et al (2009) arrived at similar conclusions in their study which initially set out to
examine the relationship between JAK2 V617F, del13q and del20q in a patient with MF using
haemopoietic colony analysis. They noted that two V617F-positive populations were apparent,
each of which carried a different cytogenetic abnormality and appeared to have acquired JAK2
V617F independently. Like Jones et al (2009), they used allele-specific PCR to amplify a product
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spanning V617F and SNP rs12343867 in JAK2 intron 14, but here the purpose was to screen
MPN patients for multiple V617F events. Analysis of 109 V617F-positive MPN patients who
were heterozygous for this SNP revealed that in three cases (2.8% of the cohort) the mutation
had arisen in cis with both SNP alleles in a single individual, in keeping with more than one
V617F event. Moreover, in the 106 individuals in whom there was no evidence of multiple
V617F events, the mutation had arisen in cis with the C allele in 93 of them (88%). Examination
of a larger cohort of 333 MPN patients, of whom 213 were V617F-positive, revealed an
association between the C allele at SNP rs12343867 and V617F-positivity. Similar analysis of a
further seven JAK2 SNPs revealed that at three of them, rs3780367, rs10974944 and
rs1159782, a specific allele (G,G and C respectively) was associated with V617F-positivity. The
authors concluded that this defined a haplotype, termed ‘GGCC’, which predisposed to
acquisition of JAK2 V617F. Their work suggested that this haplotype was confined to a 10kb
region of JAK2, located within the larger LD block identified by Jones et al (2009). Since this
10kb haplotype did not contain the promoter regions of the gene, which would affect its
expression, they suggested that a difference in mutability between the two haplotypes might
explain their findings.
In the third study, Kilpivaara et al (2009) performed genome-wide SNP analysis on neutrophil
DNA from 181 ET and PV patients to investigate the hypothesis that germline variation
contributed to both predisposition to MPNs and phenotypic differences between the
disorders. They observed that, compared to 1500 haematologically normal controls, V617F-
positive MPN patients – but not, JAK2 WT ones – were significantly more likely to have a G
rather than a C allele at SNP rs10974944, located in JAK2 intron 12. This association was
present regardless of whether neutrophil or buccal DNA from the MPN patients was studied,
suggesting it was an inherited phenomenon and not due to somatic abnormalities in
neutrophils, such as acquired UPD of chromosome 9. Using allele-specific PCR to amplify a DNA
fragment spanning both the SNP and JAK2 exon 14, they also noted that 38 of 45 (84%) V617F-
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positive patients who were heterozygous for the SNP had acquired the mutation in cis with the
G allele. They concluded that their data indicated the presence of a JAK2 SNP allele which
favoured the in-cis acquisition of JAK2 V617F.
Taken together, the three seminal studies described above suggested that V617F-positive MPN
patients were more likely to have a specific JAK2 haplotype than haematologically normal
controls, and that the mutation usually, but not invariably, arose in cis with this haplotype.
Subsequent studies using a single tagged SNP have confirmed the association between the
46/1 haplotype and V617F-positive, but not JAK2 WT, MPNs (Andrikovics et al, 2010;
Pardanani et al, 2010; Trifa et al, 2010).
Establishing whether or not the association is confined to V617F-positive disorders is
important since it will strongly indicate which of the two postulated mechanisms is more likely.
If the association extends to JAK2 WT MPN, the argument for the ‘fertile ground’ hypothesis is
greatly strengthened, since it is difficult to explain how a JAK2 haplotype could influence the
mutability of other genes. Consequently, the recent finding that the 46/1 haplotype is
associated with MPL W515 mutations is potentially of great significance and supports the
‘fertile ground’ hypothesis, since the MPL gene is located on chromosome 1p (Jones et al,
2010). This study pooled data from UK, German, Italian and Greek cohorts and reported that
the frequency of 46/1 alleles in 176 MPL W515-mutated ET patients was significantly higher
than in controls (0.37 versus 0.28, P=0.0003). However much of this difference was due to a
relatively high 46/1 allele frequency in the small Greek and Italian cohorts (n = 24 and 27
respectively) of 0.46 and 0.43 respectively. By contrast, in the larger UK and German cohorts (n
= 56 and 69 respectively), the 46/1 allele frequency was 0.34 and 0.36 respectively, and not
significantly higher than in controls (P=0.164 and 0.267 respectively). Furthermore, a similar
study by Patnaik et al (2010) found that the 46/1 allele frequency amongst 22 MPL W515-
positive MPN patients (0.25) was not significantly higher than in local or WTCCC controls. The
association between the 46/1 haplotype and MPL W515 is, therefore, not strong. It is possible
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that both the ‘hypermutability’ and ‘fertile ground’ mechanisms are involved, and this would
explain the stronger association between the haplotype and V617F-positive MPN than with
JAK2 WT MPN.
6.1.3 Possible mechanisms underlying the association between the 46/1
haplotype and MPNs
In order to explain the ‘fertile ground’ mechanism, Jones et al (2009) speculated on the
existence of a functional variant in LD with 46/1 which interacted with JAK2 V617F so that
acquisition of the mutation on the background of this haplotype was more likely to result in
clinical disease than if it arose on the non-46/1 haplotype. They postulated that, if the 46/1
haplotype was preferentially expressed, then in-cis acquisition of JAK2 V617F might result in
increased expression of the mutant allele, potentially resulting in a proliferative advantage for
the mutated cells. They, therefore, investigated expression of two JAK2 SNPs which were part
of the 46/1 haplotype – rs2230724 in exon 19 in 29 normal controls, and rs10429491 in exon 6
in 40 normal controls – and found that at both loci expression of the 46/1 allele was no
different to that of the non-46/1 allele. Since only normal controls were examined, however,
the possibility of aberrant expression of the 46/1 allele in individuals with MPN, possibly due
to a functional interaction with JAK2 V617F, could not be excluded.
Another possible mechanism for the ‘fertile ground’ hypothesis postulated by Jones et al
(2009) is that the 46/1 haplotype is in LD with a functional variant which results in different
baseline myeloid proliferative activity in 46/1-positive individuals compared to non-46/1
individuals. Acquisition of JAK2 V617F might have different effects in these different contexts.
They therefore, assessed myeloid colony formation in 56 normal controls with and without the
46/1 haplotype. Peripheral blood derived from individuals who were either homo- or
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heterozygous for 46/1 grew significantly fewer granulocyte-macrophage colony-forming units
than blood from individuals who were homozygous for the non-46/1 haplotype, although
there was no difference in the number of BFU-Es. The authors interpreted this as evidence that
the 46/1 haplotype affected myeloid proliferation and that this was more suggestive of the
‘fertile ground’ rather than ‘hypermutability’ hypothesis. MPN patients were not studied, and
the authors did not speculate further on potential mechanisms for this functional interaction.
Two studies have evaluated presentation blood counts in 46/1-positive and 46/1-negative
MPN patients and found no difference in any parameter, suggesting that if any difference
exists it is very subtle (Jones et al, 2010; Pardanani et al, 2010).
Although no association between the 46/1 haplotype and blood counts has yet been
described, a genome-wide analysis of 13,943 patients did identify an association between
another chromosome 9 SNP and variability in platelet counts (Soranzo et al, 2009). This SNP,
rs505534, is located in an intergenic region of chromosome 9p23 approximately 8 megabases
upstream from JAK2. If one of the rs505534 alleles is associated with a platelet count towards
the upper limit of normal then acquisition of a mutation such as JAK2 V617F or MPL W515 by a
patient with a particular rs505534 genotype might be sufficient to generate the ET phenotype.
In this case, an association might be expected between a particular rs505534 SNP allele and
ET.
A further hypothesis to explain the association between V617F-positive MPNs and the 46/1
haplotype which has not been explored to date is that the latter affects JAK2 methylation. In
the presence of the 46/1 haplotype, at least two SNPs, rs12343867 and rs12340895, both
located in JAK2 intron 14, generate CpG dinucleotides which are lost in the absence of the 46/1
haplotype. Since cytosine bases within CpG dinucleotides may be methylated to form 5-
methylcytosine, the presence of the 46/1 haplotype might thus alter the number of CpG
dinucleotides available for methylation. Aberrant gene methylation has been implicated in the
pathogenesis of many human malignancies, including numerous haematological cancers
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(Esteller 2003; Feinberg and Vogelstein 1983). The best described mechanism involves the
hypermethylation of promoter regions of tumour suppressor genes which normally prevent
cells with DNA damage from proliferating. The consequent reduction in their expression allows
genetically-mutated cells to accumulate (Esteller 2008). Even when promoter regions are not
affected, aberrant methylation can predispose to hypermutability by altering the DNA
conformation and inhibiting DNA mismatch repair (Muheim et al, 2003). Furthermore, the
tendency of 5-methylcytosine to undergo spontaneous deamination to thymine (Coulondre et
al, 1978) can also lead to hypermutability.
Mutations in TET2, a member of the TET family of putative tumour suppressor genes which are
believed to be involved in epigenetic regulation, have been described in a small number of ET
patients and it has been suggested that these may result in abnormal methylation (Mullighan
2009; Tahiliani et al, 2009). It is possible that mutations in TET2, or other genes regulating
methylation, could interact with the 46/1 haplotype and lead to aberrant JAK2 methylation
thereby predisposing to MPN by increasing the JAK2 mutation rate.
6.1.4 Aims
The work in this chapter aimed to study the incidence of the 46/1 haplotype in the cohort of
patients described earlier in this thesis, and to investigate possible mechanisms for the ‘fertile
ground’ and ‘hypermutability’ hypotheses, namely preferential expression of the 46/1
haplotype, an association between an rs505534 allele and MPN, and aberrant JAK2
methylation in the presence of the 46/1 haplotype.
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6.2 Patients, materials and methods
6.2.1 Screening JAK2 V617F-positive patients for the 46/1 haplotype using 5 JAK2
SNPs
Initially, DNA from the 11 well-characterised ET patients described in sections 5.2.2 and 5.2.3
was screened for the presence of the 46/1 haplotype by PCR and restriction enzyme digestion.
Five SNPs which were reported to be associated with the 46/1 haplotype were selected (Figure
6.2). Primers were designed to amplify a fragment spanning the SNP and then allow
discrimination between the two possible alleles by restriction enzyme digestion. For two SNPs
(rs3780367 and rs10974944), restriction enzymes were available which could distinguish
between the two SNP alleles directly but for the other three SNPs mismatched primers were
required to generate a cutting site. Using the reagents and conditions described in Table 6.1,
GoTaq® PCR (see Section 2.2.3.2) was performed using T-cell gDNA as template for each of the
five SNPs to amplify a PCR product which was then digested using the specified restriction
enzyme. A digestion mix was prepared containing 5 units of the appropriate enzyme, 1x
appropriate buffer and where specified 100μg/mL BSA. The mix was made up to 3μL with 
ddH2O and to this 7μL PCR product was added. The resulting mix was incubated using the 
conditions shown in Table 6.1. Following 3% agarose gel electrophoresis, digestion products
were visualised by UV transillumination and the alleles identified by their size (Table 6.1). All
primer sequences are listed in Appendix 1.
6.2.2 Screening for the presence of the 46/1 haplotype using SNP rs12343867
To screen the whole ET patient cohort and a group of haematologically normal controls for the
presence of the 46/1 haplotype, each individual was genotyped for a single tagged SNP,
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rs12343867, which is in complete LD with the 46/1 haplotype. Using primers JAK2ex14/F2 and
JAK2ex14/(MM)R which spanned this SNP (Figure 6.2), a 164bp PCR product was amplified
from T-cell gDNA by GoTaq® PCR with 35 cycles of PCR and an annealing temperature of 59°C.
A digestion mix was then prepared containing 5 units BsaAI enzyme and 1x manufacturer’s
buffer 3, made up to 3μL with ddH2O, and to this 7μL PCR product was added. The resulting 
mix was incubated for 4 hours at 37°C. Following 3% agarose gel electrophoresis, digestion
products were visualised by UV transillumination. BsaAI cut the C-allele to 133 and 31bp but
did not cut the T-allele (164bp).
6.2.3 Expression analysis of the 46/1 and non-46/1 alleles
To investigate the hypothesis that preferential expression of one of the 46/1 alleles might
account for the association between JAK2 V617F and the 46/1 haplotype, the relative
expression of the two alleles (A/G) of rs2230724, a 46/1-associated SNP located in exon 19 of
JAK2 was analysed using cDNA. A PCR-restriction enzyme digestion approach was adopted to
distinguish between the two alleles, and the relative amounts of each one quantified by
fragment analysis.
6.2.3.1 Validation of the technique using neutrophil gDNA
To ensure the technique was quantitative, analysis was initially performed using neutrophil
gDNA from 22 normal controls who were heterozygous for rs2230724 where a 1:1 allelic ratio
was expected. A 214bp fragment covering JAK2 exon 19 and part of the flanking introns was
amplified by PCR using BIOTAQ™ polymerase as described in Section 2.2.3.1, with primers
JAK2ex19/F and fluorescently-labelled JAK2ex19/RF, an annealing temperature of 60°C, 25
cycles of PCR, and approximately 50ng of neutrophil gDNA as template per reaction (Figure
6.3A). A digestion mix was prepared containing 5 units BstNI, 1x manufacturer’s buffer 2,
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100μg/mL BSA, made up to 3µL with ddH2O and 5µL PCR product added. This was incubated
for 2 hours at 60°C then separated by fragment analysis using the CEQ 8000 Genetic Analysis
system. BstNI cut the G allele to 121 and 93bp but the A allele remained uncut (214bp). The
relative amount of each allele was calculated from the area under the appropriate peak and
expressed as a proportion of the total area of both peaks.
Figure 6.3 Schematic representation of PCR of JAK2 exon 19 followed by BstNI
digestion to determine expression of A and G alleles at SNP rs2230724
A. Using gDNA as template
B. Using cDNA as template
6.2.3.2 Expression analysis in neutrophil cDNA
To be suitable for analysis, subjects had to be heterozygous for the SNP and have neutrophil
RNA available. Neutrophil cDNA was generated using RNA from normal controls, JAK2 V617F-
positive ET patients, and JAK2 WT ET patients using the Invitrogen Superscript III kit as
described in Section 2.2.5. A 235bp fragment spanning JAK2 exons 18-20 was amplified by
BIOTAQ™ PCR with primers JAK2ex18/F and fluorescently-labelled JAK2ex20/RF (Figure 6.3B).
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Twenty-five cycles of PCR were performed, with an annealing temperature of 62°C and using
2µL of the cDNA diluted 1 in 4 in ddH20 as template per reaction. The PCR product was
incubated with BstNI as above which cut the G allele to 108 and 127bp but left the A allele
uncut (235bp), analysed on the CEQ 8000 system, and the relative amounts of the A and G
alleles determined by calculating the area under the appropriate peaks.
6.2.4 Analysis of SNP rs505534
The cohort of ET patients was genotyped for rs505534, a C/T SNP located on chromosome 9p,
8Mb upstream of the JAK2 gene, to investigate the possibility that it might be a 46/1-
associated variant. A 222bp fragment spanning the SNP was amplified using GoTaq® PCR (see
Section 2.2.3.2 ) with T-cell gDNA as template, a mismatched forward primer rs505534/(MM)F,
reverse primer rs505534/R, an annealing temperature of 57°C and 35 cycles of PCR. Products
were digested with BsmAI. A reaction mix was prepared containing 5 units BsmAI and 1x
manufacturer’s buffer 4, made up to 2µL with ddH2O, and to this 8µL PCR product was added
and incubated for 2 hours at 55°C, then run on a 3% agarose gel. BsmAI cut the C allele to 116,
75 and 29bp, and the T allele to 145 and 75bp.
6.2.5 Methylation analysis
To investigate the possibility that the 46/1 haplotype may affect JAK2 methylation, bisulphite
sequencing followed by pyrosequencing was used to investigate the methylation status of two
JAK2 intron 14 loci: the rs12343867 C/T SNP, and the cytosine nucleotide immediately
upstream of the rs12340895 C/G SNP, both of which potentially form a CpG dinucleotide in the
presence of the 46/1 haplotype (Figures 6.4A,B). This approach allowed methylated and non-
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methylated cytosine bases to be distinguished since treatment of DNA with bisulphite converts
unmethylated cytosine to uracil, which is converted to thymine by subsequent PCR, but does
not affect 5-methylcytosine. The ratio of cytosine to thymine at the locus being investigated,
which can be determined by pyrosequencing, reflects the degree of methylation in the original
DNA.
Figure 6.4 Effect of bisulphite treatment on possible CpG dinucleotides that
involve SNPs rs12343867 and rs12340895 (JAK2 intron 14)
Assumes that C nucleotides immediately prior to G nucleotides are methylated (CM), and 100%
conversion of unmethylated C nucleotides to T nucleotides. Vertical arrows indicate the nucleotide for
which the methylation status was determined by pyrosequencing, and the possible CpG dinucleotide is
indicated by a dashed box
A. DNA sequence around C/T SNP rs12343867 (underlined)
B. DNA sequence around C/G SNP rs12340895 (underlined)
C Schematic representation showing primers used for methylation assays
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6.2.5.1 Bisulphite treatment
Bisulphite treatment was performed using the Zymo EZ DNA methylation-gold kit (Cambridge
Bioscience Ltd, Cambridge UK) according to manufacturers’ instructions. Neutrophil gDNA,
500ng in 20µL ddH2O, was added to 130µL CT conversion agent, mixed and incubated at 98°C
for 10 minutes, 64°C for 2.5 hours, then stored at 4°C for up to 20 hours. The reaction mixture
was added to 600µL M-binding buffer in a Zymo-Spin™ IC column, mixed and spun at 14,000g
for 30 seconds at room temperature. The run-through liquid was discarded and 100µL M-wash
buffer was added to the column, which was spun again for 30 seconds at 14,000g. The run-
through was discarded and 200µL M-desulphonation buffer was added to the IC column,
incubated at room temperature for 20 minutes, then centrifuged for 30 seconds at 14,000g at
room temperature. Two washes were performed each consisting of the addition of 200µL M-
wash buffer to the IC column and a 30 second room-temperature spin at 14,000g. The IC
column was then transferred to a 1.5mL microcentrifuge tube and 16µL M-elution buffer
added. The bisulphite-treated DNA was eluted by centrifugation at 14,000g for 30 seconds and
stored at -20°C.
6.2.5.2 Qualitative analysis of SNP rs12343867 methylation status
The methylation status of C/T SNP rs12343867 within JAK2 intron 14 was determined non-
quantitatively by direct sequencing of T-cell DNA from 2 haematologically normal controls, one
known to be CC, the other TT at this locus. A 198bp product spanning rs12343867 was
amplified by GoTaq® PCR using 1.5µL bisulphite-treated DNA as template, with forward primer
JAK2ex14/(meth)F1 and reverse primer JAK2ex14/(meth)R1 (Figure 6.4C). Other reagents and
conditions were as described in Section 2.2.3.2. Thirty-three cycles of PCR were performed,
each 30 seconds at 95°C, 30 seconds at 56°C, 45 seconds at 72°C, and a final extension of 5
minutes at 72°C. PCR products were visualised by UV transillumination following 2% agarose
gel electrophoresis, then purified using the peqGold micro-spin cycle-pure kit and sequenced
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by the UCL Wolfson Institute for Biomedical Research DNA sequencing service using
JAK2ex/14(meth)F1 as the sequencing primer.
6.2.5.3 Quantitative analysis of SNP rs12343867 methylation status
Pyrosequencing was used to quantify the relative amounts of the two alleles (C or T) present at
the SNP following bisulphite treatment, from which the relative degree of methylation could
be calculated. If the sample analysed was known to be homozygous CC at the SNP, and these
cytosine bases were completely methylated, then the post-bisulphite treatment C:T ratio is
predicted to be 100%:0%. If the actual percentage C (%C) determined by pyrosequencing was
less than 100%, this would imply incomplete methylation of the cytosine at this SNP. Similarly,
if the sample was heterozygous CT, the predicted %C is 50%, and an observed %C of less than
this would indicate incomplete methylation.
Generation of a calibration curve
In order to establish whether the assay was quantitative throughout its range, a calibration
curve was first established using standards generated by mixing T-cell DNA from two normal
controls, one known to have rs12343867 genotype CC, the other TT. Results from the previous
stage indicated the C allele was completely methylated in control samples (see Section
6.3.5.1.). The control DNA samples were therefore mixed to give an expected %C of 0%, 2%,
5%, 10%, 25%, 50%, 75%, 90%, 95%, 98% and 100% and then bisulphite treated using the Zymo
EZ DNA methylation-gold kit as described above. A 198bp PCR product spanning the SNP was
then amplified in a 50µL GoTaq® PCR using 2.5µL bisulphite-treated DNA with forward primer
JAK2ex14/(meth)F1 and a biotinylated reverse primer JAK2ex14/(meth)R1, both at 0.08mM.
Fifty cycles of PCR were performed, each of 95°C for 30 seconds, 56°C for 30 seconds and 72°C
for 45 seconds followed by a 5 minute 72°C extension stage. Samples were analysed using the
PyroMark™Q96 MD pyrosequencing system (Qiagen, Crawley, UK) according to manufacturers’
recommendations by the UCL Wolfson Institute for Biomedical Research DNA sequencing
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service, using JAK2ex14/(meth)seq1 as the sequencing primer. For each of the standard mixes,
the %C determined by pyrosequencing was then plotted against the expected %C.
Analysis of neutrophil gDNA
To be suitable for analysis, subjects were either heterozygous or homozygous for the C allele at
SNP rs12343867. Neutrophil gDNA from a cohort of normal controls and ET patients was
bisulphite treated, and the 198bp PCR product spanning SNP rs12343867 amplified by PCR and
analysed by pyrosequencing as described in the preceding paragraph. Samples were analysed
in duplicate.
6.2.5.4 Quantitative analysis of methylation status near to SNP rs12340895
The degree of methylation of the cytosine immediately upstream of a second C/G SNP,
rs12340895, was analysed in the same group of normal controls and ET patients (Figure 6.4B).
A 192bp PCR product spanning SNP rs12340895 was amplified from bisulphite-treated
neutrophil gDNA with conditions as described in Section 6.2.5.3 except that here forward
primer JAK2ex14/(meth)F2 and biotinylated reverse primer JAK2ex14/(meth)R2 were used
(Figure 6.4C). Samples were then analysed by pyrosequencing using primer
JAK2ex14/(meth)seq2 as the sequencing primer.
6.3 Results
6.3.1 Screening JAK2 V617F-positive patients for the 46/1 haplotype
The 11 ET patients studied in detail in Chapter 5 were initially selected for analysis. For each
patient, the genotype at each of five JAK2 SNPs was determined (Table 6.2). Of the 11 patients,
five were homozygous at all five SNPs: TT, CC, TT, CC and TT at rs3780367, rs10974944,
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rs12343867, rs12340895 and rs1159782 respectively. From these patients a haplotype could
be deduced, with the allele sequence TCTCT, i.e. these five patients were homozygous for the
non-46/1 haplotype. The remaining six patients were heterozygous at all 5 SNPs: GT, GC, CT,
GC and CT. It therefore appeared that these six patients were heterozygous for the TCTCT
haplotype determined above, and for a second haplotype, GGCGC, i.e. the 46/1 haplotype. No
patient was homozygous for the 46/1 haplotype and none was homozygous at some SNPs and
heterozygous at others.
Table 6.2 JAK2 SNP genotypes of 11 JAK2 V617F-positive ET patients
SNP rs3780367 rs10974944 rs12343867 rs12340895 rs1159782 rs2230724
JAK2 locus Intron 10 Intron 12 Intron 14 Intron 14 Intron 15 Exon 19*
46/1 allele G G C G C
Patient E1 TT CC TT CC TT AG
Patient E2 TT CC TT CC TT AG
Patient E3 GT GC CT GC CT AG
Patient E4 TT CC TT CC TT AG
Patient E5 GT GC CT GC CT AG
Patient E6 GT GC CT GC CT AG
Patient E7 GT GC CT GC CT AG
Patient E8 TT CC TT CC TT AG
Patient E9 GT GC CT GC CT AG
Patient E10 TT CC TT CC TT AG
Patient E11 GT GC CT GC CT AG
* Determined in section 5.2.1
6.3.2 Genotyping normal controls and ET patients for the presence of the 46/1
haplotype using SNP rs12343867
SNP rs12343867, which tagged the 46/1 haplotype, was genotyped in 101 haematologically
normal controls, 122 ET patients and 24 PV patients (Table 6.3). Within each patient category,
the total number of 46/1 (i.e. C) alleles and of non-46/1 (T) alleles was calculated, assuming
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that patients who were CC homozygous at rs12343867 contributed two C alleles, those who
were heterozygous contributed one C allele, and TT homozygotes contributed none, and vice-
versa to calculate the total number of T alleles. The frequency of C alleles (as a proportion of
total alleles) in each patient group was then compared to those observed in the control cohort,
and to equivalent data published by Jones et al (2009) from the WTCCC analysis of 1,500 UK
blood donors.
Table 6.3 SNP rs12343867 genotypes of the normal controls, ET and PV patients
studied
rs12343867 genotype*
n (percent of patients)
n CC CT TT
Normal controls 101 8 (8%) 42 (42%) 51 (50%)
ET patients
Overall 122† 15 (12%) 50 (40%) 57 (46%)
By JAK2 status V617F+ 46† 6 (13%) 23 (50%) 17 (37%)
V617F- 76 9 (12%) 27 (36%) 40 (53%)
By exon 19 SNP status‡ AA 39 11 (28%) 19 (49%) 9 (23%)
AG 55 4 (7%) 26 (47%) 25 (45%)
GG 17 0 (0%) 0 (0%) 17 (100%)
PV patients 24 2 (8%) 16 (67%) 6 (25%)
* The C allele is part of the 46/1 haplotype
† The rs12343867 status was not known for 3 JAK2 V617F-positive ET patients
ΐ dŚĞĞǆŽŶϭϵ^ EWƐƚĂƚƵƐǁ ĂƐŶŽƚŬŶŽǁ ŶĨŽƌϭϰdƉĂƟĞŶƚƐ͘
Complete 9pLOH in myeloid cells would convert a patient who was heterozygous for the JAK2
SNPs in their germline DNA to homozygosity in myeloid cells and confound the calculation
above. To prevent this, T-cell gDNA was used for normal controls and ET patients. Since T-cell
gDNA was not available for PV patients, only those with V617F levels of less than 80% were
selected – i.e. without evidence of complete 9pLOH.
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The frequency of the C allele at SNP rs12343867 was 0.33 in ET patients overall, 0.38 in V617F-
positive ET patients, 0.29 in JAK2 WT ET patients, 0.42 in PV patients and 0.29 in local controls.
In no patient group was the frequency of the C allele significantly different from local controls
(P=0.41, P=0.14, P=0.91 and P=0.09 respectively, Chi square test; Table 6.4). If PV patients
were combined with V617F-positive ET patients, the C allele frequency in this group was just
significantly higher than in local controls (0.39 versus 0.29, P=0.05, Chi-square test; OR 1.61,
95%CI 1.02-2.54). Compared to the WTCCC cohort of normal controls, the rs12343867 C allele
frequency was significantly higher in ET patients overall, in V617F-positive ET patients, and in
PV patients (P=0.003, P=0.003 and P=0.008 respectively, Chi square test) but not in JAK2 WT ET
patients (P=0.14, Chi square test).
The exon 19 SNP studied in Section 5, rs2230724, has been reported to be part of the 46/1
haplotype (Jones et al, 2009). In the cohort studied here, an association was noted between
the presence of an A allele at rs2230724 and the C allele at rs12343867 (P=0.02, Chi-square
test; Table 6.4), indicating that the A allele is in LD with the 46/1 haplotype.
Of the three MPL W515-positive patients, two were heterozygous for the 46/1 haplotype and
one was homozygous for the non-46/1 haplotype.
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6.3.3 Expression analysis of the 46/1 and non-46/1 alleles
In order to investigate the hypothesis that differential expression of the 46/1 haplotype might
account for its association with V617F-positive MPN, the relative expression of the 46/1-
associated and non-46/1 alleles was analysed at the JAK2 exon 19 SNP, rs2230724. The A allele
at this locus is in LD with the 46/1 haplotype (see previous section). In patients who were
heterozygous for the JAK2 exon 19 SNP, rs2230724, the relative expression of the two possible
alleles (A/G) was determined by PCR and restriction enzyme digestion with BstNI, using a
fluorescently-labelled reverse primer to allow quantification by fragment analysis. Validation
that the technique was quantitative was performed using neutrophil gDNA from 22 controls,
where a 50%:50% ratio of A to G alleles was expected. The mean level of the A allele, which is
part of the 46/1 haplotype, in these subjects was 48.5% of the total, with an SD of 3.2%, giving
a technical range of 42.1 – 54.9% (mean ±2SD).
This technique was then used to determine relative expression of the two SNP alleles in
individuals who were heterozygous at the SNP and had neutrophil cDNA available. Eight
normal controls, 17 JAK2 V617F-positive and 8 JAK2 WT ET patients were analysed. There was
no difference in the relative expression of the A allele expression between the groups, with a
mean level of 54%, 52% and 52% in normal controls, V617F-positive ET and JAK2 WT ET
respectively (Figure 6.5B).
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Figure 6.5 Quantification of the relative levels of SNP rs2230724 alleles A/G
A. Levels of allele A in neutrophil genomic DNA from 22 normal controls
Dashed lines indicate mean ± 2 standard deviations (42.1 – 54.9%)
B. Levels of allele A expressed in neutrophil cDNA from normal controls, JAK2 V617F-positive ET
patients, and JAK2 wild-type patients.
Figures immediately above the graph give two-tailed t-test P-values, for the indicated comparisons
Mean = 48.5%
Chapter 6
209
6.3.4 Analysis of SNP rs505534
The C/T SNP, rs505534, located on chromosome 9p, has been reported to be associated with
variability in platelet count (Soranzo et al, 2009). The genotype frequency of this SNP was
therefore examined to determine whether it was in LD with the 46/1 haplotype and thereby
provide a mechanism for the association between 46/1 and MPNs. According to HapMap data,
the relative frequency of the C and T alleles in Northern European controls is 0.975 and 0.025
respectively, giving an expected CC, CT and TT genotype frequency of 95%, 5% and 0%
respectively. Of the 122 ET patients analysed, the rs505534 genotype was available for 114.
The genotype was CC in 109 (96%) patients, CT in 5 (4%) and no patient was genotype TT.
There was, therefore, no association between rs505534 genotype and ET, regardless of JAK2
V617F, rs2230724 or rs12343867 genotype (Table 6.5).
Table 6.5 SNP rs505534 genotypes of 114 ET patients
Group n Totalalleles
C-
alleles
T-
alleles
Frequency of
C allele
(% of total)
P-value
(Chi-square)
Expected 114 228 222* 6* 98
All ET patients 114 228 223 6 98 1.00
ET patients by JAK2 status
V617F-positive
patients 45 90 88 2 98 1.00
JAK2 WT patients 67 134 131 3 98 1.00
ET patients by SNP rs2230724 genotype
AA genotype 36 72 70 2 97 1.00
ET patients by SNP rs12343867 genotype
CC genotype 13 26 24 2 92 0.19
CT genotype 45 90 87 3 97 0.71
TT genotype 53 106 106 0 100 0.18
*Based on HapMap Northern European control cohort (frequency of C allele = 0.975, T allele = 0.025)
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6.3.5 Methylation analysis of normal controls and ET patients
6.3.5.1 Qualitative analysis of SNP rs12343867 methylation status
At two JAK2 SNPs, rs12343867 and rs 12340895, the 46/1 haplotype introduces two CpG
dinucleotides which are not present the non-46/1 haplotype. In order to investigate the
hypothesis that the 46/1 haplotype may affect JAK2 methylation, the degree of methylation at
these two 46/1-associated JAK2 SNPs was determined. Neutrophil gDNA was bisulphite
treated to convert unmethylated cytosine bases to thymine but leave methylated cytosine
bases unchanged. Direct sequencing of the bisulphite-treated DNA from 2 normal controls
showed that the individual with SNP rs12343867 genotype CC had a single ‘C’ peak at the
appropriate nucleotide, in keeping with complete methylation at that locus (Figure 6.6B). All
the other cytosine bases within the amplicon had been converted to thymine. As expected, the
individual with rs12343867 genotype TT had a single ‘T’ peak at the appropriate nucleotide
(Figure 6.6C).
6.3.5.2 Quantitative analysis of SNP rs12343867 methylation status
Quantitative analysis of the degree of methylation at this SNP was then performed by
pyrosequencing. To establish linearity of the assay throughout the range, 11 DNA mixes of CC
and TT gDNA were analysed, with an expected %C which varied between 0% and 100%,
assuming that all C alleles were completely methylated. A good correlation was observed
between the expected %C in the calibration samples and the observed %C at the rs12343867
locus (P<0.0001, r2=0.999; Figure 6.7). The Y-intercept was 2.5%, indicating that at the lower
end of the calibration range, the assay overestimated the %C by 2.5%. At the upper end of the
calibration range, the assay underestimated the %C by 4%, i.e. when the sample contained
100% C, the observed %C was 96%, due either to technical error or to incomplete methylation
of C alleles.
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Figure 6.6 Sequences of normal control DNA showing the region around SNP
rs12343867 (C/T)
A. DNA sequence prior to bisulphite treatment. SNP rs12343867 is indicated by a hollow arrow
B. Sequence chromatogram following bisulphite treatment in a normal control with rs12343867
genotype CC. Solid arrows indicate unmethylated cytosine bases which have been converted to
thymine bases
C Sequence chromatogram following bisulphite treatment in a normal control with rs12343867
genotype TT
Figure 6.7 Calibration curve of pyrosequencing analysis of cytosine methylation
at SNP rs12343867 using artificially created mixes
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For SNP rs12343867 results were obtained for 12 normal controls (all CT heterozygotes) and
64 ET patients (examples shown in Figure 6.8). The assay was performed in duplicate, with
good concordance for the two results for each sample (P<0.0001, r2=0.996; Figure 6.9). The
mean difference between values in the two runs was 0.1% (range 0-8%, SD=1.3%), indicating a
technical variation of 5.3% (mean±2SD).
Figure 6.8 Pyrosequencing of C/T SNP rs12343867 following bisulphite treatment
of neutrophil DNA
SNP rs12343867 is indicated by the shaded grey box. The relative percentage of each allele is calculated
using the peak heights
A Pyrosequencing trace from an ET patient with SNP genotype CC
B Pyrosequencing trace from an ET patient with SNP genotype CT
The maximum %C at the SNP locus was dependent on the individual’s SNP genotype – i.e. for
CC individuals, it was 100% and for CT individuals it was 50%. The results are therefore
analysed according to SNP genotype (Figure 6.10). For SNP heterozygous (CT) individuals the
median %C was 48% in controls (range 46-52%), 47% in JAK2 WT ET patients (range 44-64%)
and 48% in V617F-positive ET patients (range 44-75%). No patient group was different from
the controls. Of note, seventeen SNP heterozygous individuals had %C levels greater than the
theoretical maximum of 50%, of whom nine had %C more than 2 standard deviations above
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Figure 6.9 Concordance between duplicate pyrosequencing analyses of the
percentage methylation at SNP rs1234386 in normal controls and ET
patients
Open circles indicate SNP heterozygous individuals, closed circles indicate SNP homozygous individuals
the group median, comprising two JAK2 WT patients and seven V617F-positive patients. Five of
the seven V617F-positive patients had mutant levels greater than the median mutant level for
the group (19%).
For SNP homozygous (CC) individuals, the median %C was 96% in JAK2 WT ET patients (range
95-97%) and 97% in V617F-positive ET patients (range 96-97%). Reference to the calibration
curve suggests that within technical limits these values were equivalent to 100% methylation
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(Figure 6.7). The difference in median %C between JAK2 WT and V617F-positive groups was
not significant (P=0.19, t-test).
Control JAK2 WT ET V617F+ ET JAK2 WT ET V617F+ ET
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Figure 6.10 Pyrosequencing analysis of methylation at SNP rs12343867 in normal
controls and ET patients
Solid horizontal lines indicates median (value shown to the left); dashed lines indicate median ±2
standard deviations
For the V617F-positive patients, patients with mutant levels below group median (19%) are represented
by filled squares, those with mutant levels above group median are represented by open squares
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6.3.5.3 Quantitative analysis of methylation status near to SNP rs12340895
The methylation of the cytosine base which was immediately upstream of C/G SNP rs12340895
was then studied (Figure 6.4B). At this locus, a CpG dinucleotide was only possible when a G
allele was present at SNP rs12340895. For individuals who were GG homozygous at the SNP,
CpG dinucleotides were generated on both alleles and their maximum expected %C was,
therefore, 100%. For CG SNP heterozygotes, the maximum expected %C was 50%. For SNP
heterozygous individuals the median observed %C was 23% in controls (range 20-27%), 21% in
JAK2 WT ET patients (range 18-27%) and 24% in V617F-positive ET patients (range 18-52%;
Figure 6.11). The difference between the latter two groups was statistically significant
(P=0.009, t-test), due to five patients in the V617F-positive group with %C greater than two
standard deviations above the group median. No difference between any of the other groups
was observed. For SNP homozygous individuals, the median %C was 96% in both JAK2 WT ET
patients (range 23-97%) and V617F-positive ET patients (range 96-97%) in keeping with
complete methylation, within technical limits. One JAK2 WT ET patient who was classified as
GG homozygous at this SNP had an observed %C of 23%, suggesting a sampling error and that
this patient was SNP heterozygous.
6.3.5.4 Comparison of methylation data for SNP rs12343867 and SNP rs12340895
There was a strong correlation between the observed %C at the two SNPs studied (r2=0.887,
P<0.001, Figure 6.12). The four SNP-heterozygous individuals with the highest %C at SNP
rs12343867 also had the highest %C at SNP rs12340895.
Chapter 6
216
Control JAK2 WT ET V617F+ ET JAK2 WT ET V617F+ ET
0
20
40
60
80
100
23% 21%
96%
24%
96%
%
C
fo
llo
w
in
g
bi
su
lp
hi
te
tr
ea
tm
en
t
P = 0.14
P = 0.20
P = 0.009 P = 0.47
SNP genotype CG GG
Figure 6.11 Pyrosequencing analysis of methylation at SNP rs12340895 in normal
controls and ET patients
Solid horizontal lines indicates median (value shown to the left); dashed lines indicate median ±2
standard deviations
For the V617F-positive patients, patients with mutant levels below group median (19%) are represented
by filled squares, those with mutant levels above group median are represented by open squares
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Figure 6.12 Comparison of methylation analysis results at the two SNPs studied
Dashed lines indicate median %C values at the two SNPs
Triangles indicate SNP heterozygotes, circles indicate SNP homozygotes
For the V617F-positive patients, those with mutant levels below the group median (19%) are
represented by filled symbols and those with mutant levels above the group median are represented by
open symbols
6.4 Discussion
The surprising finding that a specific JAK2 haplotype predisposes to the development of an
MPN has now been corroborated by numerous independent studies (Andrikovics et al, 2010;
Guglielmelli et al, 2010; Jones et al, 2009; Kilpivaara et al, 2009; Olcaydu et al, 2009; Trifa et al,
2010; Patnaik et al, 2010). The mechanism, however, remains obscure. The experiments
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reported in this chapter were designed to investigate whether there was an association
between the 46/1 haplotype in the cohort reported in this thesis and to examine potential
mechanisms.
Eleven ET patients had been studied in detail in Chapter 5 and these individuals were studied
initially by genotyping five JAK2 SNPs reported to be involved in the 46/1 haplotype (Jones et
al, 2009; Kilpivaara et al, 2009; Olcaydu et al, 2009). Five patients were homozygous at all five
SNPs, although it is notable that they were all homozygous for the non-46/1 alleles (TCTCT),
and the other six patients were heterozygous for all five SNPs – i.e. they had one copy of the
46/1 haplotype. The fact that all 11 patients were either homozygous or heterozygous for all
five SNPs – and none was homozygous at some loci, but heterozygous at others – is consistent
with the presence of a haplotype spanning the region studied. A sixth SNP, rs2230724, located
in JAK2 exon 19 and which was studied in Chapter 5, appeared not to be in complete LD with
the haplotype, since five patients were heterozygous for rs2230724 but homozygous for the
other five SNPs. However, the presence of an A allele at rs2230724 was strongly associated
with a C allele at rs12343867 (P=0.0003; Table 6.4), indicating the A allele at this locus is part
of the 46/1 haplotype, in keeping with data from Jones et al (2009).
A cohort of normal controls, ET and PV patients was then screened for the presence of the
46/1 haplotype by genotyping a tagged intron 14 SNP, rs12343867. The frequency of the C
allele, which tagged the 46/1 haplotype, was significantly greater in PV and V617F-positive ET
patients combined than in local controls (0.39 versus 0.29, P=0.05; Table 6.4). In all other
patient groups, the C allele frequency was similar to local controls. Compared with WTCCC
controls, however, it was significantly higher in all patient groups except JAK2 WT patients
(P=0.008 for PV patients, P=0.003 for ET patients overall, P=0.003 for V617F-positive ET
patients, P<0.0001 for PV and V617F-positive ET patients combined, P=0.14 for JAK2 WT ET
patients). These results suggest that in this cohort there was evidence for an association
between the 46/1 haplotype and the development of PV and V617F-positive ET, although it
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was subtle and was only apparent if the two groups were combined or individual groups were
compared with a large WTCCC control group rather than a smaller cohort of local controls. No
association was observed in JAK2 WT ET patients.
These findings are broadly in keeping with the six published studies which have examined the
relationship between 46/1 and MPNs (Jones et al, 2009; Kilpivaara et al, 2009; Olcaydu et al,
2009; Andrikovics et al, 2010; Pardanani et al, 2010; Trifa et al, 2010). Olcaydu et al (2009) and
Kilpivaara et al (2009) analysed the frequency of particular genotypes (e.g. CC versus TT)
whereas the other studies assessed the allele frequency (i.e. C and T) in affected individuals
compared to controls. Table 6.6, therefore, shows the data from all six studies re-analysed by
allele frequency, with the results from the cohort reported in this chapter included for
comparison. All the studies which considered PV, V617F-positive ET, or both PV and V617F-
positive ET together reported that the 46/1 allele frequency was significantly higher in the
patient groups compared to local controls (Jones et al, 2009; Kilpivaara et al, 2009; Olcaydu et
al, 2009; Andrikovics et al, 2010; Pardanani et al, 2010; Trifa et al, 2010). Combining these
studies, the overall 46/1 allele frequency was 0.51 in PV patients, 0.46 in V617F-positive ET
patients, and 0.50 in both groups combined, compared to 0.26 in controls (P<0.0001 for all
three comparisons). The data from these studies provides strong evidence for an association
between the 46/1 haplotype and both PV and V617F-positive ET. This association was weaker
in the cohort reported in this thesis than in published studies, particularly comparing patient
groups to local controls, most likely due to smaller patient numbers in the cohort reported
here.
It is not clear, however, whether the 46/1 haplotype is associated with the development of
JAK2 WT ET, particularly if comparison is made to local rather than WTCCC control groups.
Although Olcaydu et al (2009) did report a difference compared to local controls, the P-value
of 0.05 was borderline, and Jones et al (2009) observed a difference in only one of the two
cohorts they studied (P=0.009 for the UK cohort, P=0.09 for the Greek cohort). Three further
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studies did not observe a difference compared to local controls (Andrikovics et al, 2010;
Pardanani et al, 2010; Trifa et al, 2010). All five of these studies did report that the 46/1 allele
frequency was significantly higher in JAK2 WT ET patients than in the WTCCC group, but
whether this was a valid control group for the non-UK studies is questionable. The overall 46/1
allele frequency amongst JAK2 WT ET patients, 0.36, was significantly higher than that
amongst all controls combined, 0.26 (P<0.0001). For the cohort reported in this thesis, no
association between the 46/1 haplotype and JAK2 WT ET was observed due to a lower 46/1
frequency in the JAK2 WT ET patients compared to the published studies overall (0.29 versus
0.36) and a higher 46/1 frequency in the normal controls (0.29 versus 0.26). These differences
may reflect variations in the ethnic composition of the groups or be due to chance.
Although the 46/1 haplotype is clearly an important risk factor for the development of some
MPNs, its role should not be overstated. Amongst the patients reported in this thesis, 46% of
ET patients and a 25% of PV patients were homozygous for the non-46/1 haplotype, suggesting
that whilst the 46/1 haplotype may predispose to the development of MPNs, it is not a pre-
requisite. In keeping with this, three of the patients reported in Chapter 5 in whom there was
evidence that JAK2 V617F had occurred more than once, the mutation arose predominantly in
cis with the non-46/1 allele (G), suggesting that the haplotype predisposes to acquisition of the
mutation on either allele. Similarly, in two of the three MPN patients reported by Olcaydu et al
(2009) to have acquired JAK2 V617F more than once, the mutation had arisen more frequently
on the non-46/1 allele.
In order to explain the association between the 46/1 haplotype and MPNs, two potential
hypotheses have been advanced. The hypermutability hypothesis suggests that this haplotype
predisposes to the acquisition of JAK2 V617F, and possibly other MPN-associated mutations.
The fertile ground hypothesis proposes that in 46/1-positive individuals, mutations arise at the
normal rate but a functional variant in LD with the haplotype means that 46/1-positive
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individuals who acquire MPN-associated mutations are more likely to develop clinical disease
than those who do not have this haplotype. In this chapter, both hypotheses have been
considered. To investigate the fertile ground hypothesis, the possibility of preferential
expression of the 46/1 allele was first investigated, since this might result in enhanced
expression of V617F if it arose in cis with the 46/1 haplotype. The relative expression of the
two possible alleles at an exonic JAK2 A/G SNP, rs2230724, was therefore studied. The A allele
at this SNP is in LD with the 46/1 haplotype (see Section 6.3.2). Expression of the two
rs2230724 alleles in neutrophil cDNA was similar in all three groups studied, 54% A-expression
in normal controls, 52% A-expression in both V617F-positive and JAK2 WT ET patients (P>0.05
for all three comparisons, Figure 6.5B). All three values suggest the expression of the A and G
alleles are balanced (i.e. 50%:50%) within the limits of technical variability for the technique.
These results do not, therefore, support the notion that preferential expression of the 46/1
allele accounts for its association with V617F-positive MPNs, although the small size of the
cohort studied means that subtle differences in expression cannot be excluded. These findings
are in keeping with those of Jones et al (2009) who investigated the relative expression of
rs2230724 alleles in 29 normal controls and of rs10429491 alleles, another 46/1-associated
SNP located in exon 6 of JAK2, in 40 normal controls. They found no difference in expression of
the 46/1 and the non-46/1 alleles.
Another possible mechanism to explain the fertile ground hypothesis is that 46/1 is in LD with
rs505534, a chromosome 9 SNP located 8Mb upstream from JAK2 that was associated with
variability in platelet counts in a study of nearly 14,000 healthy German and British controls
(Soranzo et al, 2009). If the JAK2 V617F mutation arises in the presence of an rs505534 allele
associated with higher platelet counts than average, then a clinical MPN might be more likely
to result than if it arose on the other SNP allele. There was, however, no difference in allele
frequency (C versus T) in any of the patient groups studied compared to the HapMap Northern
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European control cohort and therefore no suggestion af an association between this SNP and
ET or the 46/1 haplotype.
To investigate a possible mechanism to account for the hypermutability hypothesis, the
possibility that the 46/1 haplotype might affect DNA methylation was considered, since
changes in methylation may affect DNA conformation and influence susceptibility to
mutations. In humans, DNA methylation affects cytosine bases that precede guanine bases
(dinucleotide CpGs), and two of the reported 46/1-tagging SNPs (rs12343867 and rs12340895,
both in intron 14) result in CpG sites when the 46/1-associated allele is present but not when
the non-46/1 allele is present. To quantify the degree of methylation at these SNPs,
pyrosequencing of bisulphite-treated neutrophil DNA from normal controls and ET patients,
both JAK2 WT and V617F-positive, was performed. At SNP rs12343867, the median post-
bisulphite treatment %C was 47-48% in SNP heterozygous individuals, and 96% in SNP
homozygous individuals (Figure 6.10), in keeping with complete methylation at this locus
within the technical limits of the assay.
The degree of methylation was similar in normal controls and SNP heterozygous ET patients,
regardless of JAK2 status. It was notable, however, that a seven SNP heterozygous, mutant-
positive patients had post-bisulphite %C values of greater than 50%, a figure which is not
compatible with being CT heterozygous at this locus. Five of these patients had relatively high
V617F mutant levels and the simplest explanation for the %C being greater than 50% in these
patients was the presence of chromosome 9p LOH in some of their myeloid cells, resulting in
amplification of the C allele to more than 50%. This phenomenon would not have been
apparent when the patients’ SNP genotypes was originally determined (Section 6.2.2) since
this was done using T-cells, which are unlikely to be affected by 9pLOH. To further investigate
this, it would be necessary to repeat the pyrosequencing analysis in tandem, using bisulphite-
treated and non-bisulphite treated DNA from each individual, and then to compare the two
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results from each individual. Overall, the C allele at SNP rs12343867 appeared to be
completely methylated in both ET patients and normal controls.
At the second SNP studied, rs12340895, the median %C was 96% in SNP homozygous ET
patients, but less than 25% in all three SNP heterozygous groups: 23% in controls, 21% in JAK2
WT ET patients and 24% in V617F-positive ET patients (Figure 6.11). The %C was significantly
different in these latter two groups (P=0.009), due to five mutant-positive SNP heterozygous
patients with %C which was more than two standard deviations greater than the group
median. These patients, three of whom had relatively high mutant levels, all had %C greater
than 50% at SNP rs12343867 (Figure 6.12). The most plausible explanation is, again, the
presence of 9pLOH. No other statistically significant difference was observed between any of
the comparable groups at this SNP.
Amongst SNP heterozygous individuals the degree of methylation at SNP rs12340895 appeared
to be markedly lower than that at rs12343867 in both controls and ET patients (overall median
%C 22% versus 48%, P<0.0001). This was due, at least in part, to a software limitation which
precluded accurate calculation of %C in patients who were heterozygous at SNP rs12340895
(all the controls and 49 of the 64 ET patients). The pyrosequencing analysis software could only
interpret sequence data which varied a one locus, but the presence of a C allele at SNP
rs12340895 affected the DNA sequence at two loci: at the SNP itself and at the preceding
cytosine base, which in the presence of a C allele at the SNP was unmethylated and, therefore,
converted to thymine during bisulphite treatment (Figure 6.4B). If analysis is, therefore,
confined to ET patients who were homozygous for the 46/1 allele at the two SNPs, within
technical limits both loci were completely methylated (median %C was 96% at SNP rs12343867
versus 97% at SNP 12340895, P=0.22). Overall, the data from these experiments suggests that
the presence of the 46/1 haplotype may influence the degree of methylation of the JAK2 gene,
potentially affecting its conformation and susceptibility to acquiring mutations. It is notable
that at least two of 46/1-tagging SNPs which might affect JAK2 methylation, rs12343867 and
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rs12340895, are located in intron 14, close to the V617F mutation site in exon 14. Clearly
further study of other JAK2 SNPs in larger cohorts of controls and patients is required.
In conclusion, the experiments reported in this chapter provide further evidence for a specific
JAK2 haplotype which is associated with the development of V617F-positive MPNs, though the
association was weaker than that reported by other studies and did not extend to JAK2 WT ET.
Furthermore, nearly a half of ET patients and a quarter of PV patients were homozygous for
the non-46/1 haplotype, indicating that the presence of the 46/1 haplotype is not required for
the development of an MPN. There was no evidence that the predisposition to an MPN
observed in 46/1-positive individuals is due to preferential expression of the 46/1 allele or an
association with a nearby ‘platelet variability’ SNP. However, the two CpG dinucleotides
introduced by the 46/1 haplotype within the JAK2 gene were found to be completely
methylated, and the possibility that this may affect the susceptibility to mutations merits
further study.
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7 Conclusions and future directions
7.1 Summary of findings
Although ET has been recognised as a clinical entity for nearly 80 years, the identification in
2005 of a recurrent acquired point mutation, JAK2 V617F, in approximately 50% of cases
resulted in a fundamental change in the way the disorder is perceived, leading to its
reclassification by the WHO as a myeloproliferative neoplasm in 2008. This reclassification
reflected a belief that ET is a clonal neoplastic disease which arises as a consequence of one or
more acquired mutational events. However, it overlooked several characteristics of this
disorder, in particular that ET does not typically behave as a malignant neoplasm and that a
substantial proportion of cases are polyclonal according to XCIP data. The studies reported in
this thesis, therefore, set out to investigate the molecular origins of ET, and in particular to
consider the role of JAK2 V617F in the pathogenesis of the disease and its relationship to the
concept of clonality in ET. The aim was to gain a better understanding of this heterogeneous
disease so that its clinical phenotype might be explicable in molecular terms.
The clinical characteristics of a cohort of 133 ET patients were evaluated and their association
with haematological and molecular features examined (Chapter 3). In terms of demographic
and clinical features, as well as haematological and molecular characteristics, these patients
were similar to those described in most published studies. In keeping with most other series,
the clinical course in the majority of patients studied was relatively benign, and the most
common complications were thrombotic. Over a median time since diagnosis of 12.6 years, the
thrombotic rate was 16% and the mortality was less than 5%. Although patients who had had a
thrombosis were older at diagnosis than those who did not (median age 53 versus 44 years,
P=0.03), presenting blood counts and a history of prior thrombosis did not predict thrombotic
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risk. Of the 62 evaluable female patients, 24 (39%) had a clonal XCIP. These patients were
younger at diagnosis and had higher presenting platelet counts than those with a polyclonal
XCIP, and appeared to have a higher rate of thrombotic complications, though this did not
reach statistical significance (53% versus 28%, P=0.11), probably due to the relatively small
cohort studied. When these results were combined with data from other groups, however, a
significant association between XCIP status and thrombotic rate was observed (38% in patients
with a clonal XCIP versus 18% in patients with a polyclonal XCIP, P=0.008).
The JAK2 V617F mutation was detectable in 55 (41%) of patients and, in keeping with the
majority of published studies, these individuals were older at presentation than those with
JAK2 WT ET, had lower platelet counts and higher haemoglobin concentrations. The overall
thrombotic risk in the two groups was not significantly different (45% versus 26%, P=0.10), but
the median mutant level was higher in those who had had a thrombosis than in those who did
not (11% versus 5%, P=0.02). This is consistent with data from other groups and suggests that
the mutant level, rather than the presence of the mutation per se, may determine the
thrombotic risk. It is also in keeping with the notion that the phenotype of V617F-positive ET
lies somewhere between JAK2 WT ET and PV in terms of presenting platelet counts and
thrombotic risk. The presence of JAK2 V617F is often taken to indicate the presence of a clonal
myeloid population, yet the rate of myeloid clonality was similar amongst mutant-positive and
JAK2 WT patients (27% versus 45%, P=0.19). This may have been due to the inability of the
XCIP technique to detect small clones, and conversely to the presence of JAK2 WT patients
with clonal myelopoiesis who are likely to carry other mutations.
The relative size of JAK2 WT and V617F-positive platelet populations in ET patients was then
investigated (Chapter 4). A number of prior studies had shown that, in ET, on average less than
half the myeloid population carried the V617F mutation and that the size of the mutant-
positive population appeared to remain stable over many years, both characteristics which
might be considered unexpected for a neoplastic disease. To address the possibility that this
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phenomenon was an artefact of studying neutrophils rather than the biologically more
relevant platelets, mutant levels were quantified in platelet and neutrophil RNA from 10
V617F-positive ET patients, obtained prior to the initiation of cytoreduction. Whilst mutant
levels were significantly higher in platelet RNA than in neutrophil RNA (27% versus 21%,
P=0.002), the results indicated that on average only about half of the circulating platelets in ET
were mutant-positive. None of the 10 patients studied had evidence that JAK2 WT
thrombopoiesis was suppressed in the presence of a thrombocytosis. Whilst this might have
been due to defective regulation of thrombopoiesis in ET, possibly caused by impaired c-Mpl-
mediated TPO clearance, this observation might also suggest that the JAK2 WT platelets were
abnormal in some way. Regardless of the mechanism, the implied persistence of JAK2 WT
progenitors, combined with recent evidence that some individuals harbour an inherited
predisposition to acquire the mutation, raised the possibility that the JAK2 V617F event might
occur more than once in a single individual.
The possibility that more than one mutant-positive myeloid population might exist due to the
acquisition of JAK2 V617F on more than one occasion was, therefore, investigated (Chapter 5).
The chromosome on which the mutation had arisen was determined in 11 V617F-positive ET
patients who were heterozygous for a JAK2 exon 19 SNP by examining which SNP allele was in
cis with the mutation. In order to study only V617F-positive alleles, a PCR fragment which
spanned both the mutation site and the SNP was amplified from neutrophil cDNA. Restriction
enzyme digestion was then performed to cut JAK2 WT products so that in a second-round PCR,
only V617F-positive products were re-amplified. Analysis of the JAK2 exon 19 SNP present in
mutant-positive products revealed that in 10 of the 11 individuals studied, a mixture of SNP
alleles was present. In each of these 10 patients, therefore, the mutation appeared to have
arisen on both chromosomes, suggesting that the majority of ET patients studied had evidence
for the independent acquisition of V617F on more than one occasion in different
haematopoietic progenitors. Poisson statistics would suggest that the mutation had arisen
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more than twice. These results were confirmed by subcloning the PCR product from five
patients and determining the exon 19 SNP allele present in the mutant-positive clones. In all
five patients the mutation appeared to have arisen more than once. The SNP allele with which
the mutation was predominantly associated varied between individuals. Where samples
obtained from a single patient at different time points or from different cells (platelets rather
than neutrophils) were analysed, the SNP allele on which the mutation had predominantly
arisen was the same in the two different samples. The concordance between different samples
in a single individual suggests that the results genuinely indicated the presence of multiple
V617F events and were not due to random PCR artefact, although this cannot be fully
excluded. By contrast, in five PV patients studied there was no evidence for multiple mutant-
positive populations.
The inactivated X-chromosome was then determined in V617F-positive erythroid colonies
derived from six mutant-positive ET patients, including three previously shown to have more
than one mutant-positive population using the approaches described above. In one patient,
different mutant-positive colonies inactivated different X-chromosomes, indicating that in this
case the V617F- positive populations were clonally distinct and that in this individual JAK2
V617F had arisen more than once in phylogenetically unrelated progenitors. In the other five
cases the mutant-positive colonies inactivated the same X-chromosome. This might suggest
that in these patients – i.e. the majority – the mutant-positive populations were clonally
related and that JAK2 V617F arose more than once in different myeloid progenitors which
were all derived from a single transformed progenitor. It is also possible, however, that the
V617F-positive erythroid colonies from these five patients inactivated the same X-
chromosome by chance. These results highlight the biological heterogeneity of ET, and suggest
that in some cases at least, ET resembles a polyclonal non-malignant condition rather than a
clonal neoplastic disorder.
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The role of the 46/1 haplotype in the development of ET and the acquisition of JAK2 V617F
was also investigated (Chapter 6). A number of recently-published studies suggest that
individuals who harbour this haplotype may be at higher risk of developing MPNs than those
who do not. In keeping with this, an association was observed between the 46/1 haplotype
and V617F-positive MPN amongst the patients reported in this thesis, although it was weaker
than that reported by other groups. Moreover, nearly 50% of ET and 25% of PV patients were
homozygous for the non-46/1 haplotype, indicating that this haplotype is not required for the
development of an MPN. No association between the 46/1 haplotype and JAK2 WT MPN was
observed.
The mechanism underlying the association between the 46/1 haplotype and MPNs is
unknown, but two hypotheses have been proposed. One suggests that the haplotype increases
the mutational rate within the JAK2 gene. The other argues that the mutation does not occur
any more frequently than in non-46/1 individuals, but that when it does arise it is more likely
to result in clinical disease, possibly due to the presence of a functional variant associated with
the haplotype. A series of experiments was then performed to explore these two potential
mechanisms. The possibility that the haplotype affected the JAK2 expression or was in LD with
a SNP which was associated with platelet variability was investigated, but the results did not
support either hypothesis. The 46/1 haplotype was noted to introduce at least two CpG
dinucleotides into the JAK2 gene, which may be methylated and therefore alter the DNA
conformation and render it more susceptible to mutations. The methylation at two 46/1-
associated SNPs was, therefore, investigated using bisulphite treatment followed by
pyrosequencing. Both loci were observed to be completely methylated in the presence of the
46/1 haplotype, in both controls and ET patients, which might affect the mutability of the
gene.
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7.2 Future directions
Over the past decade, a number of important advances have been made in our understanding
of the pathogenesis of ET, in particular the identification of the JAK2 V617F and MPL W515
mutations and the recognition that the 46/1 haplotype may be a risk factor in the
development of ET. Nonetheless, many challenges remain, both in comprehending the biology
of the disease and in managing patients with it. Nearly fifty percent of patients with ET have no
detectable molecular abnormality, and in these cases making the diagnosis can be
problematic. Future work is, therefore, required to identify the causative mutations in these
cases. It is notable that in 17 (71%) of the 24 ET patients with a clonal XCIP reported in this
thesis, neither JAK2 V617F nor MPL W515 mutations could be detected. Such patients would
be suitable subjects for investigation by genome-wide approaches to mutation detection using
high-throughput technology. Screening ET patients using high-resolution SNP microarray-
profiling has not revealed any common regions of LOH or copy number alteration suitable for
candidate gene mutational analysis (Kawamata et al, 2008; Stegelmann et al, 2010). High-
throughput sequencing, for instance using sequencing by synthesis microarray technology,
might, therefore, be the most appropriate method to address this issue.
The agents currently used to treat ET can cause a range of side-effects and consequently their
use should be confined to patients at highest risk of complications. Prognostication in ET,
however, remains imprecise and is still predominantly based on clinical factors, despite
attempts to identify molecular markers of increased thrombotic risk. Myeloid XCIP status has
previously been proposed as one such marker, but the association between XCIP status and
thrombotic risk is relatively weak and only becomes clearly evident when multiple studies are
combined. Moreover, this association relates predominantly to events prior to rather than
after diagnosis and the assay is only performed in a research setting and cannot be used to
analyse men and some women. Similarly, JAK2 status does not appear to have a useful role in
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risk stratification in ET, though the mutant level might do, at least in patients with very high
mutant levels. It would worth investigating whether, in addition to the size of the V617F-
positive population, the phylogenetic relationship of its constituent cells affects prognosis.
Data presented in Chapter 5 of this thesis suggests that most ET patients have more than one
V617F-positive population, and in at least a minority of cases these populations are not
clonally related. Larger patient cohorts might usefully be studied, therefore, to determine
whether patients with more than one phylogenetically unrelated V617F-positive population
have a different natural history than those whose mutant-positive populations appear to be
derived from a common founder clone.
ET is incurable with current conventional therapies. Whilst the disease may not affect the life
expectancy of older adults, this is probably not the case in younger patients, especially those
with aggressive disease and in these cases at least, novel agents are required. Furthermore,
the majority of existing treatments target the end result of the pathogenic process, the
proliferating MK, and require lifelong, daily administration. If the initiating event could be
identified and targeted, durable medication-free remissions or even cure may become
possible. A number of new drugs which inhibit JAK2 are in development and whilst some are
showing some promise, none is currently able to reproduce in MPNs the remarkable activity of
BCR-ABL inhibitors seen in CML (Druker et al, 2006; Pardanani et al, 2011; Verstovsek et al,
2010). There is evidence for a so-far uncharacterised ‘pre-JAK2’ event in at least some V617F-
positive individuals (Campbell et al, 2006a; Theocharides et al, 2007), suggesting that V617F
may not necessarily be the pathogenic abnormality in MPN, and this might explain the relative
lack of efficacy of JAK2 inhibitors. In order to develop more effective targeted therapies,
determining the pathogenic event is critical. The observation that JAK2 WT myelopoiesis and
thrombopoiesis were not suppressed by the presence of a V617F-positive population (Chapter
4) raised the possibility that these JAK2 WT cells were themselves not normal, possibly due to
a non-JAK2 abnormality. For this reason, the JAK2 WT cells present in mutant-positive
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individuals warrant further investigation – for instance by growing up haemopoietic colonies
and selecting the JAK2 WT ones for analysis by high-throughput sequencing.
The evidence that most ET patients have more than one V617F-positive population (Chapter 5)
also has implications for therapy. Any future attempts to eliminate the mutant-positive
haemopoietic progenitor altogether and hence cure patients of the disease may prove futile if
they have a pre-existing tendency to acquire JAK2 V617F repeatedly. The role of the 46/1
haplotype in the development of MPNs warrants further research since a clearer
understanding of how this inherited genotype results in predisposition to an MPN in
individuals who harbour it may reveal potential therapeutic targets. For instance, if the 46/1
haplotype does result in increased JAK2 methylation and thereby increases its susceptibility to
acquiring mutations, then consolidating anti-JAK2 therapy with hypomethylating agents might
be appropriate. Methylation analysis of the entire JAK2 gene in larger groups of normal
controls and ET patients would, therefore, be useful to determine whether the presence of the
46/1 haplotype has a significant effect on overall gene methylation. Analysis of mutational
rates in individuals according to 46/1 haploptype status might also be informative.
Finally, the question of whether ET is always a clonal, neoplastic disorder, as stated in the 2008
WHO classification, requires careful consideration, in view of the data presented in Chapters 4
and 5 of this thesis. Labelling ET as a neoplasm can generate unnecessary anxiety in patients if
this is taken to indicate the presence of a malignant disease. Recognition that at least some ET
patients have a disorder characterised by a mutant-positive population which is not
monoclonal and remains stable in size over many years, should prompt further discussion as to
whether ET is invariably a neoplastic condition.
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7.3 Overall conclusions
In conclusion, the results presented in this thesis provide evidence for the biological
heterogeneity of ET, and that accurate prognostic markers remain to be defined. Using XCIP
analysis, a substantial proportion of ET patients appeared to have polyclonal myelopoiesis,
including the majority of V617F-positive ones. Furthermore, in the majority of mutant-positive
ET patients there was evidence which suggested that JAK2 V617F had arisen more than once,
and in at least one patient this had occurred in phylogenetically unrelated progenitors. In other
patients, the multiple mutant-positive populations may have arisen from a clonal progenitor
pool, in keeping with the existence of a pre-JAK2 mutational event. Finally, these results
provide further evidence for the presence of a specific JAK2 haplotype which predisposes to
the development of V617F-positive MPNs, but the mechanism is unclear. Together, these
observations suggest that the role of JAK2 V617F in the pathogenesis of ET is more complex
than it being a single initiating event, that this role may vary between patients, and that the
presence of the mutation does not necessarily indicate the presence of a monoclonal disorder.
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Appendix 1: Primer sequences
Primer name Primer sequence Primer meltingtemperature (°C)
HUMAR/U 5’-TCCAGAATCGTTCCAGAGCGTGC-3’ 67
HUMAR/D 5’-GCTGTGAAGGTTGCTGTTCCTCAT-3’ 66
JAK2ex10/F 5’-TGGAACGTAGGTTGTATGTTGGC-3’ 64
JAK2ex10/R 5’-CATGTAAGAAGGCAATGATAATTAATAGC-3’ 64
JAK2ex12/F2 5’-GCTGTTCAAGGGTCAACTGTAG-3’ 63
JAK2ex12/R2 5’-ACTGAGGATGTATTTACTTAAGTGTC-3’ 62
JAK2ex14/ARMS/FO 5’-TCCTCAGAACGTTGATGGCAG-3’ 62
JAK2ex14/ARMS/FWT 5’-GCATTTGGTTTTAAATTATGGAGTATATG-3’ 63
JAK2ex14/ARMS/RMU 5’-GTTTTACTTACTCTCGTCTCCACAAAA-3’ 64
JAK2ex14/ARMS/RO 5’-ATTGCTTTCCTTTTTCACAAGAT-3’ 56
JAK2ex14/F2 5’-CAAAAGAGATTATGGCAGGTTCAAC-3’ 63
JAK2ex14/(meth)F1 5’-TGTTTATGATAGTAAAAGAGATTATGG-3’ 60
JAK2ex14/(meth)R1 5’-ATTTCTATAAACACCTAAATTTAACCAAAA-3’ 60
JAK2ex14/(meth)seq1 5’-AATGGAATTGATAGAAATGATT-3’ 52
JAK2ex14/(meth)F2 5’-AAATTTATGATTTGTTTTATTATGGTAGT-3’ 58
JAK2ex14/(meth)R2 5’-CAATTTTCAAAAATATAAAAAAATATCATACA-3’ 59
JAK2ex14/(meth)seq2 5’-TTTAGAGGTATGTTTTTATTTTAGT-3’ 55
JAK2ex14/(MM)F 5’-CAAGCATTTGGTTTTAAATTATGGAGTACGT-3’ 66
JAK2ex14/(MM)F3 GAGGTATGCCTTTATTTTAGCGC-3’ 62
JAK2ex14/(MM)R 5’-AGCCAAAAAATATATCTAGTATCATATCTAC-3’ 64
JAK2ex14/R 5’-TAAATTATAGTTTACACTGACACCTAG-3’ 61
JAK2ex14/R2 5’-CATATAACAGGTTCCAAACCACTG-3’ 62
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JAK2ex15/F 5’-CTTAGAACTCATGTGAAATGGC-3’ 59
JAK2ex15/(MM)F 5’-ATTCATTTCATCACAAGCATAGAGTA-3’ 61
JAK2ex15/R2 5’-CTGGAGCATTTAGTATGTTCAAG-3’ 60
JAK2ex18/F 5’-TCAGGCCTTCTTTCAGAGCCA-3’ 62
JAK2ex19/F 5’-GTATATCAGTTTAGTCCAGAGAATG-3’ 61
JAK2ex19/R 5’-GACAATTTACCTTGCCAAGTTGC-3’ 62
JAK2ex20/R 5’-TGTAGAGGGTCATACCGGCAC-3’ 64
MPLex10/F 5’-TGGATGAGGGCGGGGCTCCG-3’ 69
MPLex10/F3 5’-GTGGGCCGAAGTCTGACCCT-3’ 65
MPLex10/R2 5’-CGCTCTGTGACCCCAGATCTC-3’ 66
MPLW515L/F 5’-TGCTGCTGAGGTTGCAGTTTCCTGC-3’ 70
MPLW515L/R 5’-GTGCAGGAAACTGCAACCTCAGCA-3’ 68
rs505534/(MM)F 5’-GTTCATATATTTCTATCCAAAATTGTCT-3’ 61
rs505534/R 5’- GCTAAGATTATACAACAATATTGTTAAG-3’ 61
237
Appendix 2: Publications arising from experiments
reported in this thesis
Lambert, J.R., Everington, T., Linch, D.C. & Gale, R.E. (2009) In essential thrombocythemia,
multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease
paradigm. Blood, 114, 3018-3023.
Lambert, J.R., Gale, R.E. & Linch, D.C. (2009) The production of JAK2 wild-type platelets is not
downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia. Br J
Haematol, 145, 128-130.
Austin, S.K. & Lambert, J.R. (2008) The JAK2 V617F mutation and thrombosis. British Journal of
Haematology, 143, 307-320.
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